Food for thought : growth of the human body and brain in early life by Roelants, J.A. (Jorine)
515078-L-os-roelants Processed on: 16-11-2017
5 
m
m
FOOD FOR THOUGHT  -  GROW
TH OF THE HUM
AN BODY AND BRAIN IN EARLY LIFE
JORINE ROELANTS
FOOD FOR 
THOUGHT 
GROWTH OF THE HUMAN BODY 
AND BRAIN IN EARLY LIFE
JORINE ROELANTS
UITNODIGING
voor het bijwonen van de 
openbare verdediging van het 
proefschrift 
FOOD FOR THOUGHT
growth of the human body and 
brain in early life
door Jorine Roelants
op woensdag 20 december 2017 
om 09:30uur
Prof. Andries Queridozaal  [Eg-370]
Erasmus MC
Dr. Molewaterplein 50
te Rotterdam
Na afloop bent u 
van harte welkom 
voor de receptie ter plaatse
Jorine Roelants
Heemskerkstraat 56B2
3038 VJ Rotterdam
jorineroelants@hotmail.com
Paranimfen
Eline Oostingh
Robert Flint 
phd jor_cover_FINAL 14mm_171115.indd   1 15/11/2017   16:48
5 
m
m
FOOD FOR THOUGHT  -  GROW
TH OF THE HUM
AN BODY AND BRAIN IN EARLY LIFE
JORINE ROELANTS
FOOD FOR 
THOUGHT 
GROWTH OF THE HUMAN BODY 
AND BRAIN I  EARLY LIFE
JORINE ROELANTS
UITNODIGING
voor het bijwonen va  de 
openbare verdediging van het 
proefschrift 
FOOD FOR THOUGHT
growth of the human body and
brain in early life
door J rine Ro lants
op w ensdag 20 decemb r 2017 
om 09:3 uur
Prof. Andries Queridozaal  [Eg-370]
Erasmu  MC
Dr. Molewaterplein 50
te Rotterdam
Na afloop bent u 
van h rte welkom 
voor de eceptie ter plaatse
Jorine Ro lants
Heemskerkstraat 56B2
3038 VJ Rotterdam
jorineroelants@hotmail.com
Paranimfen
Eline Oostingh
Robert Flint 
phd jor_cove FINAL 14mm_171115.indd   1 15/11/2017   16:48

515078-L-st-roelants
Processed on: 3-11-2017
Stellingen
1. Een kleiner embryonaal volume, gemeten met driedimensionale echoscopie-
technieken en virtual reality, is al vanaf 9 weken zwangerschapsduur geassocieerd met 
een verhoogd risico op een ongunstige zwangerschapsuitkomst [dit proefschrift]. 
2. De corpus callosum - fastigium lengte is een nieuwe echografische marker 
waarmee variatie in hersengroei tussen gezonde foetussen en foetussen met 
groeivertraging in zowel de prenatale als de postnatale periode gemeten kan worden 
[dit proefschrift].
3. De hogere dosis aminozuren en het vroeger starten van vetten bij prematuur 
geboren kinderen heeft nog niet geleid tot het behalen van de beoogde groei tijdens 
de ziekenhuisopname, noch tot een betere ontwikkeling in de eerste levensjaren 
[dit proefschrift].  
4. Een hogere gewichtstoename tijdens de ziekenhuisopname is bij prematuur 
geboren kinderen geassocieerd met een hogere relatieve vetmassa 6 weken na de 
uitgerekende datum [dit proefschrift]. 
5. Het is onmogelijk om ‘optimale groei’ te definiëren als de definitie alleen gebaseerd 
is op klassieke kwantitatieve groeimaten [dit proefschrift].
6. Er dient meer aandacht gegeven te worden aan de groei en ontwikkeling van de 
foetus bij het evalueren van groei en ontwikkeling van de pasgeborene.
7. Absence of evidence is not the same as evidence of absence. 
8. “When science becomes a business, what matters is not the quality of the product, 
but whether it sells”  [Michele Pagano, Nature 27 July 2017]. 
9. Wees zuinig op de aarde, het is de enige planeet met chocola [Loesje].
10. “Als je 10 problemen tegelijk wilt oplossen, heb je er 11. Dat lukt je nooit. Focus.” 
[Jan Schaefer]. 
11. Je moet je eigen smaak aan het leven geven. 
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“iT iS noT The STrongeST oF The SPeCieS ThaT SurviveS, 
nor The moST inTelligenT ThaT SurviveS. iT iS The one 
ThaT iS moST adaPTable To Change – CharleS darwin”
Individual experiences in early life affect long–term health. In the early 1990s, hales and 
Barker were the first to propose the ‘thrifty phenotype’ hypothesis.1 The main concept 
of this hypothesis is that poor intra–uterine conditions result in adaptation of the fetus 
to its environment, to increase short–term survival chances. This adaptive process can 
also result in altered organ growth, structure, and function. On the long term, these 
early adaptions contribute to the risk of adverse health outcomes, such as adiposity 
and cardiometabolic diseases, throughout the life course. This increased risk is mainly 
induced by a mismatch between the intra–uterine and extra–uterine environment, with 
the fetal phenotype being unsuitable for the extra–uterine environment that is often 
much richer in oxygen and nutrients.1 Later on this hypothesis was rewritten into the 
Developmental Origins of health and Disease [DOhaD] paradigm, stating that not only 
poor conditions but also subtle variations in the intra–uterine environment can affect 
the offspring’s phenotype with consequences for diseases in later life.2 Nowadays, 
the first 1000 days of life, ranging from conception to approximately 2 years of 
age, are considered the period most sensitive to environmental conditions.   
The DOhaD paradigm has mainly focused on pregnancy as the most important period 
of fetal programming. In preterm born infants this might be different, as the period in–
utero has been shortened. It is believed that in those infants postnatal environmental 
conditions can also induce relevant programming. Which organ systems are affected, 
and the magnitude of the effect, does not only depend on the severity of the adverse 
environmental conditions, but also on its timing.3 The proposed underlying mechanism 
of fetal programming are epigenetic changes, which are heritable and acquired 
variations in the genetic material that do not affect the underlying DNA sequence.4
develoPmenT oF The embryo and FeTuS 
From conception to birth, a fertilized ovum develops into a blastocyst, an embryo 
[up to 10 weeks of gestation], and then becomes a fetus. Embryonic development 
can be divided into different stages: fertilization, implantation of the fertilized 
ovum, and embryogenesis. During embryogenesis the embryo forms and organs 
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GENERAL INTRODUCTION
are developed. The placenta is also formed during the process of embryogenesis. 
The fetal period [from 10 weeks of gestation onward] is characterized by growth 
and maturation of the organs, processes that are less susceptible to environmental 
conditions. 
In the first and second trimester, fetal growth mainly consists of lean mass. After this 
period, fat mass accumulation increases rapidly, with approximately 500 gram [~10 – 
15%] of the fetal weight consisting of fat mass at the end of pregnancy.5
dohad Paradigm and The develoPmenT oF The body and brain in early liFe  
Adverse maternal health and lifestyle can have detrimental effects on the developing 
embryo and fetus, as prenatally, the mother is the fetal environment. These effects 
include increased risk of altered fetal growth, miscarriage, and fetal death, but also 
of preterm birth, fetal growth restriction, and congenital anomalies.6–9 Besides these 
short–term effects, it can also influence postnatal health [DOhaD paradigm].10 The 
predisposition for childhood obesity is, for example, thought to originate in the period 
around conception and gestation, with not only genetics but also environmental 
conditions playing an important role.11 In infancy, BMI is not sensitive as marker of 
child– and adulthood obesity, while adiposity [fat mass relative to weight] is considered 
an early marker of childhood obesity and the development of metabolic syndrome.12–14 
Adiposity tracks across infancy into childhood and is associated with altered free fatty 
acid metabolism, which is associated with dyslipidemia and insulin sensitivity. It is also 
associated with higher levels of vasoactive peptides and cytokines, and hypertension, 
thereby increasing the risk of metabolic syndrome.15–17 Fat distribution and adipose 
tissue function may be even more important for the individual cardiometabolic risk 
than absolute fat mass, as visceral fat is associated with a higher cardiometabolic 
risk than subcutaneous fat.18 The accumulation of adipose tissue by either increasing 
adipocyte size [hypertrophy] or adipocyte number [hyperplasia] is also recognized 
as an important contributor to the risk of developing metabolic syndrome. Adipocyte 
hypertrophy is associated with higher levels of proinflammatory cytokines, reduced 
levels of insulin sensitivity related adiponectin and interleukin 10, and increased stress 
levels, all associated with metabolic syndrome. Why some individuals react with 
hypertrophy while others react with hyperplasia is not fully understood. It is believed that 
both environmental and genetic conditions play a role in the underlying mechanisms, 
which is in line with the DOhaD paradigm.14 Several pathways are suggested to be 
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involved in the predisposition of childhood obesity and long–term cardiometabolic 
risk factors [Figure 1]. Environmental conditions such as maternal obesity, over– 
and undernutrition, smoking, and chronic diseases can increase oxidative stress and 
chronic inflammation in–utero, resulting in fetal reprogramming and thereby affecting 
adiposity in later life.19,20 Structural and functional brain alterations of the hypothalamus 
and hippocampus, associated with maternal overnutrition, increased free radicals, and 
chronic inflammation can also influence adiposity by altering glucose homeostasis, as 
shown in animal studies.21,22 Additionally, there might also be direct effects of maternal 
overnutrition and increased energy supply on the risk of adiposity.23 Although altered 
brain development is often a consequence of brain injury postnatally, environmental 
conditions, that are associated with pathways leading to adiposity, also influence 
brain development and functioning. A clear example is the influence of folic acid on 
central nervous system development.3 But also other environmental conditions are 
able to influence brain development in this very early stage. Chronic inflammation in 
pregnancy, associated with health and lifestyle conditions such as obesity and smoking, 
is for example associated with brain structure and function and with a higher risk for 
neurodevelopmental disorders such as autism and attention–deficit/hyperactivity 
disorder.24,25 Proinflammatory cytokines are involved in fetal brain development, as 
facilitators of cellular survival, proliferation and differentiation, axonal growth, and 
synaptogenesis. Elevated levels can influence the onset of different stages of brain 
development, thereby influencing structure and functioning of the brain.26  
moniToring embryoniC and FeTal growTh   
Traditionally, growth of the embryo and fetus is evaluated by using two–dimensional [2D] 
ultrasonography [US]. In clinical practice, the 2D measure crown–rump length [CRL] is 
used in the first trimester to evaluate embryonic growth.27 In the second and third trimester, 
other measures are used to estimate fetal growth, including femur length, abdominal 
circumference, and head circumference.28 In midgestation, a structural US for evaluation 
of fetal organ development is part of standard care.28 Overall, evaluation of fetal growth 
mainly consists of estimates of quantitative size. Although some measures are available 
for monitoring of brain growth and quality of body growth [body composition and organ 
growth], those are not implemented in standard care yet.  
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Detailed visualization of the embryo and fetus has improved tremendously as a result 
of the development of three–dimensional [3D] US techniques. Using this technique, 
it is now possible to reliably measure embryonic size from around 8 – 9 weeks of 
gestation onward.29 Also later in pregnancy, 3D US techniques are increasingly used 
in research for the detection of altered placentation, placental development, and fetal 
brain development, growth, and body composition.30–33 
FoCuS oF reSearCh 
The prevalence of adverse birth outcomes such as preterm birth, small for gestational 
age, and congenital anomalies is still high worldwide, with relatively high morbidity 
rates in the Netherlands compared to other European countries.34,35 Moreover, the last 
decades, the incidence of childhood overweight and obesity has started to increase 
exponentially worldwide.36 The harmful consequences of adverse birth outcomes and 
chilhdood obesity for long–term neurodevelopmental and cardiometabolic health 
have been well established.37,38  Many of these outcomes are believed to originate in 
the periconceptional period, with environmental conditions such as maternal health 
and lifestyle playing an important role in development of these adverse birth outcomes 
and adiposity [Figure 1].39–41 To improve fetal and neonatal health outcomes, thereby 
influencing health throughout the life course, we need to identify embryos and fetuses 
at risk of an adverse outcome as early in pregnancy as possible. 
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PreTerm inFanTS
Preterm birth, defined as birth before 37 weeks of gestation, is the leading cause of 
perinatal morbidity and mortality in the developed world. Worldwide, approximately 15 
million neonates are born preterm each year.42 In the Netherlands,  approximately 7% 
of the 175,000 infants born alive are born preterm.43 Improvements in care of preterm 
infants, such as the introduction of artificial ventilation and antenatal steroids, have 
improved survival chances tremendously the last decades.44 At this moment, mortality 
rates are around 30% at 24 weeks of gestation, and 1 – 4% at 32 weeks of gestation. 
Morbidity rates have, however, only slightly decreased.38,45–47 With the increasing survival 
rates we now increasingly face the health burden and costs of these morbidities on the 
short– and long–term. Long–term follow–up of preterm infants is thus important for 
the individual patient, and should be focus of clinical research to evaluate perinatal care 
and to support important ethical discussions in early life. 
Feeding The PreTerm inFanT 
Due to the immaturity of the gastro–intestinal tract, very preterm infants are unable 
to tolerate full enteral feeding in the first days to weeks of life. They depend on 
parenteral [intravenous] nutrition consisting of glucose [mainly provision of energy], 
amino acids [precursors of proteins], and lipids [provision of energy and in particular 
important for brain development]. Routine use of parenteral nutrition in preterm 
infants was introduced in clinical practice in the early 1970s, with improvements in 
quality of the solutions resulting in a gradual increase of its use in neonatal practice. 
The latest guideline for parenteral nutrition in preterm infants of the European Society 
of Pediatric Gastroenterology, hepatology and Nutrition [ESPGhAN] was presented 
in 2005.48 This guideline advocates the start of amino acids and lipids soon after 
birth. This more aggressive approach was implemented because of the high rates of 
postnatal growth retardation and the known association between growth retardation 
and impaired neurodevelopmental outcome.49,50 Although randomized controlled trials 
demonstrated the short–term benefits of the recommendations, implementation of 
the guideline in clinical care proved to be difficult, resulting in persistent high rates of 
growth retardation.51–54 The long–term benefits of these more aggressive practices 
need however further study.
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growTh oF The early PreTerm body 
Current opinion on optimal growth for preterm infants is that ‘quantity and quality of 
growth should be equivalent to fetal growth, to enable normal organ growth’.55,56 The 
most important feature of quantity of growth in neonatal care is weight gain. Length 
and head circumference, also measures that are frequently used in clinical care, are 
considered measures of quantity and quality of growth: length is a feature of muscle 
and bone growth [lean mass], and head circumference is a feature of brain growth and 
development. Other markers of quality of growth are body composition, and growth 
and development of organs such as the kidneys, lungs, heart, and the bones. These 
measures are not evaluated on a regular basis in clinical care.  
 
Despite the general consensus to aim for growth rates comparable to fetal growth rates 
in the postnatal period, many infants show postnatal growth retardation, defined as 
growth less than expected based on birth weight.57 Moreover, the feasibility of this target 
is under debate. First, because growth during neonatal intensive care unit [NICU] stay is 
influenced by morbidities affecting metabolic requirements, endocrine abnormalities, 
central nervous system damage, difficulties in suck– and swallow–coordination, and 
administration of drugs affecting nutrient metabolism. And second, because there are 
substantial differences between the intra–uterine and extra–uterine environment with 
regards to important regulators of growth, such as nutrient supply, environmental cues, 
and the endocrine system.  
nuTriTion Prenatally, carbohydrates are the primary energy source, while postnatally 
lipids are the main suppliers.58 Additionally, little is known on actual nutrient intake 
and circadian rhythm of nutrient supply during gestation, which likely differs from the 
continuous supply postnatally. 
environmenT Obviously, the intra–uterine and extra–uterine environment are com-
pletely different, especially in a NICU setting. Neonatal morbidities, regulation of vital 
processes, stress, and pain may all interfere with nutritional needs and the ability to 
achieve fetal growth targets postnatally.59,60
endoCrine SySTem Growth is regulated by different hormones during pregnancy. In 
the embryonic period, insulin–like growth factor II [IGF II] is the primary factor, while 
later in gestation IGF I, secreted under control of the glucose/insulin axis, becomes 
increasingly important.61 Postnatally, IGF I remains the main growth regulator, becom-
ing now growth hormone [Gh] dependent. IGF I levels are substantially lower in the 
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first weeks of life in preterm infants than observed in term born infants.62,63 Possibly, 
mimicking of fetal growth rates is not feasible before IGF I levels are normalized, which 
partly depends on nutritional, and in particular protein, intake.64 
Thus, many differences exist between important regulators of growth prenatally and 
postnatally. Possibly, it is not achievable to mimic fetal growth rates in the first weeks 
of life. 
Prenatal and postnatal growth is a major contributor to short– and long–term health 
of preterm infants. Growth retardation is associated with, amongst others, broncho–
pulmonary disease and retinopathy of prematurity on the short term, and with 
impaired neurocognitive outcome and increased occurrence of cerebral palsy on the 
long term.65,66 Growth retardation often persists after the neonatal period, with 
recovery of initial weight, length, and head circumference Z score not before 6 
months after term age, sometimes even tracking into childhood.67 After the period 
of growth retardation many infants experience catch–up growth, which is defined 
as acceleration of growth after a period of starvation.68 The benefits of catch–
up growth, but also of growth acceleration without prior growth retardation, for 
neurodevelopmental outcome have been well established.68 Several studies 
suggested however that growth acceleration and catch–up growth are also 
associated with risk factors of an adverse cardiometabolic health.69,70 This has 
resulted in debate about the definition of ‘optimal growth of preterm infants’ 
and about what neonatologists should aim for when feeding a preterm infant: 
do the neurodevelopmental benefits of rapid growth favor promotion of rapid 
growth in the early period, despite growing evidence for adverse cardiometabolic 
consequences in childhood and adulthood?68 
growTh and develoPmenT oF The early PreTerm brain   
The human brain grows rapidly in the first years of life, with the most impressive change 
during fetal life: between 20 and 40 weeks of gestation the volume of the brain increases 
10–fold, and neural proliferation and migration, organization, and myelination take 
place.3 In this period of rapid growth and development, the brain is particularly vulnerable 
to adverse conditions.3,71–73 In very preterm born infants, this period corresponds with 
extra–uterine life on the NICU, a setting in which many adverse environmental conditions 
are present. Even in preterm infants without brain injury, brain development is altered: 
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preterm born infants have smaller brain volumes, particularly of the grey matter, and 
different subcortical structures than term born infants. Moreover, neural connectivity 
is decreased.74,75 These alterations in early life partly explain the associations between 
preterm birth and impaired neurocognitive and psychomotor outcome  and mental health 
problems. Although the occurrence of impairments varies based on gestational age at 
birth, overall, 10 – 20% of the very preterm infants have severe impairment, with studies 
reporting up to 50% having any impairment.38 These impairments include neurosensory 
[deafness and blindness], but also neurocognitive [ranging from impaired executive 
functioning to severe mental retardation], motor [tone dysregulation to cerebral palsy], 
and behavioral problems [e.g., attention deficit disorder, autism, and depression].38 
Severe cases of neurodevelopmental impairment can usually be identified in the 
neonatal period when major brain injury is present. In those without major brain injury, 
we are still not able to adequately predict which infants will have [severe] impairments. 
CardiomeTaboliC healTh  
Cardiometabolic health concerns both heart disease and metabolic disorders such 
as diabetes and common cardiometabolic health risk factors including obesity, 
hypertension, dyslipidemia, and insulin resistance.76 Already in early life preterm infants 
have a different cardiometabolic profile than term born infants, possibly reflecting their 
higher cardiometabolic risk in later life.77 Body composition, representing the ratio 
between lean body mass and fat mass, is altered after preterm birth. Compared to 
those born healthy at term, preterm born infants have higher levels of fat mass relative 
to weight [adiposity] around term age, with increased visceral fat deposition.77,78  Around 
4 – 6 months after term age, adiposity levels of preterm infants normalize or even 
decrease to levels below those of term born infants.79 Only a few studies tracked body 
composition into childhood, showing inconsistent findings. Some showed that children 
born preterm have similar body composition at preschool age as full–term born infants, 
while others observed altered body composition at preschool age in boys, but not in 
girls.79–81 In adulthood, the adverse consequences of preterm birth are more evident. 
Preterm born infants have higher adiposity, higher blood pressure, and higher rates of 
metabolic syndrome than term born infants, with a dose–response relationship between 
shorter length of gestation and the occurrence of cardiometabolic risk factors.82–84 
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Relative or percentage fat mass is defined as absolute fat mass divided by total body 
weight [which is the sum of absolute fat and lean masses]. An increased relative fat 
mass can thus be the result of either a decreased absolute lean mass or an increased 
absolute fat mass relative to the overall weight. It has been suggested that, though there 
is increased visceral fat accumulation, the higher relative fat mass is mainly the result 
of decreased lean mass, and not of increased fat accumulation in preterm infants.77,85 
The effect of parenteral nutrition on adiposity in infancy is still unclear, as previous 
studies showed inconsistent results.86–89 The influence of early postnatal growth on 
body composition development, despite being recognized as important factor of health 
outcome, has neither been established yet.86,89,90 
moniToring oF growTh and develoPmenT oF PreTerm inFanTS  
STandard anThroPomeTriCS  
Evaluation of growth provides an impression of the child’s health, making monitoring 
of growth an important part of neonatal and pediatric care. In the NICU setting, growth 
is mainly evaluated by using standard anthropometrics [weight, head circumference, 
and length]. The quantitative increase in size of these measures is evaluated by using 
reference curves developed for preterm infants. Based on this growth evaluation, 
nutritional practices are adjusted. Although weight in combination with length and 
head circumference measurement indeed provides a better impression of the quality 
of growth than weight alone, it still does not provide a good impression of quality of 
growth.91 Markers of quality of growth include body composition and growth and 
functioning of specific organs, such as the brain. These markers are however not part of 
standard care in most clinics. 
evaluaTion oF body ComPoSiTion  
The human body consists of fat mass and lean mass. The latter can be divided into 
muscle, bone, water, and [organ] tissue.92 In adults, body mass index [BMI] is often 
used as proxy of obesity and body composition. This marker provides no accurate 
estimation of obesity in infancy and childhood.93 Other methods to measure body 
composition in infancy include Dual Energy X–ray Absorptiometry, double–labelled 
water, bio–impedance, and air–displacement plethysmography.92 Air–displacement 
plethysmography [PEA POD®, Infant Body Composition System, COSMED] uses direct 
measurement of body volume and weight, based on the whole–body densitometry 
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principle.94 Several studies showed that body composition measurement using air 
displacement plethysmography is accurate, precise, and safe in neonates from 30 
weeks of gestation onward. Moreover, the measurement is easily performed and 
patient–friendly.87,94–96  Still, this method is not yet part of routine follow–up. 
evaluaTion oF PreTerm brain develoPmenT 
Overall brain size and size of specific brain structures are important predictors of 
neurodevelopmental outcome.97,98 On the NICU, brain size is usually monitored 
by manual measurement of head circumference. This method has a low 
interrater agreement and does not correspond well with actual brain growth: it 
not only measures size of the brain but also of the skull and of the subarachnoid 
spaces, the latter being frequently enlarged in preterm born infants.99–101 
The correlation between head circumference and neurodevelopmental outcome on 
the long term is also limited.66 Other markers are therefore needed to provide better 
understanding of the developing preterm brain and to more adequately predict the 
risk of an adverse neurodevelopmental outcome during NICU stay. Two scanning 
techniques are available on most NICUs: magnetic resonance imaging [MRI] and cranial 
ultrasonography. Although MRI allows for more precise evaluation of structural brain 
development, brain injury, and connectivity, this technique is expensive, not bedside–
available, and does not allow for serial measurement, essential for monitoring of growth 
and development.102 Cranial ultrasonography is a bedside–available, clinically applicable 
method that allows for serial measurement. Furthermore, cranial ultrasonography 
is routinely performed for evaluation of brain injury in the neonatal period in many 
centers. Cranial ultrasonography therefore provides a better opportunity to monitor 
brain growth and development in clinical practice than MRI, but feasible and reliable 
ultrasound markers to monitor brain growth are lacking.    
After the neonatal period, infants regularly visit outpatient clinics to keep track of their 
growth and neurodevelopment. The neurodevelopmental test most frequently used in 
follow–up is the Bayley Scales of Infant and Toddler Development, third edition [BSID III], 
which was released in 2006.103 This test compromises three categories: cognition, 
language, and psychomotor functioning. Measures of specific brain functioning or 
executive functioning are less well integrated in standard follow–up programs. 
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FoCuS oF reSearCh  
In the past, researchers and clinicians advocated enhanced nutrition and rapid growth 
to improve brain development and neurodevelopmental outcome in preterm infants. 
The last years however accumulating evidence has become apparent showing an 
increased occurrence of features of an adverse cardiometabolic health in preterm 
born infants. Nutrition and growth have been identified as key factors in this increased 
risk. But despite a large number of studies focusing on growth and nutrition of 
preterm infants, we are still not able to define “optimal growth” for optimal long–term 
cardiometabolic and neurodevelopmental health. 
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aimS oF ThiS TheSiS 
In this thesis we aim to link the prenatal and postnatal life, with focus on the association 
between nutrition and growth in early life and the development of the body and the 
brain of fetuses and preterm infants. 
The main objectives are:  
1. To investigate the use of three–dimensional ultrasound measures in pregnancy as 
early markers of birth outcome and neonatal body composition.   
2. To develop ultrasound measures that can be used to monitor brain growth  
in the prenatal and postnatal period.   
3. To describe current nutritional practices in preterm infants and to study the 
influence of enhanced early nutrition on neurodevelopmental outcome of preterm 
infants.   
4. To assess the association between in–hospital growth and body composition in 
infancy in preterm born infants. 
SeTTing
This thesis is based on studies conducted at the Department of Obstetrics and Gyne-
cology and the Department of Pediatrics, division of Neonatology, of the Erasmus MC 
– Sophia Children’s hospital, Rotterdam, the Netherlands. 
roTTerdam PeriConCePTional CohorT 
The Rotterdam Periconceptional Cohort [Predict study] is a prospective cohort study 
conducted in a tertiary hospital that focuses on three research areas: [1] determinants 
of periconceptional health; [2] pregnancy course and outcome; and [3] underlying 
epigenetic mechanisms.104 Women are included in the first trimester of pregnancy 
and followed until 1 year after delivery, by using transvaginal three–dimensional [3D] 
ultrasounds at 7, 9, and 11 weeks of gestation, questionnaires throughout gestation, and 
[umbilical cord] blood withdrawals. 
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dream STudy
Embedded in the Predict study is the DREAM study. Between November 2013 and 
July 2015, women with an ongoing singleton pregnancy, enrolled in the Predict study, 
were invited to participate in the DREAM study. Participants underwent additional 
3D ultrasounds at 22, 26, and 32 weeks of gestation. After birth, a neonatal cranial 
ultrasound was performed. Between September 2014 and September 2016, neonatal 
body composition was additionally measured during the postnatal visit. 
bond STudy 
The BOND study [BOdy composition and NeuroDevelopment in preterm infants] is 
an ongoing, observational cohort study conducted at the neonatal intensive care unit 
and the outpatient clinic. The main aim of this study is to study the complex interaction 
between nutrition, growth, body composition, and neurodevelopment in preterm 
infants. Between September 2014 and April 2017, preterm infants born before 30 
weeks of gestation without congenital chromosomal anomalies or severe brain injury 
were included. From birth up to 2 years after term age, body composition and brain 
development were monitored at standardized moments. In Table 1 an overview is given 
of the different study assessments. In this thesis, we focus on the short–term results 
of this study.
Table 1 | overview oF STudy aSSeSSmenTS bond STudy
niCu stay 1st visit 2nd visit
nutrition data • • •
anthropometrics • • •
Cranial ultrasound • •
body composition • •
Questionnaire [lifestyle] •
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ouTline oF ThiS TheSiS 
PART I comprises research on the development of the early human body, with focus 
on nutrition, growth, and body composition. Chapter 2 addresses the association 
between embryonic size and growth and birth outcome. In Chapter 3 we present 
a systematic overview of current literature on prenatal markers of neonatal body 
composition. In Chapter 4 the use of fetal fractional thigh volume, a three–dimensional 
ultrasound measure, is evaluated as prenatal marker of neonatal body composition. 
Current nutritional practices for preterm infants on a large neonatal intensive care unit 
are presented in Chapter 5. In Chapter 6 the association between in–hospital growth 
and body composition in infancy is investigated in preterm infants.  
In PART II we study the human brain in pregnancy, early postnatal life, and 
childhood. In Chapter 7 and 8, a new ultrasound marker for measurement of 
brain growth is presented. Chapter 9 describes the results of a randomized 
controlled trial on parenteral nutrition in preterm infants, focusing on growth 
and neurodevelopmental outcome. Chapter 10 covers the general discussion of 
the main findings and provides suggestions for further research. In Chapter 11 
a summary of this thesis is provided in Dutch and in English. 
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abSTraCT
objeCTiveS To study associations between three–dimensional [3D] ultrasound para–
meters of embryonic size and growth in the early first trimester and the risk of adverse 
birth outcomes. 
deSign Prospective periconceptional cohort study.
SeTTing Tertiary hospital in the Netherlands. 
ParTiCiPanTS Pregnant women with a singleton pregnancy were included when they 
had one or more 3D ultrasounds examinations between 6 and 13 weeks of gestation. We 
excluded pregnancies conceived after oocyte donation, ending in a miscarriage before 
16 weeks of gestation, and those with missing information on gestational age at birth, 
birth weight, congenital anomalies, and fetal and early neonatal mortality.  
main ouTCome meaSureS Embryonic size, expressed in crown–rump length [CRL, 
mm] and embryonic volume [EV, cm3], was measured by using 3D ultrasonography 
with virtual reality. Embryonic growth trajectories were longitudinally modeled 
between 6 and 13 weeks of gestation for CRL and EV. Birth outcomes were preterm 
birth [delivery <37 weeks of gestation] and gestational age, small for gestational age 
[SGA; <10th percentile] and birth weight, major congenital anomalies, and mortality 
[fetal death from 16 of gestation onward or mortality in the first week after birth]. The 
primary analyses included associations between embryonic size parameters measured 
at 7, 9, and 11 weeks of gestation or embryonic growth and the composite outcome 
of any of the adverse birth outcomes [yes/no]. The secondary analyses were on the 
association between embryonic size or growth and the outcomes of preterm birth, 
SGA, congenital anomaly [all logistic regression], gestational age and birth weight [both 
linear regression] separately. 
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reSulTS The primary analyses showed that only a larger EV at 11 weeks of gestation 
was negatively associated with adverse birth outcome: an increase of 1 cm3 EV was 
associated with a 12% smaller odds of an adverse birth outcome [odds ratio [OR] 0.88 
[95% confidence interval [95%CI] 0.79 to 0.98], p=0.017]. The secondary analyses 
showed that larger EV and CRL at 11 weeks of gestation were negatively associated 
with SGA [EV: OR 0.84 [95%CI 0.71 ; 0.99], p=0.036; CRL: OR 0.92 [95%CI 0.86 – 
0.99], p=0.027], but no significant associations were observed between embryonic 
size parameters and the other outcomes. From 9 weeks of gestation onward, both EV 
and CRL size and growth were positively associated with birth weight. EV growth, but 
not CRL growth, was negatively associated with SGA.
ConCluSionS Already early in the first trimester, larger embryonic size and growth 
are associated with a smaller odds of an adverse birth outcome. Our data suggest 
that EV is a more sensitive marker for detection of growth deviations than CRL in early 
pregnancy. Early 3D ultrasound screening can extend the window of opportunity for 
prevention and interventions to improve embryonic, fetal, and neonatal health with 
consequences for health throughout the life course.
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inTroduCTion 
During the first trimester of pregnancy, the embryo is very sensitive to maternal health 
and lifestyle conditions, such as smoking and obesity, because of the high growth rates 
and organ development.41,105 In addition, these conditions can influence DNA methylation, 
thereby epigenetically changing gene function with subsequent consequences for not 
only organ growth, development, and function, but also for fetal and neonatal health 
[Developmental Origins of health and Disease [DOhaD] paradigm].41,106 Previous 
studies showed that impaired embryonic growth at the very end of the first trimester 
is associated with an increased risk of adverse birth outcomes such as preterm 
birth and low birth weight.107,108 With the recent development of three–dimensional 
ultrasonography [3D US], it is now possible to monitor embryonic growth reliably 
and precisely already in earlier in the first trimester.29,109 Using 3D US combined with 
virtual reality [VR] for volume measurements, we may be able to identify pregnancies 
at risk of an adverse birth outcome already early in the first trimester. This would 
extend the window for potential interventions and follow–up to improve embryonic and 
fetal health and birth outcomes, which may improve health on the long term.   
We therefore aimed to investigate the association between early first trimester 
embryonic size parameters and growth rates and adverse birth outcomes, as well as 
gestational age at birth and birth weight, in a large periconceptional cohort study.  
Common adverse birth outcomes are preterm birth, small for gestational age [SGA], 
congenital anomalies, and mortality.35 We hypothesized that at 7, 9, and 11 weeks of 
gestation a larger embryo is associated with a smaller odds of preterm birth, SGA, 
major congenital anomalies, and fetal and early neonatal mortality. Moreover, we 
hypothesized that an increased embryonic growth rate between 6 and 13 weeks 
of gestation is associated with smaller odds of an adverse birth outcome.   
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meThodS 
In this periconceptional prospective cohort study we assessed the association 
between embryonic size parameters measured using 3D US and VR at 7, 
9, and 11 weeks of gestation and adverse birth outcomes, and between 
embryonic growth between 6 and 13 weeks of gestation and adverse birth 
outcomes. Additionally we assessed the association between embryonic 
size and growth and gestational age at birth and birth weight.    
STudy deSign 
The Rotterdam Periconceptional Cohort [Predict study] is an ongoing hospital–
based prospective periconceptional cohort study conducted in the Erasmus 
University Medical Centre, Rotterdam, the Netherlands.104 For this study, we 
selected pregnant women [aged ≥ 18 years] enrolled between 2009 and 2015 with 
a singleton pregnancy, who underwent one or more 3D US examinations before the 
14th week of gestation. The following exclusion criteria were applied: oocyte donation, 
miscarriage before 16 weeks of gestation, and missing information on pregnancy 
outcome [gestational age at birth, birth weight, congenital anomalies and fetal or 
early neonatal mortality]. Of the women who repeatedly participated in the Predict 
study, only the first pregnancy was used in the analyses. 
eThiCal ConSideraTionS  
Written informed consent was obtained before enrollment from all participating women 
and their partners. The Central Committee on Research in The hague and the local 
Medical Ethical Committee approved the study [MEC–2004–227]. 
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embryoniC ulTraSound examinaTionS  
Transvaginal 3D US scanning was performed between 6 to 13 weeks of gestation 
by using a 6 – 12 Mhz transvaginal probe and GE Voluson E8 equipment combined 
with 4D View software [General Electrics Medical Systems, Zipf, Austria]. In the pilot 
phase [2009 – 2010], weekly 3D US were performed to assess the feasibility of first 
trimester growth trajectory monitoring. Based on these data, the schedule was 
changed to scanning only at 7, 9, and 11 weeks of gestation from 2013 onward.104    
The obtained 3D datasets were transformed to rectangular volumes and transferred to 
the BARCO I–Space [Barco N.V., Kortrijk, Belgium] at the Department of Bioinformatics, 
Erasmus University Medical Center, Rotterdam, the Netherlands. The BARCO I–
Space is a four–walled CAVETM–like virtual reality system which allows for depth 
perception and interaction with the projected scans [3D virtual reality].110   
For evaluation of embryonic size and growth, crown–rump length [CRL] and embryonic 
volume [EV] were measured offline by trained researchers. Reliability, technique, and 
methods of these measurements are described in detail by Rousian et al. and Verwoerd–
Dikkeboom et al, showing excellent inter– and intraobserver agreement and intraclass 
correlation coefficients of 0.98 for CRL and 0.99 for EV.29,109,111 CRL measurements were 
performed in the I–Space three times by the same researcher and the average of these 
measurements was used in the analyses. The calipers were placed on the outer border 
of the crown and the caudal rump, thereby drawing a straight line. A semi–automated 
application, using grey–scale differences, was used to measure EV once.   
Details on the study protocol and questionnaires have been reported previously.104 In 
short, additional data were obtained via questionnaires completed at enrollment [first 
trimester], at 24 weeks of gestation, and shortly after delivery. These questionnaires 
contained questions on maternal health and lifestyle, pregnancy course, and neonatal 
outcome. All obstetrical and neonatal outcomes were crosschecked in the electronic 
medical file and delivery reports, which were considered the gold standard.  
baSeline daTa  
We obtained the following maternal and neonatal characteristics: maternal age, 
geographical background [Western, non–Western], parity [nulliparous, multiparous], 
mode of conception [spontaneous, in vitro fertilization [IVF] with or without intra–
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cytoplasmic sperm injection [ICSI]], periconceptional maternal smoking [yes/no], 
periconceptional vitamin and folic acid use [yes/no], date of delivery, neonatal sex, birth 
weight, occurrence of mortality between 16 – 42 weeks of gestation [fetal] or within 
1 week after birth [early neonatal mortality], and the presence of major congenital 
anomalies according to the EUROCAT criteria.112 Periconceptional BMI of the mother 
was calculated based on body weight before the last menstrual period and height 
obtained in the first questionnaire. If not available, weight and height measured at the 
first visit were used to calculate BMI. Birth weight percentiles adjusted for gestational 
age, parity, and sex were calculated using Dutch reference standards.113 SGA was 
defined as birth weight below the 10th percentile.  
Missing data were mainly due to incomplete questionnaires, which were completed 
based on patients’ electronic medical file, if available.   
PregnanCy daTing 
Data on mode of conception, first day of the last menstrual period [LMP], 
and regularity and duration of the menstrual cycle were obtained at the 
first visit by the research team and in the first questionnaire. Afterwards, 
these data were crosschecked with information in the electronic medical file.  
In spontaneous pregnancies [including intra–uterine insemination and hormonal 
stimulation], dating was based on first day of the LMP if there was a regular [25 – 
35 days] and known duration of the last menstrual cycle. If the menstrual cycle was 
prolonged [32 – 35 days], we adjusted for duration of the cycle. In spontaneous 
pregnancies with either an irregular menstrual cycle [<25 or >35 days] or an unknown 
date of the first day of the last menstrual period, dating was based on two–dimensional 
[2D] CRL measurement performed at [or close to] 9 weeks of gestation.   
As previous studies showed a recall bias with regard to the LMP, we checked whether the 
calculated due date based on the menstrual cycle corresponded with dating on CRL.114 
If there was a difference of ≥ 7 days between the due date calculated by using LMP and 
CRL, we used the due date based on CRL measurement for the analyses.  
In pregnancies conceived after IVF, with or without ICSI procedures, the due date 
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was calculated from the date of oocyte retrieval plus 14 days. The due date 
of pregnancies conceived after the transfer of cryopreserved embryos was 
calculated from the day of embryo transfer plus 18 days.  
 
ouTCome meaSureS 
Our main outcome measure was an adverse birth outcome, defined as the combined 
outcome of preterm birth [birth before 37 completed weeks of gestation], SGA, 
major congenital anomalies, and fetal or early neonatal mortality.  
The secondary outcome measures were preterm birth, gestational age at birth, SGA, 
birth weight, and major congenital anomalies. Because of the low mortality rates, 
mortality was not studied separately. 
STaTiSTiCal analySeS 
Data are presented as mean [standard deviation, SD], median  [interquartile range, 
IQR] or n [%]. 
First, we assessed the association between mean embryonic size [CRL and EV] at 7, 9, 
and 11 weeks of gestation, and adverse birth outcomes, by using logistic [odds ratio [OR] 
and 95% confidence interval [CI]] regression analyses for dichotomous outcomes and 
linear regression [effect estimates and 95%CI] for continuous outcome measures.  
All associations were explored in three models: a crude model, a basic model [model 1] 
and a fully adjusted model [model 2]. The crude model only adjusted for gestational age 
at 3D US. Model 1 additionally included maternal educational level and fetal sex, which 
were selected based on differences in baseline characteristics between those with [cases] 
and without [controls] an adverse birth outcome [Table 1]. Model 2 additionally included 
parity, maternal age, maternal periconceptional BMI, maternal geographical background, 
and mode of conception. Folic acid use and periconceptional smoking, important factors 
influencing embryonic growth and birth outcome, were not included in this model because 
of the respectively very high and low frequencies. All cases with an adverse birth outcome 
[n=156] were compared to all non–cases [controls, n=601]. For each of the secondary 
outcomes [preterm birth, SGA, and congenital anomalies], cases were compared with 
the controls of the primary analysis [having none of the adverse outcomes, n=601]. 
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Second, individual CRL and EV growth trajectories were created to assess the association 
between embryonic growth and adverse birth outcomes. For optimal use of the available 
growth data, and taking into account the correlation between serial measurements 
per pregnancy, we used a 2–step approach. First, we modelled the individual growth 
trajectories in a linear mixed model. Approximately normal distributions and linear 
associations were obtained by square root transformation of CRL and cube root 
transformation of EV. The subject–specific random effects [intercept and slope], that 
summarize the individual growth trajectories, were then used as covariates in the 
second step of the analyses. In this step, again regression analyses including a crude, 
basic and fully adjusted model were applied, as described above.  
SenSiTiviTy analySeS One fourth of the pregnancies were dated based on CRL 
measured at 9 weeks of gestation, assuming uniform embryonic growth. This may 
have diluted the associations between embryonic size and growth and adverse birth 
outcome. We therefore performed sensitivity analyses in pregnancies with a strict 
regular cycle that were conceived spontaneously. We assume that there is limited 
variation in growth based on incorrect dating in those pregnancies, and no bias of the 
outcome because we do not use our exposure [CRL] to calculate the due date. In these 
analyses, the same models were applied as in the primary and secondary analyses, only 
mode of conception was deleted from the fully adjusted model [model 2].    
The dataset was nearly complete, with only a few covariates missing for a small group 
of patients [n=18, 2.4%]. Therefore we chose not to impute missing data, but to report 
sample sizes in each analysis based on complete cases.  
A two–tailed p value of <0.05 was considered statistically significant. Data were analyzed 
using SPSS [SPSS package 21.0, IBM, USA] and R [R: A language and Environment for 
Statistical Computing, version 3.4.1, R Core Team, Vienna, Austria].  
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reSulTS
The Predict study included 897 pregnant women with 3D US examination in the 
first trimester. We excluded pregnancies conceived after oocyte donation [n=14], 
miscarriages before the 16th week of gestation [n=9], and missing outcome data 
[n=70]. Exclusion of repeated participation [n=47], resulted in a study sample of 757 
[84%] for analyses [Figure 1]. The baseline characteristics are shown in Table 1. Of the 
757 pregnancies, 156 [21%] resulted in an adverse outcome. 
Per patient, 1 – 8 3D US examinations were performed with successful measurements 
[median 3, interquartile range [IQR], 2 – 6]. In Table 2, the results of CRL and EV 
measurements at 7, 9, and 11 weeks of gestation are shown. CRL increased from median 
12.9 [IQR 10.8 – 14.8] mm at 7 weeks to 50.2 [IQR 46.0 – 54.3] mm at 11 weeks of 
gestation. EV increased from median 0.28 [IQR 0.16 – 0.41] cm3 at 7 weeks to 10.30 
[IQR 8.31 – 12.25] cm3 at 11 weeks of gestation.
Primary analySeS  
The association between CRL and adverse birth outcome was not statistically significant 
at any of the time points in any of the 3 models. Similar to CRL, the ORs for EV showed 
a lower odds at all time points, but were only statistically significant at 11 weeks of 
gestation [OR 0.88; 95% confidence interval [CI] 0.79 – 0.98]: a larger EV at 11 weeks of 
gestation is thus associated with smaller odds of an adverse birth outcome [Table 3A]. 
Studying the first trimester data longitudinally, we did not observe a statistically 
significant association between CRL or EV growth trajectories between 6 and 13 weeks 
of gestation and an adverse birth outcome [data not shown].
SeCondary analySeS  
We did not observe an association between CRL or EV and preterm birth or gestational 
age at birth at any of the time points [Table 3B and 4A].  
The association between both embryonic size parameters and SGA was significant 
at 11 weeks of gestation, again showing a negative association [OR 0.92, 95%CI 
0.86;0.99]. At 7 and 9 weeks, all ORs showed a negative association as well, but no 
statistically significant associations were found [Table 3C]. A positive association 
was found from 9 weeks of gestation onward between CRL and EV and birth weight: 
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Predict study
n=960
No ultrasound
measurements
n=63
Oocyte donation
n=14
Miscarriages
n=9
Missing outcome data
 n=70
Repeated 
participation
n=47
n=897
n=874
n=757
IVF/ICSI
n=218 [29%]
Dated on conception 
date
n=218 [29%]
Dated on CRL
n=187 [25%]
Dated on LMP
n=352 [46%]
Spontaneous
n=539 [71%]
n=804
Figure 1 | FlowCharT
Abbreviations: n, number; LMP, last menstrual period; CRL, crown-rump length
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larger CRL and EV were associated with a higher birth weight [Table 4B].   
Although nearly all ORs showed a negative association, no statistically significant 
associations were found between embryonic size parameters and congenital anomalies 
[Supplemental table 1].
We did not observe an association between CRL or EV growth trajectories and preterm 
birth or congenital anomalies. CRL and EV growth trajectories were significantly 
associated with SGA: a higher CRL and EV growth rate between 6 and 13 weeks of 
gestation were associated with an smaller odds of SGA [data not shown]. 
Table 2 | ulTraSound meaSuremenTS
ga [iQr] n median iQr min – max
uS at 7 weeks
CRL [mm] 7+3 [7+2;7+5] 415 12.9 10.8 – 14.8 5.4 – 20.3
EV [cm3] 7+3 [7+2;7+5] 346 0.28 0.16 – 0.41 0.01 – 0.95
uS at 9 weeks
CRL [mm] 9+3 [9+1;9+5] 590 26.7 24.3 – 29.5 17.4 – 41.4
EV [cm3] 9+3 [9+2;9+5] 467 2.18 1.73 – 2.79 0.56 – 5.78
uS at 11 weeks
CRL [mm] 11+3 [11+1;11+5] 620 50.2 46.0 – 54.3 34.3 – 67.8
EV [cm3] 11+3 [11+1;11+5] 451 10.30 8.31 – 12.25 3.69 – 21.11
Abbreviations: GA, gestational age; IQR, interquartile range; min, minimum;  max; maximum; US, ultrasound; 
CRL, crown–rump length; EV, embryonic volume; mm, millimeter; cm3, cubic centimeter.
SenSiTiviTy analySeS  
To explore whether potential bias introduced by dating based on CRL affected 
our findings, we performed sensitivity analyses in 352 spontaneously conceived 
pregnancies with a regular menstrual cycle. The baseline characteristics and embryonic 
size measurements of this subgroup are shown in Supplemental table 2 and 3. 
These analyses showed effect estimates comparable to those observed in the primary 
analyses, but only CRL at 9 weeks showed a statistically significant association with 
SGA in the fully adjusted model [Supplemental table 4].  
No significant associations were observed between embryonic size or growth 
parameters at any of the time points and gestational age and birth weight 
[Supplemental table 5].
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diSCuSSion 
STaTemenT oF PrinCiPal FindingS  
In this periconceptional cohort of 757 pregnancies we observed that a larger embryonic 
size at 11 weeks of gestation was associated with smaller odds of an adverse birth 
outcome, in particular of SGA. Increased embryonic growth trajectories between 6 and 
13 weeks of gestation were also associated with smaller odds of SGA. Moreover, already 
at 9 weeks of association, embryonic size was positively associated with birth weight. 
We did not observe statistically significant associations between embryonic size or 
growth and the occurrence of preterm birth and congenital anomalies.
ComPariSon wiTh oTher STudieS  
To the best of our knowledge, we are the first to assess the associations between 
embryonic growth parameters and adverse birth outcomes this early in the first 
trimester of pregnancy. Our findings show that association between first trimester size 
and birth outcome can already be detected before 13 weeks of gestation. A large study 
[n=1,631] of Mook–Kanamori et al., conducted in the general population, also observed 
that a smaller CRL measured on two–dimensional [2D] US before 14 weeks of gestation 
is associated with an increased risk of SGA.115 We could however not reproduce the 
significant association between CRL and preterm birth. After adjustment for maternal 
health status and socioeconomic factors, it may, however, seem unlikely that common 
causes of preterm birth, such as maternal infection, are associated with first trimester 
growth. Several aspects may explain why we did not observe this association: the 
association may become visible after our observation period, is only detectable in 
very large cohorts, or is not observed in our study due to differences in methodology 
and statistical methods. Because of the large sample size of 1,631 participants, they 
were able to adjust for more health and social covariates then we were. We were not 
able to adjust for covariates such as diastolic blood pressure and hematocrit levels.115 
We did not adjust for folic acid use and smoking because of the respectively high and 
low frequency in our study population, and the equal distribution between the cases 
and controls.  
Another study on embryonic size and birth weight also observed a positive association 
between CRL measured on 2D US scans before 14 weeks of gestation and birth weight, 
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and a positive association between CRL and the odds of delivering an SGA infant.116 
This study by Bukowksi et al. was conducted in an  IVF/ICSI population. Although 
the known timing of conception in those patients facilitates proper study of this 
association, extrapolation to spontaneously conceived pregnancies may be limited. 
Though one third of our population consists of pregnancies conceived via IVF/ICSI, the 
absolute number was small, limiting the possibility to study all birth outcomes in this 
subgroup. We performed a post–hoc exploratory analysis on our primary outcome in 
this subgroup. This showed a stronger association than in the total study population, 
with already at 7 weeks of gestation a negative association between CRL or EV and 
adverse birth outcome [Supplemental table 6]. Possibly, the stronger associations 
than observed in the sensitivity analyses are caused by the exactly known timing of 
conception, which seems more reliably than in spontaneously conceived pregnancies 
with regular cycle. 
We did not observe an association between embryonic size and congenital anomalies, 
although the direction of the effect estimates [OR<1.0] were similar on all time points. 
A previous study, with patients derived from the same source population showed that 
EV, but not CRL, was smaller in the first trimester in fetuses with severe structural 
congenital anomalies.117 The absence of a statistical significant association in our 
cohort may be the result of the small sample size. Moreover, probably not all congenital 
anomalies are accompanied by altered growth. The large variety of congenital anomalies 
in our study, ranging from mild anomalies such as polydactyly to complex anomalies 
such as severe heart defects, may therefore have diluted our results. 
STrengThS and limiTaTionS  
Main strengths of our study are the large sample size, the standardized 3D US 
examinations and VR measurements which are performed already early in the first 
trimester – providing more precise and reliable measurements.111 Another strength is 
the evaluation of growth trajectories rather than only evaluation size.  
Several limitations should be noted. This study was carried out in a selected population 
in a tertiary hospital setting. This resulted in a higher maternal age, mainly Western 
geographical background, higher educational level, and higher IVF/ICSI rate than 
expected in the general population, which may have decreased the external validity. 
Validation of our findings in a general population is therefore needed, but this is 
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complicated by difficulty in enrolling patients this early in gestation. Last, although our 
sample size was large, and the relative number of cases was comparable or even higher 
than observed in previous studies, the power was still limited to study the separate birth 
outcomes which may have reduced our ability to detect potentially clinically relevant 
differences.107,116 
imPliCaTionS For CliniCal Care and reSearCh  
Our data confirm that embryonic growth is not uniform and that already in the first 
trimester a larger embryo has a smaller odds of an adverse birth outcome: an increase 
of 1 cm3 at 11 weeks of gestation is associated with a 12% smaller odds of having an 
adverse birth outcome. Earlier in pregnancy, the effect estimate is even larger, which is 
the result of the small absolute EV [~0.3 cm3] and the small absolute variance [IQR 0.16 
– 0.41] at 7 weeks. The associations with birth weight and SGA emphasize the relevance 
of adequate embryonic growth, because birth weight is associated with various traits 
and diseases in adult life.118  
Knowing that embryonic growth is not uniform and that poor growth has clinical 
consequences again raises debate on the different methods of pregnancy dating. Often 
dating is based on the menstrual cycle, but frequently reliable information is lacking on 
the menstrual cycle.114 In those women, pregnancy dating is performed by using CRL. 
In our study population, approximately one fourth of the study population was dated 
based on CRL. The most important downside of CRL dating is that this method ignores 
all [patho]physiological variation in embryonic growth. Thus, from a scientific point of 
view, pregnancies dated on CRL are less suitable for studying early embryonic growth 
and are therefore often excluded for analyses.115 When designing our study, we argued 
that misclassification may also occur in dating based on the menstrual cycle, due to 
recall bias and variation in timing of ovulation and implementation.119,120 
Moreover, our clinical research question on the impact of early embryonic growth 
was relevant in all pregnancies, including those dated on CRL. Furthermore, we were 
able to date pregnancy already at 9 weeks of gestation, which is earlier than usual in 
clinical care.28 We argued that the earlier in pregnancy the due date is determined, 
the smaller the bias of ignoring variation in growth. Therefore, the primary analyses 
were conducted in the total study sample. We additionally performed a sensitivity 
analyses in pregnancies dated on the menstrual cycle only. Compared to the main 
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analyses, although not statistically significant, the associations of embryonic size 
and growth and the outcome measures were comparable with regards to magnitude 
and direction of the effect estimates. This suggest that our main analyses are 
not importantly biased by dating on CRL. Lack of statistical significant findings is 
likely the result of lack of power in the smaller subgroup [n=352 versus n=757 in 
the full sample]. To increase the generalizability to clinical care, we suggest that in 
future studies CRL dating should not be considered an exclusion criteria, but that 
subgroup analyses should be performed to evaluate the effect in this subgroup.   
CRL dating should be performed as early in gestation as possible, which is nowadays 
possible from 7 – 8 weeks of gestation onward by using 3D US techniques and VR. 
For implementation in clinical practice, the use of 3D US is limited by standard 2D 
evaluation of the scans. The recent development of a desktop version of the Barco I–
Space is promising to enable application of 3D evaluation in clinical care, as it allows 
for real–time bedside evaluation of 3D scans.121 Improvements in 3D techniques and 
development of new measures might also improve detection of growth differences even 
before 9 weeks of gestation.
In conclusion, our study shows that associations between embryonic growth and birth 
outcome can already be detected from 9 weeks of gestation onward. The results support 
the relevance of the preconceptional period for preparing pregnancy for embryonic, 
fetal, and neonatal health – thereby also influencing health on the long term. Future 
studies should establish if stricter monitoring of embryos with smaller than expected 
size or growth is beneficial for birth outcome, and whether those embryos may benefit 
from support for parents–to–be in optimizing their health and lifestyle.  
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SuPPlemenTal Table 2 | baSeline CharaCTeriSTiCS oF SPonTaneouSly ConCeived 
and STriCTly daTed PregnanCieS       
          
Subgroup [n=352] missing data [n]
maternal characteristics
Age [years] 32.2 [29.1;35.8] 0
Geographical background Western 294 [84%] 2
Non-Western 56 [16%]
Educational level high 205 [58%] 7
Middle 107 [30%]
Low 33 [9%]
Periconceptional BMI [kg/m2] 23.9 [21.5;27.6] 0
Folic acid use 343 [97%] 1
Preconceptional initation 245 [71%] 5
Periconceptional smoking 66 [19%] 0
Nulliparous 145 [41%] 0
Conception mode Spontaneous 352 [100%] 0
IVF/ICSI 0 0
neonatal characteristics
Gestational age at birth [weeks+days] 39+0 [38+0;40+1] 0
Preterm birth 32 [9%] 0
Birth weight [grams] 3342 [3011;3715] 0
Birth weight percentile 47.4 [26.4;75.3] 0
SGA 30 [9%] 0
Sex Male 179 [52%] 0
Major congenital anomaly 11 [3%] 5
Mortality Fetal 6 [2%] 0
Early neonatal 1 [0.3%] 0
Adverse birth outcome 71 [20%] 0
Legend: Data are presented in median [interquartile range] or number [percentages]. 
Abbreviations: [k]g, [kilo]grams; BMI, body mass index; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm 
injection; SGA, small for gestational age.
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SuPPlemenTal Table 3 | ulTraSound meaSuremenTS oF SPonTaneouSly 
ConCeived and STriCTly daTed PregnanCieS
ga [iQr] n median iQr min - max
number of uS 4 2 – 6 1 – 8 
uS at 7 weeks
CRL [mm] 7+3 [7+1;7+5] 180 12.9 10.3 – 14.9 5.5 – 20.3
EV [cm3] 7+3 [7+1;7+5] 159 0.24 0.13 – 0.39 0.01 – 0.95
uS at 9 weeks
CRL [mm] 9+3 [9+1;9+4] 260 26.3 23.6 – 29.2 17.4 – 41.4
EV [cm3] 9+3 [9+1;9+4] 217 2.08 1.57 – 2.78 0.56 – 5.78
uS at 11 weeks
CRL [mm] 11+3 [11+1;11+5] 291 49.8 45.3 – 54.1 34.3 – 67.8
EV [cm3] 11+3 [11+1;11+4] 236 10.22 8.02 – 12.09 3.69 – 21.11
Abbreviations: US, ultrasound; CRL, crown-rump length; EV, embryonic volume; mm, millimeter; cm3, cubic 
centimeter; GA, gestational age; N, number; IQR, interquartile; range; min, minimum; max, maximum. 
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abSTraCT
baCkground Environmental influences during pregnancy are able to affect offspring 
phenotype with lifelong effects. Clinical applicable markers are needed to identify 
fetuses at risk for neonatal adiposity. This systematic review aims to [1] review the 
current literature on prenatal markers of neonatal fat mass, and [2] appraise the clinical 
applicability of the assessed markers. 
meThodS A systematic literature search was conducted to identify studies meeting 
the following inclusion criteria: [1] original research papers in English; [2] research 
on dynamic and measurable prenatal markers of neonatal fat mass; [3] neonatal fat 
mass measurement within one month after birth, using the four–compartment model, 
magnetic resonance imaging, dual–energy X–ray absorptiometry, or air displacement 
plethysmography. Two reviewers independently performed study selection, 
assessment of methodological [QUADAS–II] and statistical quality, and appraisal of 
clinical applicability. 
reSulTS Of 2333 studies primarily identified by the search strategy, 16 studies were 
included. Four of these were both methodologically and statistically of moderate or 
high quality. Prenatal markers investigated were ultrasound parameters, maternal 
biochemical markers, and maternal characteristics. Markers of predefined interest 
were maternal prepregnancy body mass index, fasting glucose, and hbA1c, showing 
varying results. A meta–analysis was not possible due to substantial methodological 
heterogeneity. Clinical applicability of all markers was rated poor. 
ConCluSionS Although associations were found, no useful marker was identified, due 
to lack of methodological and statistical quality, inconsistent results, and poor clinical 
applicability. No markers were investigated in the periconceptional and embryonic 
period. 
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inTroduCTion
The worldwide increasing prevalence of obesity and features of metabolic syndrome 
in children leads to increasing morbidity and mortality at young age.122 Obesity is a 
multifactorial condition, caused by environmental, biological, and genetic factors, 
initiated in early life. The hypothesis of ‘developmental origins of health and disease’ 
[DOhaD] states that environmental influences during pregnancy are able to affect 
offspring phenotype with lifelong effects.2,107,123 Epigenetic changes are thought to 
be pivotal in this long–term programming of fetal endocrine and cardio–metabolic 
functioning and consequently fat and lean mass development.124–126 Both fetal over– and 
undernutrition have been related to obesity, and consequently increased susceptibility 
for non–communicable diseases later in life.123 Birth weight is often used as a proxy 
of fetal growth. however, birth weight alone poorly predicts long–term risks as it does 
not fully reflect the effects of fetal growth and programming of fat mass.127 Therefore, 
neonatal body composition, rather than birth weight, may be a more accurate 
predictor of risk for non–communicable diseases later in life.128 If we would be able to 
predict neonatal fat mass in the prenatal period, infants at risk for adiposity could be 
identified earlier. This would allow for early interventions to optimize fetal and neonatal 
growth and metabolic development. Prevention of unfavorable programming might 
help reduce non–communicable diseases in children, adults, and their offspring.129 
The aims of this study are to: [1] provide a systematic review of the literature on prenatal 
markers or predictors of neonatal fat mass, and [2] appraise the clinical applicability of 
the assessed markers. 
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meThodS 
liTeraTure SearCh and STudy SeleCTion 
A systematic search was conducted using computerized bibliography databases until 
February 2015 to identify original articles on prenatal markers of neonatal fat mass. 
Medline, Google Scholar, Web of Science, Pubmed Publisher, Cochrane, and Embase 
were comprehensively searched using keywords as described in the supplements. Two 
authors [JR and MV] independently screened the titles and abstracts of all citations 
retrieved and excluded those clearly outside the scope of the study. Papers potentially 
eligible for inclusion were read in full text and included after consensus. Reference lists of 
all included papers were screened for potentially relevant publications not identified by 
our search. Studies were included for analysis if they met the following criteria, defined 
prior to the search; [1] Assessment of potential prenatal markers of neonatal fat mass 
in neonates; [2] Full report articles, written in English, with no limitation on publication 
date; [3] Use of measurable and dynamic prenatal parameters as markers, e.g., body 
mass index [BMI], laboratory diagnostics, or ultrasound parameters; [4] Fat mass as 
primary outcome measure, measured within one month after birth; [5] Use of accurate 
methods to measure body composition, comprising the four–compartment model, air 
displacement plethysmography [ADP], magnetic resonance imaging [MRI], and dual–
energy X–ray absorptiometry [DXA].130–132 Details of these methods are provided in 
Table 1. Studies using less accurate methods for measurement of body composition in 
neonates, such as double–labelled water, skinfold, and bioelectrical impedance analysis 
[BIA], were excluded. These methods are considered less accurate due to influences 
of fluid distribution and high inter–observer differences.133,134 Secondly, studies using 
only static pregnancy characteristics [e.g., sex and parity] as prenatal markers were 
excluded because these cannot be influenced by interventions.
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Table 1 | overview oF inCluded meThodS For neonaTal body ComPoSiTion 
meaSuremenT
adP mri dxa Four compartment model
whole body or regional 
estimates?
Whole body Whole body and 
regional estimates
Whole body and 
regional estimates
Whole body
outcome measure FM, FFM FM FM, FFM, BMC FM, TBW, BMC, 
protein
outcome unit gram or %FM ml or m³ gram or %FM gram or %FM
Pro's No radiation 
exposure
Whole body vs 
regional fat
Whole body vs 
regional fat
Use of different 
methods to 
determine body 
composition
high level of 
accuracy 
No radiation 
exposure
Fast
Contra's Expensive device Very sensitive to 
subject motion 
Differences 
between 
manufacturers, 
hardware and 
software algorithms
Impractical
Only whole body 
data
Expensive Radiation exposure Time consuming
Very sensitive to 
subject motion 
Abbreviations: ADP, air displacement plethysmography; MRI, magnetic resonance imaging; DXA, dual energy 
X–ray absorptiometry; FFM, fat free mass; ml, milliliter; m3, cubic meter; BMC, bone mineral content; FM, fat 
mass 
QualiTy aSSeSSmenT 
Methodological quality of the included studies was assessed using the QUADAS–II 
checklist by two researchers [JR and MV] independently.135 This tool is designed to 
assess the quality of primary diagnostic accuracy studies, with high interrater reliability, 
construct validity, and internal consistency.136 Four main domains [patient selection, 
index test, reference test, and patient flow] are assessed in terms of risk of bias [low, 
high, or unclear]. The first three domains are also assessed on applicability of the study 
for the review question. On the basis of the degree of risk of bias of the different domains, 
methodological quality was rated as high, moderate, or poor. Quality of studies with 
an unclear risk of bias in two or more domains and with ‘high risk of bias’ in at least 
one domain was classified as poor in any case. Any disagreements were resolved via 
discussion and consensus with JR, MV, and RJ. 
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STaTiSTiCal QualiTy As the QUADAS–II checklist does not take into account statistical 
methods for interpretation of study quality, we rated the statistical quality separately. 
Statistical quality was considered high when prediction models were developed. Studies 
of moderate statistical quality used well described and performed prognostic models 
derived from multivariable analysis or well described and performed association 
models. Studies using poorly described and performed prognostic or association 
models, using only univariable analysis methods or correlation coefficients were 
considered to be poor of statistical quality.137
CliniCal aPPliCabiliTy We considered only the results of studies with moderate or 
high methodological and statistical quality as evidence for potentially relevant markers 
and assessed clinical applicability only in studies meeting these criteria. Clinical 
applicability was assessed from the following items; logistic availability [possible to 
perform measurements in every setting], costs of measurement, level of difficulty to 
perform measurements, time to result after performance of measurement, and clinical 
relevance of the effect size.
meTa–analySiS Meta–analysis was considered suitable provided [1] studies showed 
limited heterogeneity with respect to methodology and statistical methods, and [2] the 
same prenatal marker was used in two or more studies of moderate or high quality. 
heterogeneity was assessed based on [1] patient inclusion criteria; [2] design of the 
studies [both methodological and statistical]; and [3] prenatal and postnatal outcome 
measures and timing and technique of measurements. 
STudy CharaCTeriSTiCS and daTa ColleCTion The following data were extracted: 
[1] characteristics of study population [maternal, pregnancy related, and neonatal 
characteristics; [2] design of study, including prenatal markers and postnatal measurement 
of fat mass; [3] methods of analyses; and [4] results [including effect sizes] of the study.
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reSulTS
SearCh reSulTS 
Figure 1 presents a flow chart of the study selection procedure. A search, performed 
on February 12th 2015, resulted in 2333 unique studies. After reference checking of the 
studies identified by the search, five more studies were included, leading to a final of 16 
included studies.   
Figure 1 | FlowCharT oF inCluded STudieS 
STudy CharaCTeriSTiCS 
Table 2 provides details of these 16 studies. All studies were published between 2008 
and 2015. Sample sizes varied between 23 and 948 infants. Inclusion and exclusion 
criteria differed between studies. Three studies specifically included obese pregnant 
Abstracts identified 
by search [n=2333]
Excluded based on 
abstract [n=2276]
Excluded based on 
full–text [n=46]
Included after 
reference checking 
[n=5]
Full–text 
assessment
 [n=57]
Included [n=11]
Total included 
[n=16]
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women.138–140 One study investigated women with gestational diabetes mellitus [GDM].141 
The prenatal markers studied can be divided in 3 categories; ultrasound measures, 
biochemical markers from maternal blood, and maternal characteristics. Six studies 
investigated associations between ultrasound [2D and 3D] measures and neonatal 
fat mass. All ultrasound measures were assessed in the third trimester of pregnancy. 
Not only commonly used measures were assessed, such as expected fetal weight 
[EFW] and abdominal circumference [AC]142–144, but also newly developed techniques, 
including factional thigh volume [TVol], fractional arm volume [AVol], thigh fat [TF], fetal 
liver blood flow, and fetal abdominal subcutaneous tissue [FAST].143,145–147 Six studies 
investigated the association between biochemical markers and neonatal fat mass. 
Maternal blood samples were obtained in the second and third trimester of pregnancy. 
Assessed were fasting glucose and postprandial glucose, hbA1c, insulin, leptin, total 
cholesterol, high–density lipoprotein cholesterol [hDL–c], triglycerides [TG], free fatty 
acids [FFA], C–peptide, insulin–like growth factor 1 [IGF 1], insulin–like growth factor 
binding protein 3 [IGFBP 3], and adiponectin.140,141,144,148–150 In nine studies maternal 
characteristics were assessed, including prepregnancy BMI and gestational weight 
gain [GWG].138,139,141,144,148,150–153 Eleven studies used ADP, four used DXA, and one used 
MRI scans for the assessment of neonatal fat mass [Table 2]. None of the studies used 
the four–compartment model. 
QualiTy aSSeSSmenT
Details of methodological quality assessment are presented in Table 3, for each 
study separately. Methodological quality of two studies was assessed as high, of 
seven studies as moderate, and of seven studies as poor. Two or three domains of 
twelve studies could not be assessed due to missing information.  Assessment of 
different domains addressed by the QUADAS–II is discussed in more detail below. 
generalizabiliTy Study populations ranged from very small [n=23] to large 
[n=948], and exceeded 100 subjects in eight studies.138,145,148–153 Patient inclusion 
criteria differed widely between the studies. Most studies only included healthy 
women, singleton pregnancies, and healthy term born infants and excluded 
mothers with non–communicable diseases and medication use that could influence 
fetal growth and fat mass deposition. Two studies did not describe exclusion 
criteria.145,152 In two studies only Caucasian women were included, while others only 
included women with diabetes mellitus or pregnancies at high risk for intra–uterine 
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growth retardation.141,142,146,147 Some studies did not adequately describe the study 
characteristics.144,145,148,151,153
SeleCTion biaS Many studies did not adequately describe the methods used for 
patient selection; in most cases it was unclear whether a random sample of patients 
was selected. Three studies included patients from a larger study, but the selection 
process was not described in two of these studies.138,145,150 None of the studies reported 
specifically whether the study population was derived from the general population or 
from a hospital population. 
reProduCibiliTy One study did not report on the methodology of a newly developed 
ultrasound measurement.145 One study mentioned the reproducibility of a new 
ultrasound parameter, TVol, but did not report the concrete values.147 No other study 
reported on the reproducibility of the assessed marker. 
blinding One study explicitly mentioned blinding of prenatal test results until the data 
analysis.152 None of the other studies mentioned blinding for prenatal test results during 
body composition measurement or data collection. 
QualiTy oF STaTiSTiCal aPProaCh 
Two studies reported on sample size calculation.140,142 Statistical methods used in the 
different studies differed widely, as shown in Table 4. Four studies used correlation 
coefficients to evaluate the association between the prenatal marker and neonatal fat 
mass.141,145,148,152 Six studies used association models142,144,146,147,151,153 and ten prognostic 
models.138–141,143,145,148–150,152 No prediction models were reported. The prognostic [regression] 
models were often of poor quality, due to inadequate description of the [pre]selection of 
variables into the model. No study scored ‘high’ on statistical quality. 
aPPraiSal oF CliniCal aPPliCabiliTy
None of the reports discussed the clinical value of the expected or observed findings. 
In total, four studies were both methodologically and statistically of moderate or high 
quality.148,149,152,153 In these studies, three markers were assessed in more than one study 
including prepregnancy BMI [in three studies], maternal fasting glucose, and hbA1c 
[both in two studies]. All three were considered to be of poor clinical applicability 
because they predicted slight differences in fat mass. 
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meTa–analySiS 
A meta–analysis was not performed because of substantial heterogeneity between 
studies. This judgement was based on differences in design [including inclusion and 
exclusion criteria, selection process, and timing and technique of measurements] and 
methodological and statistical quality. This is also illustrated in Table 2, in which the 
main characteristics of all studies are provided, and in Table 3 and 4, which respectively 
offer a quick overview of quality of the studies and of used statistical methods.  
ouTComeS
The results of the separate studies are presented in Table 4. Overall findings for each 
separate method of body composition measurement are described below.  
air diSPlaCemenT PleThySmograPhy Five ADP studies assessed the use of prenatal 
ultrasound parameters for predicting neonatal fat mass. Fractional thigh volume was the 
only parameter assessed in two studies, with conflicting results.143,147 Studies assessing 
the association between common ultrasound parameters [e.g., EFW and AC] and fat 
mass found varying results, with explained variances ranging from 0.14 to 0.28.142–144
Maternal blood glucose levels [BGLs] and hbA1c were assessed in respectively four 
and two studies, with conflicting results between the studies, and between boys and 
girls.140,141,148,149 Assessment of leptin showed inconsistent results as well.140,144 Insulin and 
triglycerides were not associated with neonatal fat mass in two studies. Maternal BMI 
and GWG were assessed in 5 studies using ADP.139,141,144,148,153 Two studies did not find a 
significant association between fat mass and maternal BMI and GWG.139,144 In contrast, 
three others found a significant increase in percentage body fat [%BF] with increasing 
prepregnancy BMI and GWG.141,148,153  
dual–energy x–ray abSorPTiomeTry Positive relationships were found between fetal 
liver blood flow, fasting glucose, GWG, obesity and neonatal fat mass [gram and %] 
using DXA.138,145,150,151 One study, assessing the association between GWG and neonatal 
fat mass, developed internal Z scores for fat mass, and expressed the found association 
using these Z scores. They did not report on their internal mean and Z score.151  
mri MRI was used in one study. A positive association was found between maternal BMI 
and total adipose tissue.152 
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Table 3 | aSSeSSmenT oF meThodologiCal QualiTy baSed on QuadaS–ii, SeParaTely 
For eaCh STudy 
Study riSk oF biaS aPPliCabiliTy ConCernS
Patient 
selection
index test reference 
standard
Flow and 
timing
Patient 
selection
index
 test
reference 
standard
o’Connor [28] + ? ? – – + +
o’Connor [29]  – ? ? + – + +
law [36] – + ? + – + +
lee [25] – ? ? ? ? + +
moyer–mileur [26] + ? ? + – + +
Crume [30] + ? ? + + + +
josefson [22] + – ? – + + +
au [24] + ? ? + + + +
lingwood [23] + ? ? + – + +
Starling [34] + ? ? + + + +
hull [21] + + ? + + + +
godfrey [27] – ? ? – + + +
Friis [31] + ? ? ? + + +
Carlsen [20] – ? ? + – + +
Crozier [32] + ? ? – + + +
modi [33] – + + + + + +
+ Low Risk  – high Risk  ? Unclear Risk [not reported in paper]
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d|SCuSSion 
This review provides a complete overview and a systematic methodological quality 
assessment of 16 studies on prenatal dynamic markers associated with neonatal fat 
mass. We aimed to appraise the clinical applicability of the large number of assessed 
markers. Only four studies met our criteria, resulting in three markers of interest; 
maternal prepregnancy BMI, fasting glucose, and hbA1c. yet, none of these appeared 
to be clinical applicable to identify fetuses at risk for neonatal adiposity. 
The association between maternal prepregnancy BMI and neonatal fat mass appears to 
be complex. When analyzed as continuous variable, maternal prepregnancy BMI was 
positively associated with neonatal fat mass.152,153 however when assessed categorical, 
results per category were conflicting.148 This can partly be explained by the association 
between maternal over– and undernutrition and offspring obesity.123 Moreover, one could 
argue that this artificial categorizing of BMI could, in theory, lead to conflicting results 
by itself. Nevertheless, the earlier reported impact of prepregnancy BMI on offspring 
cardiovascular health confirms the clinical importance of this marker.154 The dynamic 
character of prepregnancy BMI can be questioned. As we defined in the inclusion criteria, 
we aimed to focus on dynamic markers, which may be influenced by [lifestyle] interventions. 
In general, BMI is a dynamic marker, however, when assessed at one time point it is rather 
static. The ‘prepregnancy period’ was not well defined and may have included a long 
time span before pregnancy. Still, we decided to consider maternal prepregnancy BMI 
a dynamic marker and to include it in the review. Several studies included in this review 
did investigate GWG, but all were of poor quality. None investigated the influence of the 
change in BMI or maternal body composition during pregnancy on neonatal fat mass. 
Fasting glucose levels and hbA1c are the other markers of interest. Only one study found 
a positive association with neonatal fat mass, while others did not find a significant 
association.148,149 Glucose homeostasis during pregnancy is altered by impaired insulin 
sensitivity and increased fetal glucose consumption. Both insulin resistance and fetal 
glucose consumption start in the second trimester, and peak in the third trimester of 
pregnancy.155 Timing of measurements is therefore crucial, and differences in timing 
[either in the second or third trimester of pregnancy] limit the comparison and 
interpretation of these studies. The findings of O’Connor et al. stress the importance 
of timing of measurements as well; they showed inconsistent results of TF and FAST 
measurements at different gestational ages.147 
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Ultrasound measurements are performed routinely in most pregnancies. Unfortunately, 
all studies investigating ultrasound markers were of poor methodological or statistical 
quality. Standard ultrasound parameters do not seem to be associated with neonatal 
fat mass. however, whereas some of the newly developed ultrasound parameters were 
associated with neonatal fat mass [Table 4], the clinical applicability of these markers 
could not be judged due to poor methodological quality.
limiTaTionS oF reviewed STudieS
Substantial methodological heterogeneity and incomplete reporting complicated 
the interpretation of results and made it impossible to perform a meta–analysis. For 
example, incomplete reporting on selection criteria or selection of specific patient 
groups limited generalizability. Also, statistical methods differed widely. Some studies 
only performed univariable analyses or calculated correlation coefficients, with limited 
scientific value. Appropriate methods accounting for confounders are multivariable 
and prognostic models, as performed in the higher quality studies. None of these 
studies used prediction modeling, which is considered the optimal method for risk 
prediction. Only two studies reported on sample size calculation. Lack of statistical 
significance in many studies may well be due to lack of power. Due to wide ranges in 
normal distribution of fat mass in neonates85, a relatively large sample size is required 
to determine a significant association. Furthermore, only one study mentioned blinding 
for the prenatal results, while blinding for prenatal and postnatal test results is essential 
to prevent risk of bias.152 Computerized methods for measuring body composition, 
such as DEXA or ADP, may theoretically reduce the risk of selection bias, but still do not 
exclude it as the results can be interpreted in the light of knowledge of prenatal data. 
Timing of measurement needs to be addressed, from two perspectives. For practical 
reasons, almost all assessed markers were investigated in the third trimester of 
pregnancy. As the DOhaD hypothesis states that the embryonic and fetal periods are 
crucial phases in fetal programming, it may be relevant to look for markers at an earlier 
stage of pregnancy.125 The earlier detection of fetuses at risk would probably result in 
better opportunities to improve environmental factors and alter long–term outcome. 
Timing of body composition measurement after birth is also relevant. This varied between 
within 24 hours to 35 days postpartum in the reviewed studies. Measurement soon after 
birth highly reflects fetal nutritional status and growth, while after days to weeks body 
composition is influenced by factors such as volume and type of feeding.156 however, the 
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most sensitive moment for prediction of long–term outcome still needs to be determined. 
Moreover, we faced problems with the interpretation of clinical applicability as statistically 
significant associations are not always of clinical value. A small increase of 0.12% in %BF 
per unit increase in BMI may be statistically significant in large cohorts but not relevant in 
individual patients.153 As mentioned above, we aimed to take several factors into account for 
assessment of clinical applicability. In practice, we noticed that all markers had such small 
effect sizes that we did not have to assess the other factors to decide on the applicability of 
the marker. Evidence is still lacking on the exact effect of neonatal fat mass on long–term 
health. Whether such small differences in fat mass are related to increased risk of childhood 
obesity later in life is not clear yet. Markedly, clinical applicability of findings was neither 
addressed nor discussed in any of the papers.
STrengThS oF ThiS review
Strength of this review are the use of multiple electronic database searches and clearly 
defined inclusion criteria to identify all relevant studies on prenatal markers of neonatal 
fat mass. The overview of methodological quality and effect sizes provide an insight into 
studies on this subject. Methodological quality was systematically evaluated with the 
QUADAS–II, a widely used and validated tool, with high interrater reliability.136 A good 
measure of reliability was further ensured by having the QUADAS–II scored by two 
authors independently and discussing discrepancies in consensus meetings. Some 
items were difficult to score and many items were rated “unclear”, as also reported 
by others.136 As the QUADAS–II does not provide assessment of statistical quality, we 
added rating of the statistical approaches, based on current expert opinion on studies 
assessing associations or predictors.
limiTaTionS oF ThiS review
Our search strategy was limited to full report papers, written in English. This may 
theoretically have led to missing of relevant studies. We did not provide a meta–
analysis of the data due to heterogeneity of the results, which might facilitate an 
easier interpretation of the results. It should be noted that meta–analyses are very 
useful for randomized controlled trials [RCTs], but for cohort studies its value is 
often debated. In cohort studies, the risk for publication bias [studies with negative 
results not being published] is considerably higher compared to RCTs, which 
influences the results of a meta–analysis substantially.157 Moreover, differences in 
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quality often lead to a too diverse collection of data to provide a meta–analysis. 
Therefore, a clear overview of the literature is often of more value than an artificially 
performed meta–analysis with high heterogeneity and studies of poor quality.158  
An extra complicating factor of comparison of the different studies is the inclusion 
of different methods for determination of neonatal fat mass, which are difficult to 
compare. For example, it is known that DXA systematically overestimates fat mass 
compared to ADP.159 however, we aimed to provide an up–to–date overview of the 
literature on all validated and accurate methods of body composition measurement 
in neonates.133 Only dynamic markers were included in this review, as the primary aim 
of this review was to detect markers that can be monitored [and possibly influenced] 
during gestation. In our opinion, the ultimate goal is to have a prediction model, which 
can serve as a clinical tool to determine the risk of adverse long–term health. For such 
a model to be accurate, static parameters, such as parity or ethnicity, likely need to be 
entered in the model as well.160 
FuTure PerSPeCTiveS
Radiological techniques have evolved over the last decades and offer new opportunities 
to measure very small structures, even in early pregnancy. An interesting method, 
not yet examined, may be assessment of [abdominal] fat mass by fetal MRI. This 
method is not yet widely available, however, and is expensive. Ultrasonography might 
be a more promising method, as it is relatively cheap, patient friendly, repeatable, 
and can be performed in all clinical and outpatient settings. The development and 
implementation of 3D ultrasonography in clinical practice, allowing for measurement 
of specific structures, has high potential.161 Moreover, individual longitudinal growth 
patterns presumably have more predictive value for long–term health than a single 
measurement.162 Although some studies measured ultrasound markers repeatedly 
over time, none have analyzed growth data longitudinally yet. Moreover, as mentioned 
above, screening earlier in pregnancy would lengthen the window of opportunities 
for interventions to prevent adverse programming, and thereby adverse growth and 
development.41,124 For future development of risk profiling, it may be helpful to combine 
earlier mentioned markers with complex factors assumed to be related to the underlying 
fetal programming. Promising in this respect are fetal and maternal epigenetic patterns 
and the fetal hippocampus–hypothalamo–pituitary–adrenal [hhPA] axis, which is 
known to be associated with the risk of non–communicable diseases in adulthood.123 
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ConCluSion
We conclude that so far clinically validated and applicable markers for identification of 
fetuses at risk for neonatal adiposity are lacking. Ultrasound measures, biochemical 
markers and maternal characteristics were evaluated in studies with generally poor 
methodological and statistical quality and inconsistent results. Fat mass is determined 
by multiple factors and may only be predicted prenatally by complex prediction 
models. Further development of sophisticated fetal radiographic parameters, probably 
combined with laboratory measures and possibly with [epi]genetic risk profiling, is 
needed to identify fetuses at risk for altered neonatal fat mass.
phd jor_book.indb   86 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 87
87
Prenatal markers of neonatal fat mass: a systematic review
SuPPlemenTS
embase.com
['body composition'/exp OR 'lean body weight'/de OR [[body NEAR/3 [composit* OR distribut* OR water OR 
potassium OR fat OR lean]] OR [[fat OR lean OR adipose] NEAR/3 [distribut* OR percent* OR composit* OR mass 
OR tissue]]]:ab,ti] AND ['immature and premature labor'/exp OR 'low birth weight'/exp OR 'intrauterine growth 
retardation'/de OR 'prenatal growth'/exp OR macrosomia/de OR [[[prematur* OR 'pre mature' OR 'pre maturity' OR 
preterm* OR 'pre term'] NEAR/6 [infant* OR neonat* OR birth*  OR child* OR newborn* OR baby OR babies OR 
born]] OR [low* NEAR/3 ['birth weight' OR birthweight]] OR LBW OR VLBW OR ELBW OR SGA OR [small NEAR/3 
[age OR date]] OR IUGR OR [[intrauterine OR 'intra uterine'] NEAR/3 [retard* OR restrict*]] OR [[fetus OR fetal OR 
foetus OR foetal OR prenatal OR embryo*] NEAR/6 [growth* OR develop* OR lean OR fat]] OR macrosom*]:ab,ti] 
NOT [[animals]/lim NOT [humans]/lim] NOT [[adult/exp OR adulthood/de OR adolescent/exp OR adolescence/exp 
OR child/de OR 'preschool child'/de OR 'school child'/de] NOT newborn/exp]
medline [ovidSP]
[exp "body composition"/ OR [[body ADJ3 [composit* OR distribut* OR water OR potassium OR fat OR 
lean]] OR [[fat OR lean OR adipose] ADJ3 [distribut* OR percent* OR composit* OR mass OR tissue]]].ab,ti.] 
AND ["Premature Birth"/ OR exp "Infant, Premature"/ OR exp "Infant, Low Birth Weight"/ OR "Fetal Growth 
Retardation"/ OR fetus/gd OR "Fetal Development"/ OR "Fetal Macrosomia"/ OR [[[prematur* OR "pre mature" 
OR "pre maturity" OR preterm* OR "pre term"] ADJ6 [infant* OR neonat* OR birth*  OR child* OR newborn* OR 
baby OR babies OR born]] OR [low* ADJ3 ["birth weight" OR birthweight]] OR LBW OR VLBW OR ELBW OR SGA 
OR [small ADJ3 [age OR date]] OR IUGR OR [[intrauterine OR "intra uterine"] ADJ3 [retard* OR restrict*]] OR 
[[fetus OR fetal OR foetus OR foetal OR prenatal OR embryo*] ADJ6 [growth* OR develop* OR lean OR fat]] OR 
macrosom*].ab,ti.]  NOT [exp animals/ NOT humans/] NOT [[exp adult/ OR adolescent/ OR exp child/ OR exp 
"infant"/] NOT "infant, newborn"/]
Cochrane 
[[[body NEAR/3 [composit* OR distribut* OR water OR potassium OR fat OR lean]] OR [[fat OR lean OR adipose] 
NEAR/3 [distribut* OR percent* OR composit* OR mass OR tissue]]]:ab,ti] AND [[[[prematur* OR 'pre mature' 
OR 'pre maturity' OR preterm* OR 'pre term'] NEAR/6 [infant* OR neonat* OR birth*  OR child* OR newborn* 
OR baby OR babies OR born]] OR [low* NEAR/3 ['birth weight' OR birthweight]] OR LBW OR VLBW OR ELBW 
OR SGA OR [small NEAR/3 [age OR date]] OR IUGR OR [[intrauterine OR 'intra uterine'] NEAR/3 [retard* OR 
restrict*]] OR [[fetus OR fetal OR foetus OR foetal OR prenatal OR embryo*] NEAR/6 [growth* OR develop* OR 
lean OR fat]] OR macrosom*]:ab,ti]  NOT [[[mh ^adult] OR [mh ^adolescent] OR [mh ^child] OR [mh ^infant]] 
NOT [mh ^"infant, newborn"]]
web–of–science 
TS=[[[[body NEAR/3 [composit* OR distribut* OR water OR potassium OR fat OR lean]] OR [[fat OR lean OR 
adipose] NEAR/3 [distribut* OR percent* OR composit* OR mass OR tissue]]]] AND [[[[prematur* OR "pre 
mature" OR "pre maturity" OR preterm* OR "pre term"] NEAR/6 [infant* OR neonat* OR birth*  OR child* OR 
newborn* OR baby OR babies OR born]] OR [low* NEAR/3 ["birth weight" OR birthweight]] OR LBW OR VLBW 
OR ELBW OR SGA OR [small NEAR/3 [age OR date]] OR IUGR OR [[intrauterine OR "intra uterine"] NEAR/3 
[retard* OR restrict*]] OR [[fetus OR fetal OR foetus OR foetal OR prenatal OR embryo*] NEAR/6 [growth* 
OR develop* OR lean OR fat]] OR macrosom*]]  NOT [[adult* OR adolescen* OR child*] NOT newborn*] NOT 
[[animal* OR rat OR rats OR mouse OR mice OR rodent* OR pig OR pigs OR swine* OR sheep OR babboon OR 
monkey OR primate*] NOT [human*]]]  
Pubmed publisher
["body composition"[mh] OR [[body composit*[tiab] OR body fat*[tiab]]] OR [[fat[tiab] OR lean[tiab] OR 
adipose[tiab]] AND [distribut*[tiab] OR percent*[tiab] OR composit*[tiab] OR mass[tiab] OR tissue[tiab]]]]] 
AND ["Premature Birth"[mh] OR "Infant, Premature"[mh] OR "Infant, Low Birth Weight"[mh] OR "Fetal 
Growth Retardation"[mh] OR fetus[mh]gd OR "Fetal Development"[mh] OR "Fetal Macrosomia"[mh] OR 
[[[prematur*[tiab] OR pre matur*[tiab] OR preterm*[tiab] OR pre term*[tiab]] AND [infant*[tiab] OR 
neonat*[tiab] OR birth*[tiab]  OR child*[tiab] OR newborn*[tiab] OR baby[tiab] OR babies[tiab] OR born[tiab]]] 
OR low birth weight*[tiab] OR low birthweight*[tiab] OR LBW OR VLBW OR ELBW OR SGA[tiab] OR small for 
gestational age*[tiab] OR small for date[tiab] OR IUGR[tiab] OR [[intrauterine[tiab] OR intra uterine*[tiab]] AND 
[retard*[tiab] OR restrict*[tiab]]] OR [[fetus[tiab] OR fetal[tiab] OR foetus[tiab] OR foetal[tiab] OR prenatal[tiab] 
OR embryo*[tiab]] AND [growth*[tiab] OR develop*[tiab] OR lean[tiab] OR fat[tiab]]] OR macrosom*[tiab]]] 
NOT [animals[mh] NOT humans[mh]] NOT [[adult[mh] OR adolescent[mh] OR child[mh] OR "infant"[mh]] NOT 
"infant, newborn"[mh]] AND publisher[sb]
google Scholar 
"body composition|distribution|water|potassium|fat"|"fat  distribution|percentage|composition" 
prematurity|prematur|preterm|LBW|VLBW|ELBW|SGA|IUGR –adult –adulthood –adolescent –adolescence
  
phd jor_book.indb   87 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 88
phd jor_book.indb   88 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 89
FeTal FraCTional 
Thigh volume: 
an early 3d 
ulTraSound 
marker oF 
neonaTal 
adiPoSiTy
Pediatr Obesity. 
2017 Jul 28. 
Jorine A. Roelants
Marijn J. Vermeulen
Irene V. Koning
Irene A.L. Groenenberg 
Sten P. Willemsen
Anita C.S. hokken–Koelega
Koen F.M. Joosten 
Irwin K.M. Reiss
Régine P.M. Steegers–Theunissen
phd jor_book.indb   89 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 90
CHAPTER 04
90
abSTraCT 
baCkground The predisposition for obesity is suggested to originate in the prenatal 
period. Prenatal markers are needed to identify fetuses at risk for neonatal adiposity, as 
early marker of childhood obesity. 
objeCTive The aim of this study is to assess the association between fetal fractional 
thigh volume [TVol] and neonatal percentage body fat from midgestation onward.    
meThodS In this perinatal cohort study, singleton pregnancies with term born infants 
were included. Fetal TVol was measured on three–dimensional ultrasound scans 
[3D US] obtained at 22, 26, and 32 weeks of gestation. Neonatal body composition 
measurement [percentage body fat, [%BF]] was planned between 42+0 and 42+6 weeks 
postmenstrual age. Cross–sectional and longitudinal linear regression analyses were 
performed.
reSulTS Seventy–nine mother–child pairs were included. Median [interquartile 
range] TVol increased from 7.6 [7.1;8.5] cm3 at 22 weeks to 36.5 [33.8;40.9] cm3 at 
32 weeks. Median neonatal %BF was 14.3% [11.7;17.0]. TVol at 22 weeks [β=–1.58, 
95%CI 2.45; –0.70, explained variance 31%] was negatively associated with %BF, but 
no associations were found at 26 and 32 weeks of gestation. TVol growth between 22 
and 32 weeks of gestation [explained variance 18%] was also statistically significantly 
negatively associated with %BF. 
ConCluSionS Fetal TVol is a promising 3D US marker for prediction of neonatal 
adiposity from mid–gestation onward. 
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inTroduCTion
The increasing prevalence of childhood obesity and its long–term health consequences lead 
to higher disease burden and healthcare costs already in early life.163,164 Lifestyle programs 
and interventions focusing on secondary prevention of childhood obesity have limited 
effects as the predisposition of obesity is suggested to originate in the periconceptional 
and prenatal periods.4,165 Prenatal markers of neonatal adiposity, considered a proxy of 
childhood obesity, are needed to predict the risk for neonatal adiposity and to monitor the 
effect of future prenatal prevention strategies for childhood obesity. 
Previous studies have assessed the use of prenatal imaging as marker for neonatal 
adiposity.166 Standard obstetrical two–dimensional [2D] biometric measures, such 
as estimated fetal weight, do not predict neonatal adiposity well.144,167,168 A promising 
three–dimensional ultrasound [3D US] marker is fractional thigh volume [TVol].167 
In the third trimester of pregnancy, this soft–tissue marker is highly associated with 
neonatal percentage fat mass.167,169 To the best of our knowledge, the usefulness 
of earlier TVol measurement or TVol measured serially has not yet been studied. 
As fetal fat accumulation increases exponentially in the third trimester, TVol may be 
most informative in late pregnancy.31 On the other hand, both 3D US scanning and 
TVol measurements are technically easier to perform earlier in pregnancy, and early 
measurements provide a longer time frame for prevention strategies.    
The primary aim of our study was to assess the association between TVol at different 
time points during the second half of pregnancy and neonatal adiposity. The 
secondary aim was to evaluate the association between TVol growth, based on serial 
measurements, and neonatal adiposity. We hypothesized that TVol is associated with 
neonatal percentage fat mass from midgestation onward, and that the association 
between TVol growth and neonatal percentage fat mass is stronger than the association 
between single TVol measurements and neonatal percentage fat mass.
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meThodS
This study was embedded in the ongoing Rotterdam Periconceptional Cohort study.104 
Between November 2013 and July 2015, we invited women with an ongoing singleton 
pregnancy for prenatal 3D US examinations in the second and third trimesters of 
pregnancy and for cranial ultrasound in the neonatal period. Between September 2014 
and September 2016, body composition [BC] measurement was added to the postnatal 
follow–up visit. For the present analysis, we selected infants who were term born 
[≥ 37 weeks of gestation at birth], without congenital anomalies [EUROCAT criteria] 
and who had a BC measurement at the postnatal visit.170 All participating women and 
their partners gave written informed consent for both the Predict study and the follow–
up study. The study was performed at the Erasmus MC – Sophia Children’s hospital, 
Rotterdam, the Netherlands. Both the Central Committee of human Research in The 
hague, the Netherlands and the regional Medical Ethical and Institutional Review Board 
of Erasmus MC, University Medical Center, Rotterdam, the Netherlands, approved the 
study [MEC 2004–227, amendment 08 Nov 2014]. 
PrenaTal SCanning 
Serial 3D US examinations were performed at 22, 26, and 32 weeks of gestation by 
a certified sonographer [IK] by using the Voluson E8 system [GE Medical Systems, 
Zipf, Australia] with a 1–7 Mhz transabdominal transducer. Standard 2D biometric 
measurements were performed during the examinations. 3D volumes of the fetal 
thigh were obtained in the standard acquisition plane for femur diaphysis length 
measurement.28 TVol [cm3] was measured offline by one operator [JR] using validated 
commercially available 3D software [4DView, version 5.0 or higher, GE Medical Systems]. 
Volume measurement of the fetal thigh is based on 50% of the femoral diaphysis 
length. Five equidistant axial limb slices are shown by the software and are traced 
manually for each image slice. TVol is calculated automatically after tracing five slices 
[Supplemental Figure 1].167 As there is no evidence for length or volume differences 
between the left and right femur, measurements were performed on the thigh closest 
to the transducer. TVol measurements were performed in triplicate on each scan. If the 
smallest and largest TVol measurement differed more than 10%, a fourth measurement 
was performed. hereafter, the outlier of the four measurements was removed. 
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The mean of the three measurements was used in the analyses. 3D scans of very low 
quality, with severe movement artefacts or an inadequate sweep angle, were excluded. 
We performed reliability analyses of TVol in this cohort by having TVol measurements of 
30 randomly selected scans repeated by a second operator [IK]. The analyses showed 
excellent intra– and interobserver reliability [intraclass correlation coefficients above 0.9]. 
ouTCome meaSure
The outcome measure was neonatal body fat as percentage of total body weight [%BF], 
obtained via air displacement plethysmography [PEA POD®, COSMED]. This validated 
method calculates the absolute fat mass and fat free mass by direct measurement of 
body volume and body mass, based on the whole–body densitometry principle.95,96 
BC measurements were planned in the early neonatal period, between 42+0 and 42+6 
weeks postmenstrual age, independent of gestational age [GA] at birth. After having 
been trained by a dedicated research team, JR performed all BC measurements using 
a standardized protocol. 
daTa ColleCTion 
Maternal, obstetrical and neonatal outcome data were collected from questionnaires at 
enrolment, at 24 weeks of gestation, and after birth.104 Postnatal data included sex, GA 
at birth, and birth weight. Birth weight Z scores corrected for GA and sex were calculated 
by using Fenton growth data.171 
GA was calculated during the routine clinical intake visit, by using crown–rump length 
as dating measure for spontaneous pregnancies.172 In pregnancies conceived through 
assisted reproductive technologies, dating was based on the date of oocyte retrieval, 
embryo transfer or insemination date, depending on the method of assisted reproductive 
technology. We defined fetal growth restriction [FGR] as estimated fetal weight or abdominal 
circumference below the fifth percentile.173,174 Being small for gestational age at birth [SGA] 
was defined as birth weight below the fifth percentile for GA. 
There were no missing covariates nor missing outcome data. As we assume that the 
missing fetal US data were missing at random, and linear mixed models make optimal 
use of all available data points, imputation was not needed.175  
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STaTiSTiCal analySeS
First, the association between TVol and neonatal fat mass was estimated for each 
measurement separately, i.e. 22, 26, and 32 weeks of gestation [cross–sectional 
analyses]. Second, individual TVol growth trajectories were created to assess the 
association between TVol growth and neonatal fat mass [longitudinal analyses]. All 
associations were explored in 2 models: a basic [model 1] and fully adjusted [model 2] 
model.  
CroSS–SeCTional analySeS In model 1 we adjusted for GA at moment of fetal 3D US 
examination and GA at postnatal BC measurement. Model 2 included the covariates 
of model 1 plus a predefined set of covariates based on plausible biological effects and 
existing literature including sex, parity, maternal age, prepregnancy BMI, and smoking 
during pregnancy. The residuals of the linear regression analyses were approximately 
normally distributed. 
longiTudinal analySeS Regression analyses on growth trajectories of TVol between 22 
and 32 weeks of gestation and neonatal %BF were performed in two steps. First, a linear 
mixed model was estimated with the cube root of TVol as the response and GA at 3D 
US examination as covariate. The cube root transformation was opted for as this made 
the residuals approximately homoscedastic and the relationship with GA approximately 
linear. The intercept and the GA were entered as random [i.e., subject specific] effects, 
providing individual intercepts and slopes for each fetus. The origin of the GA scale was 
placed at 160 days [baseline TVol size] and the TVol slope was measured as the increase 
in the cube root of TVol between 160 days and 220 days  [∆TVol] to aid interpretation and 
break the strong correlation between the two random effects. The subject–specific 
random effects were used as covariates in the second step in a linear regression model 
with %BF as outcome. In the second step, a basic and a complex model were applied. 
For the longitudinal analyses, model 1 included only GA at postnatal BC measurement. 
Model 2 included the covariates of model 1 plus the covariates included in model 2 of 
the single measurements. 
To compare the predictive ability of the longitudinal model with the models using single 
measurements we used leave–one–out cross validation. For this, we deleted a single 
subject from the dataset on which we estimated our model and used this model to 
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predict the outcome from the subject we deleted. This was carried out for all subjects. 
For the longitudinal model, this required computing the best linear unbiased predictions. 
The models were then compared using the root mean squared error [RMSE] to select 
the model with the highest predictive value [lowest RMSE].  
SenSiTiviTy analySeS In a tertiary hospital–based population, cases of pathologic fetal 
growth patterns are likely oversampled, which may influence the results. We therefore a 
priori planned sensitivity analyses with exclusion of those fetuses with FGR and infants 
who were SGA at birth, applying the same models as in the primary analyses. 
The data are presented as number [percentage] or median [interquartile range]. A 2–
tailed p value of <0.05 was considered statistically significant. Data were analyzed by 
using SPSS package 21.0 [IBM SPSS Statistics, Armonk, Ny] and R [R: A language and 
Environment for Statistical Computing, version 3.1.3, 2015 for Windows, R Core Team, 
Vienna, Austria].
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reSulTS
Postnatal BC measurement was available for 99 infants during the study period. 
BC measurement was not successful in eight infants because of logistic or child–
related reasons [i.e., crying], and six parents gave no consent. Six infants were born 
prematurely, and therefore excluded. The baseline characteristics of the 79 mother–
child pairs included are presented in Table 1.
Table 1 | baSeline CharaCTeriSTiCS
n=79
maternal characteristics
age [years] 32.2 [28.2 – 34.2]
geographic origin [western]* 68 [86%]
education [high]* 42 [53%]
nulliparous 35 [44%]
Prepregnancy bmi [kg/m2] 23.8 [20.7 – 27.4]
mode of conception [ivF/iCSi] 27 [34%]
Periconceptional folic acid supplement use* 75 [93%]
Periconceptional smoking 15 [19%]
neonatal characteristics
gender [male] 44 [56%]
birth weight [grams] 3215 [3055 – 3530]
gestational age at birth [weeks+ days] 39+0 [38+1 – 40+0]
Legend: All data are presented in median [interquartile range] or n[%]. *2 missing values. 
Abbreviations: IVF, in vitro insemination; ICSI, intracytoplasmic sperm injection.
In total, 229 3D US examinations were performed of which 37 scans, equally distributed 
over the three time points, were not usable for TVol measurement, resulting in 192 
TVol measurements. Standard fetal biometry data are presented in Table 2. Median 
[interquartile range] TVol increased from 7.6 [7.1; 8.5] cm3 at 22 weeks to 36.5 [33.8; 
40.9] cm3 at 32 weeks of gestation. Median neonatal %BF was 14.3% [11.7; 17.0]. 
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Table 2 | FeTal biomeTry
n=79 22 weeks of gestation 26 weeks of gestation 32 weeks of gestation
ga at uS examination [weeks] 22+3  [22+1;22+5] 26+3 [26+2;26+5] 32+3 [32+1;32+5]
Tvol [cm3] 7.6 [7.1;8.5] 16.7 [15.2;18.2] 36.5 [33.8;40.9]
eFw [gram] 530 [489;556] 983 [909;1057] 2028 [1862;2177]
bPd [mm] 55.5 [54.6;57.4] 69.1 [67.2;71.0] 84.8 [82.8;87.3]
hC [mm] 201.1 [196.2;206.4] 247.0 [242.8;253.7] 296.8 [291.3;302.7]
aC [mm] 182.4 [176.8;188.0] 225.8 [218.7;233.6] 290.1 [276.7;301.3]
Fl [mm] 38.2 [37.0;39.5] 48.6 [47.2;49.6] 60.6 [59.2;62.3]
Abbreviations: GA, gestational age; US, ultrasound; TVol, fractional thigh volume; EFW, estimated fetal weight; 
BPD, biparietal diameter; hC, head circumference; AC, abdominal circumference; FL, femur length.
CroSS–SeCTional analySiS
Both models showed a statistically significant negative association between TVol at 22 
weeks of gestation and neonatal %BF. The explained variance was 21% in model 1 and 
31% in model 2. None of the models showed a significant association between TVol 
measured at 26 or 32 weeks of gestation and neonatal %BF [Table 3]. 
longiTudinal analySiS 
Both models showed a statistically significant negative association between TVol 
growth and neonatal %BF, explained by baseline TVol size and not by increase in TVol 
between 22 and 32 weeks of gestation [∆TVol]. The explained variance was 11% in Model 
1, and 18% in model 2 [Table 3]. 
rooT mean SQuare error
Comparison of the predictive ability of the different models showed the lowest [most 
optimal] RMSE for the model at 22 weeks of gestation [RMSE 4.11]. The RMSEs of the 
models at 26 and 32 weeks of gestation were respectively 4.48 and 4.38, and of the 
longitudinal model 4.29.
SenSiTiviTy analySiS
The sensitivity analyses were performed in infants with normal fetal growth [n=73], by 
excluding those with FGR [n=1], SGA [n=3], or both [n=2]. Again, both models showed 
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a statistically significant negative association between TVol at 22 weeks of gestation 
and neonatal %BF. TVols at 26 and 32 weeks were not significantly associated with 
%BF. The sensitivity analyses for TVol growth also showed a negative association, again 
explained by baseline TVol size and not by ∆TVol [Supplemental table 1]. 
Table 3 | aSSoCiaTionS beTween FeTal Thigh volume and 
neonaTal PerCenTage body FaT
model 1† model 2‡
unit β 95%Ci p value r2 β 95%Ci p value r2
Cross–sectional analysis: 
Tvol 22w ga 
[n=60]
cm3 –1.53 –2.38;–0.68 0.001 21% –1.58 –2.45;–0.70 0.001 31%
Tvol 26w ga 
[n=68]
cm3 –0.26 –0.78;0.27 0.331 4% –0.29 –0.82;0.25 0.285 14%
Tvol 32w ga 
[n=64]
cm3 –0.02 –0.23;0.18 0.828 5% –0.024 –0.23;0.18 0.810 21%
longitudinal analysis: Tvol growth [n=79] 11% 18%
baseline Tvol size 3    cm3 –31 –53;–10 0.004 –28 –52;–4 0.02
∆Tvol
3    cm3/week 0.175 –0.76;1.12 0.71 0.53 –0.56;1.62 0.33
Legend:  Significant results are depicted in bold [p<0.05].  
† model 1: adjusted for gestational age at moment of 3D–scanning and gestational age at body composition 
measurement. In the TVol growth analyses we did not adjust for gestational age at moment of 3D 
scanning. 
‡ model 2: adjusted for covariates in Model 1 plus for maternal prepregnancy BMI, maternal age, maternal 
smoking during, parity, and sex.
Abbreviations: β, effect size; CI, confidence interval; GA, gestational age; n, number of scans available; R2, 
explained variance for all covariates in the model; TVol, fractional thigh volume; w, weeks. 
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diSCuSSion
In this prospective perinatal cohort study, we evaluated the use of fetal TVol measured 
from midgestation onward as marker of neonatal adiposity. A statistically significant 
association between TVol and neonatal %BF was found at 22 weeks of gestation. This 
finding confirms our hypothesis that TVol in midgestation might be useful to predict 
neonatal adiposity. We did not observe a significant association at 26 and 32 weeks of 
gestation. The longitudinal analyses of TVol growth showed a less strong association 
with neonatal %BF than TVol at 22 weeks of gestation, negating our second hypothesis. 
We are the first to report that TVol at 22 weeks is negatively associated with neonatal 
%BF [i.e., a lower TVol is associated with a higher neonatal %BF]. Future studies should 
confirm this finding. To understand this, at first glance on paradoxical finding, one 
should keep in mind the physiological growth pattern of a fetus. In early pregnancy, fetal 
growth only consists of lean mass, while from 28 weeks of gestation onward fetal growth 
increasingly consists of fat mass.31 Thus, extrapolating overall fetal growth to the fetal 
thigh: TVol in midgestation solely measures lean mass, while at the end of pregnancy, it 
measures both fat and lean mass. 
The used measure for adiposity, %FM, is defined as absolute fat mass divided by total 
body weight [sum of fat and lean mass]. An increased %FM can thus be the result 
of either a decreased absolute lean mass or an increased absolute fat mass; it is not 
necessarily contributed to fat mass alone. 
In literature, it has been described that low birth weight and SGA infants carry a higher 
risk for obesity and cardiovascular risk factors.176 Our findings confirm the results of these 
studies, but the underlying mechanisms are not fully unraveled yet. The validity of our finding 
is supported by the sensitivity analysis, showing an even stronger association in fetuses 
with normal growth. To gain more insight in the underlying mechanism, we performed a 
post–hoc analysis on the association between TVol at 22 weeks and the absolute amounts 
of neonatal fat and lean mass. We observed a negative association with absolute fat mass 
and no association with lean mass, indicating that a lower TVol is associated with a higher 
absolute fat mass in the neonatal period. This suggests that in fetuses with low lean mass in 
early pregnancy, it is fat accumulation that explains the higher neonatal %BF. 
The clinical implications of this association, and of increased neonatal adiposity, 
are unclear. Although the effect size seems large [+1.6 %BF [≈ +1/2 SD %FM] per 
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cm3 increase in TVol], the effect is limited due to the small absolute variance in TVol 
at 22 weeks [Table 2]. Altogether, our data suggest that effects of cardiometabolic 
programming are already present and detectable in–utero. 
The potential of fetal thigh volume as predictor of neonatal adiposity in midgestation has 
not been described before as previous studies assessed the use of TVol after 27 weeks 
of gestation. They all used air displacement plethysmography for BC measurement, 
similar to our method. In 2009, Lee et al. were the first to report a positive association 
between TVol, measured shortly before delivery, and neonatal %BF.167 Later, O’Connor 
et al. did not find any significant correlation between TVol measured at 28, 33, and 37 
weeks of gestation and neonatal %BF, which corresponds with our findings.147 The 
most recently published study by Moore et al. found no association at 36 weeks, but 
did find a strong positive association between TVol measured at 28 weeks of gestation 
and neonatal %BF.169 Despite their sample size of only 32 mother–child pairs, they 
estimated an explained variance of almost 70% [effect size not reported]. Such a 
strong association at this time point has not been described before and is in contrast 
to our findings and those of O’Connor et al. As they do not speculate on the underlying 
absolute fat and lean masses, it is difficult to interpret their findings. Still, differences in 
study design and study population may explain the contrasting findings. 
We consider the prospective design with serial standardized measurements and 
the longitudinal analyses of the serial data the main strengths of our study. Another 
strength is that both prenatal and postnatal measurements were performed around 
the same postconceptional age, allowing for better cross–sectional comparison. Of 
interest is the relatively high %BF in our population compared to data from previous 
studies.144,177,178 This is likely explained by timing of BC measurement between 42 and 
43 weeks of gestation that includes the period of physiological increase in body fat in 
the first weeks after term age.94 Interpretation of fat mass measured sooner after birth 
is complicated by the initial physiological process of weight and fat loss, and regain of 
weight thereafter in the first days after birth.168,179 In an additional post–hoc analysis, 
we studied the effect of variation in postnatal age at BC measurement [median 25, 
range 7 – 40 days] by adding this term to the final adjusted models. No improvement of 
model fit for all analyses suggests that differences in postnatal age did not importantly 
influence our results [data not shown]. Breastfeeding was not taken into account in the 
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analyses because misclassification is likely in our partially breastfed population. 
Related to the design and the sample size of our study, we face some limitations. We did 
not perform 3D US examinations after 32 weeks of gestation, which would have given us 
a more complete overview of the development of TVol and its association with neonatal 
adiposity. Moreover, larger studies are needed to determine the long–term consequences 
of increased fat accumulation in the prenatal and early postnatal period. The external validity 
may be reduced as the women studied were relatively old, highly educated and mainly of 
Caucasian ethnicity. Moreover, our tertiary hospital population included high numbers of in 
vitro insemination/intracytoplasmic sperm injection pregnancies [Table 1].
We believe that TVol measurement is easy to perform in 4DView, but we also experienced 
the technical limitations described earlier.167 We expect that the ongoing development 
of automated image analysis tools with higher precision and faster calculations will 
increase the clinical feasibility of TVol measurement as an additional bedside–available 
technique for monitoring of fetal growth.180  
In the future, TVol might be used in prediction models for neonatal adiposity, including 
other relevant predictors such as maternal BMI.166 TVol might also be a useful tool to 
evaluate the effect of interventions and may help to unravel the complex interaction 
between environmental risk factors and recently identified genetic risk factors for 
childhood obesity.181 
ConCluSion
This prospective perinatal study showed that fetal TVol in midgestation is a promising 
3D US soft tissue marker for prediction of neonatal adiposity and for monitoring of 
effects of prenatal prevention strategies for childhood obesity. Serial assessment for 
TVol growth between 22 and 32 weeks of gestation showed little additional value for 
prediction of neonatal adiposity when compared to single TVol measurement at 22 
weeks. 
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SuPPlemenTal Figure 1 | Tvol meaSuremenT in 4dview
SuPPlemenTal Table 1 | SenSiTiviTy analySeS oF aSSoCiaTion beTween FeTal 
Thigh volume and neonaTal PerCenTage body FaT in inFanTS wiTh normal 
FeTal growTh
model 1† model 2‡
unit β 95%Ci p value r2 β 95%Ci p value r2
Cross–sectional analysis: 
Tvol 22 w ga 
[n=57]
cm3 –1.72 –2.57;–0.88 0.000 26% –1.76 –2.61;–0.90 0.000 38%
Tvol 26 w ga 
[n=64]
cm3 –0.27 –0.88;0.35 0.395 7% –0.37 –1.00;0.28 0.258 17%
Tvol 32 w ga          
[n=58]
cm3 0.02 –0.23;0.28 0.856 5% –0.033 –0.28;0.21 0.786 25%
longitudinal analysis: Tvol growth [n=73] 0.007 15% 0.014 22%
baseline Tvol size 3    cm3 –32 –55;–8 0.008 –33 –59;–7 0.01
∆Tvol
3    cm3/week 0.06 –1.23;1.35 0.926 –0.08 –1.5;1.35 0.915
Legend: Normal fetal growth is defined as absence of FGR of SGA at birth. Significant results are depicted in bold [p<0.05]. 
† Model 1: Adjusted for gestational age at moment of 3D–scanning and gestational age at body composition measurement. In the 
TVol growth analyses we did not adjust for gestational age at moment of 3D–scanning.  
‡ Model 2: Adjusted for covariates in Model 1 plus for maternal prepregnancy BMI, maternal age, maternal smoking during, parity, 
and fetal sex.
Abbrevations: β, effect size; CI, confidence interval; n, number of scans available; R2, explained variance of all covariates in the 
model; TVol, fractional thigh volume; w, weeks. 
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abSTraCT
baCkground & aimS Aggressive parenteral nutritional practices were implemented 
in clinical practice over a decade ago to prevent early growth retardation in preterm 
infants. We aimed to study adherence to current nutritional recommendations in a 
population of very preterm infants, and to evaluate growth in early life.  
meThodS Preterm infants [gestational age <30 weeks and birth weight <1500 grams] 
were included in a prospective observational cohort study. Data on parenteral and 
enteral intake were collected on days 1–7, 14, 21, and 28 [d28] of life. Growth data were 
collected at birth, at moment of maximal weight loss [dip], and either at discharge from 
the neonatal intensive care unit or at d28, whichever came first. Nutritional intakes were 
compared to recommendations of current guidelines. The target growth rate was 15 – 
20 g/kg/d. 
reSulTS Fifty–nine infants [63% male] were included. Median gestational age was 
27+3 [interquartile range 25+6;28+4], and birth weight was 920 gram [720;1200]. Median 
macronutrient intakes were within or above the targets on all study days, but energy 
targets were not met before day 5. Median growth rates were 9.5 and 18.1 g/kg/d, when 
calculated from respectively birth and dip to discharge/d28. Eight [14%] versus 46 
[78%] infants met the growth targets, when evaluated from respectively birth and dip 
to discharge/d28. 
ConCluSionS In this cohort, only energy intake up to day 5 was lower than 
recommended. Growth targets were achieved in the majority of the infants, but only 
when evaluated from dip onward, not from birth onward. 
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inTroduCTion
Early nutrition and growth are pivotal for short– and long–term health of very 
preterm infants, with growth retardation being associated with mortality and poor 
neurodevelopmental outcome.50,182 Adequate energy and protein intakes via the 
parenteral route can significantly increase postnatal growth in very preterm infants.183–185 
In 1977, the American Academy of Pediatrics stated that postnatal growth of very 
preterm infants ideally should mimic fetal growth.56 Despite the implementation 
of parenteral nutrition in neonatal care in the early 1970s, growth retardation during 
hospital stay remained very common in the following decades.186–188 In 2005 and 
2002 the latest guidelines for parenteral nutrition in preterm infants were released 
by respectively the European Society for Pediatric Gastroenterology, hepatology and 
Nutrition [ESPGhAN] and the American Society for Parenteral and Enteral Nutrition 
[ASPEN].48 Both guidelines recommended aggressive parenteral nutrition regimes for 
preterm infants, with the start of amino acids and lipids soon after birth. Randomized 
controlled trials showed that these recommendations were safe and improved growth 
on the short term.53,189,190 however, soon after the release of the guidelines, concerns 
were expressed about the feasibility of the recommendations in clinical practice, 
and about the persistent high rates of in–hospital growth retardation.191–193 This was 
supported by a survey in 2013 showing that parenteral nutrition practices are frequently 
not compliant with current recommendations, especially in the first days of life.51 
The aggressive nutritional practices have been introduced in clinical neonatal practice 
over a decade ago. We presume that general improvements of perinatal and neonatal 
care over time affect nutritional practices and growth. We therefore aimed to evaluate 
adherence to current nutritional recommendations in a population of very preterm 
infants on a tertiary neonatal intensive care unit [NICU]. Additionally, we aimed to 
evaluate their growth in the first month of life. 
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meThodS 
This prospective observational study was part of an ongoing cohort study at the level 
IV NICU of the Erasmus MC – Sophia Children’s hospital, Rotterdam, the Netherlands. 
Infants born before 30 weeks of gestational age [GA] and birth weight below 1500 
grams were included between September 2014 and December 2015. Exclusion criteria 
included congenital anomalies [including chromosomal defects], severe brain injury [i.e., 
intraventricular hemorrhage grade III/IV and post–hemorrhagic ventricular dilatation], 
and admission to the NICU after 48 hours of life.194 Informed consent was asked shortly 
before expected discharge [around 30 weeks GA]. This study was conducted according 
to the guidelines laid down in the Declaration of helsinki, and approved by the local 
medical ethical review board [MEC–2014–379]. Written parental informed consent was 
obtained prior to enrollment in the study.  
loCal nuTriTional ProToCol 
All infants were treated according to our local nutritional protocol, which is based on 
the parenteral [2005] and enteral [2009] ESPGhAN guidelines.48,55 In short, parenteral 
glucose administration was started directly after birth, with a minimum of 4.0 mg/
kg/min and a maximum of 12 mg/kg/min. Amino acid administration [Primene 10%, 
Baxter, Utrecht, the Netherlands] was also started directly after birth at 2.4 g/kg/d, and 
increased to 2.9 g/kg/d the next day. The target dose of amino acids was 3.5 – 4.0 
g/kg/d. Lipids were started on the day after birth [Intralipid 20% or SMOFlipid 20%, 
both Fresenius Kabi, Bad homburg, Germany] at 1.4 g/kg/d, and increased to 2.8 g/
kg/d on the next day. The target dose for lipids was 2.5 – 3 g/kg/d. Parenteral intake 
was gradually increased with ~20 ml/kg/d to reach the target of 160 – 180 ml/kg/d. 
At an enteral intake of 130 ml/kg/d, parenteral nutrition was ceased. Triglyceride and 
urea levels were monitored on regular basis. Parenteral amino acid administration 
was temporarily lowered if plasma urea concentrations were above 10 mmol/l, and 
interrupted when above 14 mmol/l. Similarly, lipid administration was temporary 
lowered when triacylglycerol concentrations were above 3 mmol/l and interrupted 
when above 5 mmol/l. Enteral bolus feeding was started on day 1, and increased daily 
according to our local protocol.195 Only if expressed breast milk was insufficiently 
available, preterm formula was supplemented [Nenatal start, Nutricia Advanced 
Medical Nutrition, Zoetermeer, the Netherlands]. Breast milk fortification was started 
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at an enteral intake of 100 ml/kg/d [Nenatal Breast Milk Fortifier, BMF, Nutricia, 
Zoetermeer, the Netherlands]. 
daTa ColleCTion
Maternal, obstetrical, and neonatal data were collected from electronic medical 
records. Intake data were collected from the bedside Patient Data Monitoring System 
on 10 study days: day [d] 1 to 7, 14, 21, and 28 of life. These intake data included [1] 
parenteral and enteral nutritional intake of fluids, macronutrients and energy, and [2] 
fluid, carbohydrate and energy intake via intravenous drug administration if either 
continuously administered or if intermittent boluses exceeded 2 ml/day. 
Intakes are expressed in ml/kg/d for fluids, in mg/kg/min for carbohydrates, in g/kg/d 
for amino acids and lipids, and in kcal/kg/d for energy. 
As infants are born around the clock, duration of the “first day of life” ranges form 0 – 24 
hours. Locally, daily planned changes in [nutritional] therapy are carried out at 4pm. 
Therefore, in infants born before 4pm, day 1 was defined as day of birth. In those born 
after 4pm, day 1 was defined as the period from birth until 11:59:59pm of the day after 
birth. Duration of day 1 thus ranged from 8 to 32 hours. To adjust to an intake per 24 
hours, the following formula was used:    
Intakes were adjusted for observation duration at the day of discharge similarly. 
In the first week of life, birth weight was used to calculate intake per kg. From day 14 
onward, actual weight was used, defined as weight measured closest to the study day. 
The macronutrient and energy composition of the parenteral nutrition solutions and 
of formula feeding were based on the manufacturer’s product information. For breast 
milk, the composition was based on the meta–analysis of Gidrewicz and Fenton. This 
meta–analysis takes into account postnatal age after birth, but not GA at birth.196  
growTh 
GA and sex–corrected Z scores for weight and head circumference were calculated 
using international growth charts at the following time points: birth, moment of maximal 
postnatal weight loss [weight dip], and transfer from the NICU to a high care center 
            cummulative intake day 1
duration of day 1 [in hours] 
  24 hours 
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[NICU discharge at or before day 28 of life] or at day 28 [NICU discharge after 28 days 
of life].197,198 Length data were not available. Calculated growth parameters included 
days until regain of birth weight, day of weight dip, maximal weight loss as percentage of 
birth weight, and weight Z score change. Short–term weight growth rate was calculated 
using the following formula [exponential method]: 
Growth retardation was defined as a decrease in weight Z score of ≥0.67 between two 
time points. Weight Z score change, weight growth rate, and growth retardation were all 
calculated for both the period between birth and discharge/d28 and between weight 
dip and discharge/d28. 
daTa analySiS 
Data are presented as number [percentage] or median [interquartile range [IQR]]. 
A sample size calculation was not deemed necessary because of the descriptive nature 
of the study. 
Fluid, energy and macronutrient intakes were compared with recommendations of 
the ESPGhAN guidelines, on which our local protocol is based. In the first week we 
compared nutrient intake with the parenteral nutrition recommendations, and from day 
14 onward with the enteral nutrition recommendations [Table 1].48,55 For each patient, 
adherence to the guideline was scored per nutritional component at each study day as 
below, within, or above the target, using a margin of 5% on the lower and upper limits. 
The growth target was defined as growth rate between 15 to 20 g/kg/d. 
Because of the heterogeneity in our NICU population and the use of two different 
time points, possibly influencing our growth analyses, we a priori planned a sensitivity 
analysis. here, we distinguished between infants with a short NICU stay [≤28 days, 
growth evaluation at transfer to a high care center] and long NICU stay [>28 days, growth 
evaluation at day 28 of life]. The latter group represents the most immature infants and 
those with the most severe complications, who may have received different intakes and 
may have grown differently. As we did not perform a sample size calculation on this, and 
1000 x ln 
   
Final weight [grams]
Birth weight [grams]
[Day of final weight – Day of birth] 199,200  
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to prevent type 1 errors due to multiple testing, we mostly provide a descriptive overview 
of the data and performed only a few statistical tests [Mann–Whitney U test for 
non–parametric data]. Data were analyzed using Excel 2010 and SPSS package 21.0 
[IBM SPSS statistics, Armonk, Ny].
Table 1 | Summary oF reCommendaTionS oF eSPghan guidelineS in 
PreTerm inFanTS 
Parenteral nutrition [2005] 
day 1 – 7
enteral nutrition [2009]
day 14, 21, 28
Fluid [ml/kg/d] Day 1 80 – 90 135 – 200
Day 2 100 – 110
Day 3 120 – 130
Day 4 130 – 150
Day 5 140 – 160
Day 6 160 – 180
Day 7 140 – 180
energy [kcal/kg/d] Starting day Day 1 110 – 135
Dose 110 – 120, no increment 
scheme provided
Carbohydrate [mg/kg/min] Starting day Day 1 8.05 – 9.20
Dose 4 – 8, no increment 
scheme provided
amino acid [g/kg/d] Starting day Day 1 <1 kg: 4 – 4.5
1 – 1.8 kg: 3.5 – 4.0
Dose 1.5 – 4,
no increment scheme 
provided
lipids [g/kg/d] Starting day Start supply no later than 
3rd day of life, but may 
start on day 1
4.8 – 6.6
Dose Maximum of 3–4,
no starting dose, 
minimum dose, or 
increment scheme 
provided
Abbrevations: ESPGhAN, European Society for Pediatric Gastroenterology hepatology and Nutrition; ml, 
milliliter; d, day; [k]g, [kilo]gram; kcal, kilocalories; mg, milligram; min, minute.
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reSulTS
Figure 1 illustrates the selection of the study population [n=59], which was not different 
from the target population [n=159] in sex, GA at birth, or birth weight [data not shown]. 
In Table 2 the baseline and neonatal characteristics of the study population are shown. 
Figure 1 | Flow diagram oF enrollmenT in STudy
Legend: * Not approached due to language barrier or lost to follow–up.
Abbreviations: D, day; IC, informed consent; NICU; neonatal intensive care unit; N, number.
Actual intakes for all study days are presented in Table 3. In Figure 2, the intakes relative 
to the target ranges of the ESPGhAN guidelines are shown.
Fluid Median fluid intakes were above the target ranges on day 1 to 3, and within the 
target ranges thereafter. In the first days of life, over 50% had intakes outside the target 
ranges. At day 7, all intakes were within the target range, and nearly all [96 – 98%] from 
day 14 onward.
Infants admitted to NICU
n=159
Excluded   n=42
Congenital anomaly  n=3
Severe brain injury  n=9
Deceased before IC  n=23
Other   n=7
Not approached*  n=28
No consent  n=30
Infants included in study
n=59
Data obtained at day
D1: n=58
D2–7: n=59
D14: n=53
D21: n=45
D28: n=39
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Table 2 | STudy CharaCTeriSTiCS 
Study population [n=59]
gestational age at birth [weeks+days] 27+3 [25+6;28+4]
birth weight [grams] 920 [733;1193]
Sex [male] 36 [61%]
5’ min aPgar score 7 [6;8]
Culture–proven sepsis 28 [47%]
Severe bronchopulmonary disease 11 [19%]
Surgical necrotizing enterocolitis 3 [5%]
days on parenteral nutrition 11 [9;17]
length of niCu stay [days]1 43 [21;77]
length of hospital stay [days]2 89 [73;110]
Legend: Data are expressed in median [interquartile range] or n [%]. 
1 2 infants deceased before NICU discharge.
2 3 missing data. 
CarbohydraTeS Median carbohydrate intakes were within the target range during 
the entire first week, and above the target range thereafter. The carbohydrate intake of 
most infants was above the target from day 14 onward.  
amino aCidS Median amino acid intakes were within the target range on all study days. 
From day 14 onward, 9 – 34% of the infants had intakes below the target range. Of these 
infants, 45 – 65% still received parenteral nutrition.
liPidS Median lipid intakes were within or above the target ranges on all study days. 
From day 14 onward, 15 – 31% of the infants had intakes below the target range. Of these 
infants, 66 – 72% were still receiving parenteral nutrition. 
energy Median energy intakes were below the target range during the entire first week. 
None of the infants met the target intake before day 5. At day 28, 89% of the infants had 
intakes within or above the target range. All infants not meeting the recommendations 
after the first week still received parenteral nutrition, most as a consequence of surgical 
necrotizing enterocolitis [n=3]. 
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Table 3 | Combined inTakeS oF ParenTeral and enTeral nuTriTion 
and mediCaTion Per day
Fluid
[ml/kg/d]
Carbohydrates
[mg/kg/min]
aa
[g/kg/d]
lipids
[g/kg/d]
energy
[kcal/kg/d]
d1 96.4 4.9 2.3 0.09 38.9
[n=58]1 [88.5;112.9] [4.3;5.4] [2.1;2.4] [0.03;0.14] [35.3;41.6]
d2 113.3 5.2 2.7 0.88 48.9
[n=59] [95.7;122.8] [4.4;6.0] [2.5;2.9] [0.66;1.11] [44.9;55.5]
d3  133.1 5.6 3.2 2.4 67.4
[n =59] [116.8;141.4] [4.9;6.8] [2.8;3.4] [2.1;2.7] [63.4;76.7]
d4 149.3 6.3 3.4 2.9 77.8
[n=59] [134.3;158.2] [5.3;6.8] [3.1;3.8] [2.4;3.8] [71.3;86.1]
d5 156.8 6.7 3.6 3.0 82.8
[n=59] [149.1;162.1] [6.1;7.6] [3.1;4.0] [2.3;3.8] [72.0;93.0]
d6 160.6 7.2 3.7 3.3 86.2
[n=59] [153.8;167.5] [6.4;8.0] [3.3;4.1] [2.7;3.9] [79.1;98.2]
d7 160.2 7.5 3.9 3.4 90.3
[n=59] [153.9;166.5] [6.4;9.0] [3.2;4.3] [2.8;3.8] [82.2;104.2]
d14 158.7 10.9 3.9 5.0 123.3
[n=53] [148.2;167.7] [8.7;12.2] [3.4;4.1] [4.2;5.6] [106.6;137.0]
d21 155.0 13.0 3.8 5.3 137.9
[n=45] [147.8;162.3] [10.4;13.8] [3.5;4.2] [4.7;5.5] [119.6;144.7]
d28 150.0 13.3 4.2 5.2 141.2
[n=39]2 [144.0;160.5] [11.3;13.7] [3.8;4.7] [4.9;5.4] [128.6;146.5]
Legend: Data are presented in median [interquartile range]. 
1 One missing case [outborn patient]. 
2 One infant was readmitted to our NICU.  
Abbreviations: Ml, milliliter; [k]g, [kilo]gram; D, day; mg, milligram; AA, amino acids; kcal, kilocalories.
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growTh Overall growth data are presented in Table 4 and Figure 3. Both weight and 
head circumference Z score declined more than 0.67 Z score during NICU stay. Birth 
Z score was not regained at discharge home [Figure 3A]. Median weight dip relative to 
birth weight was 10.4%, and reached on median day 4. Weight at NICU discharge/d28 was 
129% higher relative to birth weight, and 145% higher relative to dip weight [Figure 3B]. 
Median growth rate between birth and discharge/d28 was 9.5 g/kg/d [6.3; 13.3]. 
Growth retardation was present in 39 infants [66%]. Eight [14%] infants met the growth 
targets of 15 – 20 g/kg/d, when evaluated between birth and discharge/d28. Evaluation 
of growth between weight dip and discharge/d28 resulted in a higher median growth 
rate [18.1 g/kg/d [IQR 15.5; 21.1]], and the majority of the infants [n=46, 78%] meeting 
the growth targets.
SenSiTiviTy analySiS
The infants with a short NICU stay [≤28 days] were more mature at birth [median 
GA 28+3 [IQR 27+5;29+0] than the infants in the long-stay group [median GA 26+1 [IQR 
24+6;27+5]]. Small differences in amino acid and lipid intake [higher in the short–stay 
group], and in carbohydrate, energy, and fluid intake [higher in the long–stay group] 
were found in the first days of life [data not shown]. 
The groups showed a similar pattern of Z score decline between birth and dip, and 
hardly any regain in Z score between dip and discharge home [Figure 3C]. In the short–
stay group, the dip was 1 day later than in the long–stay group [median day 5 versus day 
4]. The weight dip was also deeper in the short–stay group, with a median weight loss 
of 12% relative to birth weight, compared to 10% in the long–stay group [p=0.033]. The 
growth rate calculated between birth and transfer was lower in the short–stay group 
[5.2 g/kg/d] than in the long–stay group [11.1 g/kg/d, p<0.00]. When evaluated from 
dip onward, median growth rates were similar in both groups, with 18.0 g/kg/d in the 
short–stay and 18.2 g/kg/d in the long–stay group [p=0.79]. 
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Figure 2 | maCronuTrienT inTake 
Legend: Boxplots of median [interquartile range and 95 percent interval] fluid, macronutrients, and energy 
intake on day 1 to day 7, day 14, 21, and 28, and percentages of infants meeting the recommendations per day. 
The white areas represent the recommendations of the ESPGhAN guidelines. 
Abbreviations: D, day; [k]g, kilogram; min, minute; %, percentages.
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Figure 3 | growTh ouTComeS
Legend: Three figures showing growth measures of preterm infants at several time points during hospital stay: 
birth [a], weight dip [b], transfer from NICU to high care hospital [c], day 28 [e] and/or discharge home [f].
3A. Weight during hospital stay of the total study population [N=59]. 
On the x–axis is depicted the postnatal age in weeks with the time points and on the y–axis the weight Z score 
[sex and gestational age adjusted, Fenton growth charts22]. The vertical bars represent the interquartile ranges, 
the solid line the reference [Z score = zero].
3B. Two different calculations of growth velocity in the first month in the total study population. 
On the x–axis is depicted the postnatal age in weeks with the time points, and on the y–axis the percentage of 
weight change, relative to starting weight [100%]. The squares depict the percentages weight relative to weight 
at birth, with the dashed line showing the growth velocity. The solid line with the circles starts at the weight dip 
and represents the weight gain relative to dip weight. 
3C. Weight during hospital stay in patients with short [≤28 days] and long [>28 days] NICU stay. 
On the x–axis are depicted gestational ages in weeks and the time points and on the y–axis the weight Z score 
is shown. The Z scores are depicted separately for the short–stay [n=22, triangles] and the long–stay group 
[n=39, diamonds] at the different time points. The vertical bars represent the interquartile ranges, the solid line 
the reference [Z score = zero].
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Table 4 | growTh ouTComeS
n=59
regain of birth weight [day] 11 [9;13]a
maximal weight loss [%] 10.4% [8.4;14.0]
weight z score at birth 0.09 [–0.40;0.62]
weight z score at discharge/d28 –0.7 [–1.0;–0.5]
weight z score change between birth and discharge/d28 –0.8 [–1.1;–0.5]
hC z score at birthb –0.08 [–0.69;0.48]
hC z score at discharge/d28b –0.9 [–1.6;–0.6]
growth retardation during hospital stayc 39 [66%]
growth rate [g/kg/d] 9.5 [6.3;13.3]
Legend: Data are presented in median [interquartile range] or n[%]. a3 missing cases, b2 missing cases, 
c growth retardation was defined as decrease of ≥0.67 in weight Z score from birth to discharge/d28. 
Abbreviations: hC, head circumference; d, day. 
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diSCuSSion
In this study, we showed that in preterm infants admitted to a tertiary NICU adherence 
to macronutrient recommendations of current guidelines was good in the first month 
of life. Despite this, energy targets were not met before day 5 of life. Growth targets were 
achieved in the majority of the infants, but only when evaluated from postnatal weight 
dip onward. Overall, the first week [nearly] 1–point drop in Z score was not regained 
during hospital stay. These findings underline the importance of nutritional intake and 
growth, especially duration and amount of weight loss, in the first days of life for short–
term growth outcomes after preterm birth. 
The only nutritional component that was below the targets in the first days of life was 
energy. This resulted in a cumulative energy deficit of ±266 kcal/kg after the first week 
of life. This deficit may have influenced duration and amount of weight loss, and the poor 
growth outcomes, as each gram growth costs approximately 5 kcal. A deficit of 266 
kcal/kg results in a potential growth loss of 266/5 = 53 g/week, or 7.5 g/day in an infant 
of 1000 g – equal to the difference between the actual and the recommended growth 
rates when evaluated from birth onward. Moreover, previous studies, using stable 
isotopes, showed that for adequate growth at least 100 kcal/kg/day are needed.201 
Over the last 10 years whilst there has been more understanding of protein and other 
nutrient needs, optimal energy intakes for preterm infants have not been determined 
yet. A few studies attempted to determine the optimal protein:energy ratio, and only 
some have examined the effect of lipid compared to carbohydrate intake as energy 
source on growth.202 
Prevention of energy deficits is difficult in clinical practice. First, because of the limitation 
in fluid intake, as excessive fluid intake may have serious side effects such as necrotizing 
enteral colitis and bronchopulmonary disease.203 Second, higher concentrations of 
glucose solutions can be used in preterm born infants, but only with central venous 
catheters in place.204 In those without central venous access, solutions above 1000 
mOsm/L are generally regarded unsafe, limiting the possibility to increase energy 
intake while respecting fluid targets.205,206 The third option is to start parenteral lipid 
administration immediately after birth, which is likely safe and effectively increases 
energy intake.53,207 The ESPGhAN guideline states that lipid supply may be started 
immediately after birth, but should be initiated no later than on the third day of life. In 
phd jor_book.indb   119 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 120
CHAPTER 05
120
our study, parenteral lipid administration was started on the second day of life in the 
majority of the infants, partly explaining the energy deficit. 
We observed that growth targets of 15 – 20 g/kg/d are feasible during the first month 
of life, but only when evaluated from weight dip onward. Our data show that this early 
weight loss greatly influences growth outcomes in early life, of which we know that 
they are important for long–term health and development.208 The weight dip is mainly 
the result of the infants’ adaptation to extra–uterine life by losing fluid. In term born 
infants, up to 10% weight loss in the first days of life is considered physiological. Studies 
on postnatal weight loss in preterm infants report losses of 5 to 15%.209, 210 Based on 
current literature we do not know to what extend postnatal weight loss should be 
considered physiological in preterm infants. Early growth capacity may be limited by 
the low levels of insulin–like growth factor type 1 [IGF 1] during the stage of adaptation 
from placental nutrient supply to enteral nutrient uptake in preterm infants.64 As early 
weight loss largely determines growth outcomes in the first month of life, it deserves 
more attention in research and in clinical practice.  
The sensitivity analyses showed only small differences in nutritional intake between 
infants with a short and long NICU stay. The differences observed are largely explained 
by our local protocol, and criteria for central venous catheters insertion. Growth 
also differed slightly between the groups. The weight dip was deeper, and occurred 
later in infants with a short NICU stay. As a consequence, poorer growth outcomes 
were observed in the short–stay group, which is probably the result of the shorter 
observation period. Interestingly, both groups showed a similar growth pattern with a Z 
score decline between birth and weight dip, and stabilization thereafter until discharge 
home. These findings support more attention for nutritional practices in all preterm 
infants, regardless of their gestational age at birth.
Previous studies evaluating adherence to the guidelines obtained different growth 
results. We note that comparison of studies on growth and nutrition is complex. First, 
because different definitions are used to describe growth, as recently discussed by 
Fenton et al.198 Second, varying inclusion criteria hamper the comparability of study 
populations. Third, growth partly depends on the level of care and on local policies, 
even when centers use the same guidelines. Last, current guidelines are based on 
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scarce evidence and on consensus of experts in the field, and leave ample room for 
interpretation and local differences in practice. 
We have addressed the following strengths and limitations of our study.  
First, our study population may not represent the general preterm NICU population 
on our ward, although baseline characteristics were not different from the target 
population.Second, we used the macronutrient and energy composition as provided 
by the manufacturers and did not correct for bioavailability of enteral and parenteral 
nutrients or for individual variability in breast milk content. Third, in this study we 
only describe in–hospital growth from a quantitative perspective, without answering 
the question which growth pattern is most beneficial for long–term health. Current 
opinion of optimal growth is that ‘quantity and quality of growth should be equivalent 
to fetal growth’. Quality of growth is not defined, and a scientific basis for the long–
term benefits of fetal growth rates is lacking. Features of quality of growth considered 
relevant are, amongst others, markers of cardiometabolic health including body 
composition, neurodevelopment, and bone health. Previous cohort studies irrefutable 
showed that growth retardation and nutritional deficits in early life have harmful 
effects on development of the brain, but long–term outcome data of nutritional 
intervention trials are scarce.211 To prevent growth retardation, early enhanced feeding 
was recommended in the latest guidelines. however, concerns have been expressed 
about the effects of early high amino acid administration on morbidity rates and brain 
development.212 – 214 Concerns have also been expressed on the effect of rapid growth 
on later cardiometabolic health, but the exact magnitude has not been unraveled yet.215 
Whether we should consider the early weight loss as an essential part of adaptation to 
extra–uterine life in preterm infants, or whether we should interfere more aggressively 
in the first days of life, needs further study in nutrition intervention studies with long–
term follow up. In this exploration, the results of a recent study in sick term infants 
and children may provide new insights. That study showed short–term benefits of 
withholding parenteral nutrition during periods of stress, especially in neonates.216 
Whether this also counts for preterm infants deserves further study. 
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ConCluSion
Despite general improvement of neonatal care and drastic changes in nutritional 
practices, poor growth outcomes remain common after preterm birth. The first week 
weight dip seems to be most relevant for growth outcomes in the first month of life. 
Future research should define optimal nutritional intake and optimal growth in the first 
week of life, with focus on energy intake and long–term health benefits. 
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abSTraCT
baCkground Rapid postnatal weight gain is beneficial for neurodevelopment of 
preterm infants. Concerns are raised however on the influence of rapid weight gain on 
fat mass gain in early life and cardiometabolic health on the long term. In this study, 
we evaluated the association between postnatal weight gain and body composition in 
infancy in preterm infants. 
meThodS In a prospective cohort study, we included preterm infants born before 30 
weeks of gestation without major congenital anomalies or severe brain injury, admitted 
to the neonatal intensive care unit [NICU]. Growth trajectories of weight Z scores 
were estimated by using linear mixed models over four time periods: from moment of 
maximal weight loss postnatally [1] until transfer from the NICU to a secondary hospital 
[in–NICU growth]; [2] until discharge home [in–hospital growth]; [3] until 6 weeks 
corrected age [ca]; and [4] until 6 months ca. We evaluated the association between 
these growth trajectories and relative fat mass [%FM], absolute fat mass, and absolute 
lean mass measured at 6 weeks and 6 months ca. 
reSulTS In 117 infants, 181 body composition measurements were performed; 101 
at 6 weeks and 80 at 6 months ca. Median %FM was 21.9% at 6 weeks and 20.3% 
at 6 months ca. Growth after hospital stay was most strongly associated with body 
composition in infancy. In–NICU growth was significantly associated with increased 
absolute lean mass in infancy, explaining 4.7% of the variance in lean mas at 6 weeks 
ca. higher in–hospital weight gain was positively associated with %FM, explaining 6% 
of the variance in %FM at 6 weeks ca. 
ConCluSionS In–hospital growth of preterm infants was significantly associated with 
body composition in infancy. Although the overall effect was mainly on lean mass, faster 
weight gain after discharge to a secondary hospital was also associated with increased 
fat accumulation, resulting in increased %FM. The long–term relevance of these 
findings for cardiometabolic health needs further study.    
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inTroduCTion
Preterm infants are born in a critical period for growth and development and they are 
at high risk of postnatal growth retardation.50,182 Aggressive nutritional practices are 
recommended in early life, to accomplish rapid growth after the initial period of growth 
retardation.48,56 The last years, however, evidence obtained in human and animal 
studies raised concerns on the influence of high nutritional intake and rapid growth on 
cardiometabolic health of preterm infants.217 
The underlying theory is covered in the Developmental Origins of health and Disease 
[DOhaD] paradigm, stating that after a period of nutritional deprivation, stress, or 
inflammation, an environment much richer in oxygen and nutrients can result in an 
increased risk of an adverse cardiometabolic health.10 This had led to a debate on 
which growth pattern should be aimed for: do the neurodevelopmental benefits of 
rapid growth outweigh the potential risk of adverse cardiometabolic consequences in 
childhood and adulthood?68 
To answer this question, more knowledge should be obtained on the period during 
which rapid growth is harmful for cardiometabolic health of preterm infants.217  Although 
in term born infants the first three months of life have been identified as most critical, in 
preterm infants this is not clear yet. Some studies showed that rapid growth in the first 
years after preterm birth is beneficial for both neurodevelopment and cardiometabolic 
health, while others report harmful effects of rapid growth in the first years of life on 
markers of cardiometabolic health in childhood and adulthood.79,218 
Body composition in early life is considered a marker of cardiometabolic health and can 
be measured reliably in the outpatient setting.13 The human body consists of absolute 
lean and fat mass, which increase with increasing weight. Based on lean and fat mass, 
relative fat mass can be determined, which is the amount of absolute fat mass relative 
to weight.Physiologically, fat accumulation starts in the third trimester, increasing the 
relative fat mass until a plateau is reached around 3 – 6 months after term age.5,219 
In this study, we aimed to gain more insights in the association between postnatal 
weight gain in the first months of life and body composition of preterm infants in infancy. 
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We expected that the later you evaluate growth, the stronger the association with body 
composition would be, but that also the early postnatal periods are important for body 
composition in infancy. Additionally, we hypothesized that increased weight gain during 
hospital stay is associated with higher relative fat mass due to decreased lean mass 
rather than to increased fat mass accumulation. 
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meThodS
In this prospective cohort study we assessed the association between weight gain in the 
first months of life and body composition measured at 6 weeks and 6 months corrected 
age [ca]. To identify during which time periods postnatal growth is most strongly associated 
with relative fat mass [fat mass relative to weight, often referred to as adiposity], we 
distinguished between the period of neonatal intensive care unit [NICU] stay, the period 
of secondary hospital stay, and the periods at home until the 6 weeks and 6 months 
visits. These time periods were chosen based on differences in settings [NICU, secondary 
hospital, home] and related nutritional practices [respectively parenteral nutrition and tube 
feeding, increasing bottle or breast feeding, and self–drinking with decreasing enrichment].
SeTTing
This prospective observational cohort study was conducted at the level IV NICU and 
the outpatient clinic of the Erasmus MC – Sophia Children’s hospital, Rotterdam, the 
Netherlands, between September 2014 and April 2017. Infants born before 30 weeks 
of gestation who were admitted to our ward within 48 hours after birth were eligible 
for inclusion in the study. Exclusion criteria were congenital anomalies [including 
chromosomal defects] that may interfere with growth, severe brain injury [i.e., 
intraventricular hemorrhage grade III/IV and posthemorrhagic ventricular dilatation 
requiring lumbar punctures], congenital infections, and perinatal asphyxia [umbilical cord 
ph < 7.00 and APGAR score at 5’min < 5]. The study was conducted according to the 
guidelines laid down in the Declaration of helsinki, and was approved by the local ethical 
review board [MEC–2014–379]. Written parental informed consent was obtained before 
inclusion in the study.   
loCal nuTriTion ProToCol  
During NICU stay, all infants were treated according to our local protocol which is based 
on the parenteral and enteral ESPGhAN guidelines.48,55 In short, parenteral glucose 
administration was started directly after birth, with a minimum of 4 and maximum of 12 
mg/kg/min. Amino acid administration was also started directly after birth at 2.4 g/kg/d 
and gradually increased to a target dose of 3.5 – 4.0 g/kg/d. Lipids were started the 
day after birth at 1.4 g/kg/d and gradually increased to a target dose of 2.5 – 3 g/kg/d. 
Parenteral nutrition was ceased at an enteral intake of 130 ml/kg/d. 
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Enteral bolus feeding was started on the day of birth and increased daily according to 
our local protocol.220 Expressed breast milk was the first choice of enteral feeding. If 
not [sufficiently] available, preterm formula was supplemented [Nenatal start, Nutricia 
Advanced Medical Nutrition, Zoetermeer, the Netherlands]. Breast milk fortification 
was started at an enteral intake of 100 ml/kg/d [Breast Milk Fortifier, Nutricia Advanced 
Medical Nutrition, Zoetermeer, the Netherlands]. 
CliniCal daTa 
Maternal characteristics and obstetrical and neonatal data were prospectively 
collected. Gestational age was calculated on the basis of the first day of the last 
menstrual period or the first trimester ultrasound. Postnatal age was defined as 
days after birth, with the day of birth corresponding with day 1. Corrected age was 
postnatal age adjusted for prematurity. At each visit, parents filled out a questionnaire 
on their infants’ feeding practices to collect data on type of feeding, fortification, and 
complementary feeding. Socio–economic status was expressed in ZIP code based 
SD scores which are calculated based on local average income, low–income rate, low 
educational level rate, and unemployment rate.221
growTh 
Body weight, head circumference, and length measurements were performed 
according to local protocols. Body weight was measured on an electronic scale to the 
nearest gram. head circumference and length measurements were performed in a 
standardized way by using a tape measure and an Infantometer [Seca], respectively. 
Weight and head circumference were measured from birth onward as part of standard 
care in all infants, length measurements were only measured after transfer from the 
NICU to a secondary hospital.  
Gestational age and sex–corrected Z scores for weight, head circumference, and length 
were calculated at the following time points: birth, initial weight dip [maximal weight 
loss postnatally], 30 weeks of gestation, NICU transfer, discharge home, and at both 
outpatient clinic visits [6 weeks and 6 months ca]. As recommended by Cormack et al., 
Z scores were based on the Fenton growth charts from birth until discharge home, and 
on the World health Organization [WhO] growth charts thereafter.171,197,222 The WhO Z 
scores were adjusted for prematurity.  
phd jor_book.indb   130 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 131
131
Growth and body composition in preterm infants
Calculated growth parameters included day of maximum weight loss, maximum weight 
loss as percentage of birth weight, and days until regain of birth weight. We defined a 
decrease in Δ Z score of >0.67 Z score as growth retardation and an increase of >0.67 
Z score as catch–up growth.223
ouTPaTienT CliniC viSiTS 
As part of our standard follow–up program, preterm infants born before 30 weeks of 
gestation visited our outpatient clinic for medical and neurodevelopmental assessment 
at 6 weeks and 6 months ca. Body composition was measured at those visits by using 
the validated method of air displacement plethysmography [PEA POD®, Infant Body 
Composition System, COSMED].96,130 By direct measurements of body volume and 
body mass, fat mass as percentage of total body weight [%FM] and absolute fat and 
lean mass are estimated.  
Due to changes in national policies, the 6 weeks visit was shifted to 12 weeks ca in 
infants born after 1st of January 2017 [n=12] and visits of those born above 28 weeks of 
gestation could take place in the secondary hospital. 
STaTiSTiCal analySeS 
Descriptive data are expressed as median [interquartile range [IQR]] or number 
[percentage] of observations.
First, growth trajectories were estimated by using linear mixed models. Because infants 
experience weight loss in the first days of life, the growth trajectory was estimated from 
moment of maximum weight loss onward [median day 5]. We estimated four growth 
trajectories for weight Z score from the moment of weight dip until: [1] transfer to a 
secondary hospital [in–NICU growth]; [2] discharge home [in–hospital growth]; [3] first 
body composition measurement around 6 weeks ca [6 weeks growth]; and [4] second 
body composition measurement around 6 months ca [6 months growth]. The growth 
trajectories were estimated by using weight Z score [dependent] as the response over 
time with postnatal age at weight examination as covariate. No transformation was 
needed to make the residuals approximately homoscedastic and the relationship with 
postnatal age approximately linear. The random intercept and slopes were entered as 
subject–specific effects, reflecting individual growth trajectories for each infant. In the 
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second step of the analysis, the subject–specific effects were used as covariates in 
the linear regression analyses with %FM and absolute fat and lean mass as outcome 
measures. The basic regression model included the subject–specific effects, sex, 
gestational age at birth, birth weight Z score, and corrected age at body composition 
measurement. The adjusted model included the covariates of the basic model and 
days on parenteral nutrition during NICU stay, days on mechanical ventilation, socio–
economic status, and the use of any breast milk at the 6 weeks visit. To evaluate the 
contribution of the growth trajectories to all measures of body composition at 6 weeks 
and 6 months ca, we compared the explained variances of the model with and without 
including the subject specific–effects. The difference in explained variance can be 
contributed to the subject–specific effects of growth.  
A 2–tailed p value <0.05 was considered statistically significant.  
Analyses were performed using SPSS package 21.0 [IBM SPSS Statistics, Armonk, Ny] 
and R [R: A language and environment for Statistical Computing, version 3.1.3, 2015 for 
Windows, R Core Team, Vienna, Austria]. 
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Figure 1 | FlowCharT
Study population
n=142
Deceased before first outpatient 
clinic visit n=3
Congenital anomaly interfering 
with growth n=1
Lost to follow–up n=4
No body composition
measurements n=16
Number of body composition measurements at each visit
n=138
n=134
Final sample
n=118
6 weeks ca
n=102
6 weeks ca
n=80
Abbrevations: n, number; ca, corrected age. 
reSulTS
In total, 142 infants were enrolled in the study. After excluding one infant with 
a congenital anomaly interfering with growth, three infants who deceased before 
discharge home, three with follow–up at another hospital, and 18 without body 
composition measurements, the study population consisted of 118 infants [Figure 1].  
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baSeline CharaCTeriSTiCS 
The baseline characteristics of the study population are provided in Table 1. Median 
gestational age at birth was 27+5 weeks [interquartile range, 26+1;28+5] with a birth 
weight of 1015 grams [800;1250]. Duration of parenteral nutrition [amino acid or lipid 
administration] during NICU stay was 10 days [8;16]. The majority of the infants [75%, 
n=88] received both own mothers milk and formula during NICU stay. The infants were 
transferred from the NICU to a secondary hospital at median postnatal age of 29 days 
[17;69], and were discharged home at a median postnatal age of 84 days [70;105]. 
growTh
Growth data during hospital stay are shown in Supplemental Table 1. Maximum weight 
loss of birth weight was 10.5% [7.8;13.6] which was reached on day 5 [3;6]. The majority 
of infants experienced growth retardation [weight and head circumference] during 
hospital stay, with catch–up rates starting to increase after discharge to a secondary 
hospital [Figure 2 and Supplemental Table 2]. Of the 117 infants, 102 [87%] had a 
body composition measurement at 6 weeks ca and 80 [81%] at 6 months ca [Table 2]. 
The %FM was within the same range at 6 weeks and 6 months ca. 
aSSoCiaTion beTween growTh and body ComPoSiTion 
The results of the regression analyses are presented in Supplemental Table 3 [basic 
model] and Table 3 [fully adjusted model]. In NICU–growth was positively associated 
with lean mass at 6 weeks of gestation in both the basic and fully adjusted model, and 
explains 4.7% of the variance in lean mass at 6 weeks ca. No association was observed 
between in–NICU growth and absolute fat mass and %FM. The association between 
in–NICU growth and absolute lean mass at 6 months ca was not statistically significant. 
In–hospital growth showed an association with all components of body composition 
at 6 weeks ca: a higher weight gain was associated with increased absolute lean 
mass, absolute fat mass, and %FM, with explained variances of 10.2, 10.8, and 6.3% 
respectively in the adjusted models. At 6 months ca, we only observed an association 
between in–hospital growth and absolute lean mass [explained variance 5.9%]. 
Growth up to 6 weeks ca was strongly associated with all measures of body composition 
at 6 weeks ca, but not at 6 months ca. At 6 months ca we observed an association 
with absolute lean and fat mass. Positive associations were also found between growth 
up to 6 months ca and all measures of body composition: a higher weight gain was 
associated with absolute lean mass, absolute fat mass, and %FM. 
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Table 1 | maTernal and inFanT baSeline CharaCTeriSTiCS
n=118 n=118 missing
maternal characteristics
Age at delivery [years] 30 [27;34] 0
Prepregnancy BMI [kg/m2] 24.8 [21.8;29.1] 13
Pregnancy complications [G]DM 7 [6%] 0
hypertension1 8 [7%] 0
PE/hELLP 20 [17%] 0
IUGR2 22 [19%] 4
PPROM 24 [20%] 0
Singleton 92 [78%] 0
Antenatal corticosteroids 0/1/2 doses 7/33/78 [6/28/66%] 0
Caesarean section 69 [59%] 0
fetal distress 58 [49%] 0
infant characteristics
Sex [male] 73 [62%] 0
GA at birth [weeks+days] 27+5 [26+1;28+5] 0
Birth weight [grams] 1015 [800;1250] 0
[Z score] 0.1 [–0.4;0.7] 0
Apgar [5’ min] 8 [6;9] 1
ph umbilical cord 7.31 [7.26;7.36] 10
SNAPPE–II score 27 [14;39] 2
Culture–proven sepsis 41 [35%] 0
early onset3 3 [3%] 0
late onset 38 [32%] 0
NEC Bell stage ≥2 5 [5%] 0
Treated PDA 38 [32%] 0
BPD4 mild 27 [23%] 0
severe 17 [14%] 0
Postnatal steroid use 20 [17%] 4
Brain injury5 36 [31%] 0
Treated ROP10 6 [5%] 0
Mechanical ventilation11 [days] 2 [0;11] 0
NICU stay [days] 29 [17;69] 0
GA at NICU transfer [weeks+days] 32+0 [30+3;36+2] 0
hospital stay [days] 84 [70;105] 3
GA at discharge home [weeks+days] 39+5 [38+0;41+5] 3
Legend: All data are expressed in median [interquartile range] or number [percentages]. 1 Either pre–existent 
or pregnancy induced; 2 Estimated fetal weight or abdominal circumference below 10th percentile on Robinson 
curve; 3 Positive blood culture within 72h after birth; 4 BPD: >28 days O2 + X–ray abnormalities, severe BPD: 
endotracheal or CPAP at 36 weeks of gestation or >30% fiO2 or >1L/min flow via nasal prongs; 5 Brain injury 
includes IVh gr I/II, cerebellar bleeding, arterial/venous stroke, periventricular leukomalacia and convulsions;  
6 Endotracheal mechanical ventilation. 
Abbreviations; n, number; IQR, interquartile range; BMI, body mass index; [G]DM, [gestational] diabetes 
mellitus; PE, pre–eclampsia; IUGR, intra–uterine growth retardation; PPROM, preterm premature rupture of 
membranes; GA, gestational age; CRIB, clinical risk index for babies; NEC, necrotizing enterocolitis; PDA, patent 
ductus arteriosus; BPD, bronchopulmonary disease; ROP, retinopathy of prematurity. 
phd jor_book.indb   135 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 136
CHAPTER 06
136
Figure 2 | weighT z SCore CourSe From birTh To 6 monThS CorreCTed age
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Legend: on the x–axis are depicted postnatal age in days, on the y–axis the weight Z score.
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Table 2 | growTh and nuTriTional ParameTerS aT body ComPoSiTion 
meaSuremenTS
6w – visit 6m – visit
n 117 [99%] 99 [84%]
Corrected age [days] 52 [45;67] 185 [177;195]
Postnatal age [days] 136 [128;161] 273 [260;287]
weight [kg] 4.68 [4.14;5.21] 7.08 [6.45;7.66]
[Z score] –0.9 [–1.6;–0.1] –0.7 [–1.5;0.0]
head circumference [cm] 38.6 [37.5;40.0] 43.2 [42.0;44.2]
[Z score] 0.2 [–0.7;0.9] 0.2 [–0.6;1.0]
length [cm] 55.2 [53.4;57.1] 66.4 [64.0;68.5]
[Z score] –1.1 [–1.9;–0.3] –0.2 [–1.1;0.5]
body composition measurement 102 [87%] 80 [81%]
relative Fm [%] 21.9 [17.8;23.8] 20.3 [17.9;23.3]
absolute Fm [kg] 0.98 [0.77;1.28] 1.43 [1.12;1.68]
absolute FFm [kg] 3.69 [3.33;4.02] 5.61 [5.10;6.06]
Feeding type1 Own mothers milk 19 [16%] 5 [4%]
Formula feeding 76 [64%] 88 [75%]
Mixed feeding 22 [19%] 3 [3%]
enriched nutrition2 24 [20%] 5 [4%]
Tube feeding 16 [14%] 3 [3%]
Parenteral nutrition 2 [2%] 1 [1%]
oxygen supply 9 [8%] 3 [3%]
Legend: 1 1 missing feeding data at 6 weeks and 3 at 6 months ca; 2 Either preterm formula or fortified human 
milk enriched with extra protein, or with fat or carbohydrates [rare].  
Abbreviations: kg, kilograms; cm, centimeters; %, percentage; FM, fat mass; FFM, fat free mass.
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Table 3 | aSSoCiaTion beTween growTh [weighT gain] and body ComPoSiTion aT 6 
weekS and 6 monThS Ca [Fully adjuSTed]
6 weeks [n=101] 6 months [n=79]
%Fm absolute Fm absolute lm %Fm absolute Fm absolute lm
in–niCu – – 4.7%** – – 2.0%#
in–hospital 6.3%* 10.8%*** 10.2%*** – – 5.9%**
up to 6 weeks ca 34.5%*** 48.9%*** 24.1%*** – 10.2%** 10.9%***
up to 6 months ca NA NA NA 27.9%*** 47.9%*** 27.3%***
Legend: The variance [%] in body composition explained by early growth trajectories is presented. In the 
regression analyses, we adjusted for gestational age at birth, birth weight Z score, sex, corrected age at body 
composition measurement, days on parenteral nutrition during NICU stay, days on invasive respiratory 
support, socio–economic status, and breast milk at 6 weeks corrected age [any/no].  
Symbols: – indicates p value >0.1; # p value between 0.5 – 0.1; * p value between 0.5 – 0.01; ** p value between 
0.01 and 0.001; *** p value <0.001. 
Abbreviations: %FM, percentage fat mass relative to weight; FM, fat mass; LM, lean mass; NA, not applicable; 
ca, corrected age.
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diSCuSSion
In this prospective cohort study in very preterm infants we studied the association 
between postnatal weight gain and body composition in infancy. As expected, we 
found that the effect of growth on later body composition was larger with smaller time 
intervals between the evaluated growth trajectory and body composition measurement. 
Still, we observed that in–NICU growth was associated with lean body mass at 6 weeks 
corrected age, which was median 15 weeks later. Evaluating the subsequent trajectories 
including growth in the secondary hospital and at home, we found an association with 
absolute and relative fat mass: higher in–hospital and home weight gains are associated 
with increased relative fat mass in infancy.  
We focused on growth during hospital stay as this is likely easier to manipulate by 
changing intake in infants with parenteral and tube feeding, than in those who are self–
drinking at home. Moreover, we hypothesized that programming mainly takes place in 
this early period, and may therefore be more important for later health.10 We found that 
in–NICU growth was only positively associated with lean mass, and not with fat mass 
at 6 weeks ca. In–hospital growth including the secondary hospital stay, however, was 
not only associated with absolute lean mass, but higher weight gain was also associated 
with increased relative fat mass, explaining 6% of the variance in relative fat mass at 6 
weeks ca. Unlike our hypothesis, this was the result of increased fat mass, and not of 
decreased lean mass.  
At 6 months, the effects already seem more diluted: both in–NICU and in–hospital growth 
are only associated with absolute lean mass, and even growth up to 6 weeks ca shows little 
association with fat and lean mass. Growth up to 6 months ca again showed the strongest 
association with all components of body composition at 6 months ca.  
Previous studies looking at the association between growth and body composition 
in preterm infants did not evaluate growth over different time periods, and nearly all 
focused on body composition at discharge, not on later effects. Simon et al. showed in 
141 infants born before 35 weeks of gestation that weight Z score change between day 
5 [moment of weight dip] and discharge was not associated with the risk of being in 
the upper %FM tertile at discharge home. This is in contrast to our findings with body 
composition measurement in infancy. This may be explained by differences in inclusion 
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criteria [<35w versus <30w gestational age], methodology [different growth charts], 
feeding practices, and timing of body composition measurement [37 weeks versus 47 
weeks gestational age].86 Other studies found results more similar to ours. Trembley 
et al. included infants more similar to our population [born <29 weeks, no severe 
brain injury or chromosomal abnormalities] and they also found a positive association 
between in–hospital weight gain and lean mass at discharge.88 A study of Griffin and 
Cooke also observed a positive association with relative fat mass at discharge and in 
infancy, which is in accordance with our findings at 6 weeks ca.79 
All associations found were positive, indicating that higher weight gain results in 
increased absolute lean and fat mass deposition. Only from around 32 weeks of 
gestation [after transfer from the NICU to a secondary hospital] higher weight gain 
resulted in a higher relative fat mass. Thus, in–NICU growth and relative fat mass, or 
adiposity, were not clearly related yet. An explanation might be found in the biological 
fetal development with in–utero fat accumulation starting in the third trimester.5 This 
corresponds with the period of secondary hospital stay in our study. Our data indeed 
support the theory that preterm infants merely mimic this physiological pattern of 
growth in–utero; with in–NICU growth primarily relating to lean mass gain, and the 
period after NICU stay to both fat and lean mass growth.215,224 Another explanation is 
that shortly after birth, preterm infants need all the energy they have for maturation of 
organs, breathing, and adaptation to the extra–uterine environment. Since providing 
adequate amounts of energy is challenging and may be insufficient in the first period of 
postnatal life in preterm infants, all calories will be used, and little will be stored as fat.
Cautiously extrapolating our findings to clinical practice, it suggests that rapid growth 
in the first week of life after the initial period of weight loss results in increased lean 
mass gain, which may be beneficial for both neurodevelopmental outcome and 
cardiometabolic health. This questions the increasing concerns on the potential 
harmful effects of influence of early enhanced nutrition on later body composition. 
In the period from circa 32 weeks to discharge, enteral nutrition becomes the main 
source of nutrition, usually provided via tube feeding, and enriched to promote rapid 
growth. Caution may however be required as high growth rates in this period were 
not only associated with lean mass, but also with fat mass accumulation, resulting in 
increased relative fat mass at follow–up. Also after discharge home, rapid weight gain 
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was associated with increased relative fat mass. In this period, many infants receive 
postdischarge formula, enriched in energy and proteins. Close monitoring of growth 
parameters and timely tempering of intake seem to be advisable in that stage. Studies 
on postdischarge formulas and body composition show, however, conflicting results, 
and have not yet elucidated the optimal ratio between energy and protein supply.225–227 
Rapid growth in early life may be harmful, but still no clinical thresholds have been 
defined for relative fat mass or adiposity. This is complicated by most effects not being 
detectable until late childhood or even adulthood.228 Follow–up into school age and 
adulthood is therefore warranted to provide a complete view of the influence of early 
postnatal growth on cardiometabolic health of preterm infants and to determine clinical 
relevant cut–offs for body composition in infants.  
Both at group and at individual level, relative fat mass at 6 weeks and 6 months ca 
was generally within the same range, suggesting that fat mass accumulation remains 
relatively stable in this period, after an earlier phase of rapid increase. This corresponds 
with body composition data observed in other studies conducted in preterm and term 
born infants.219,229,230 Body composition data earlier in life could have provided a better 
view on the exact timing of rapid fat accumulation in our patients, but this is hampered 
by the practical problem that body composition measurement is only possible without 
respiratory support.   
Previous studies demonstrated that %FM is higher around term age in preterm infants, 
but normalizes or decreases even below levels of term born infant 3 – 4 months after 
term age.77,231  We confirmed that at 6 weeks ca, %FM seems comparable or already 
lower than %FM of term born infants, with comparable lean mass but decreased 
fat mass. At 6 months ca, %FM was almost 1 SD lower than observed in term born 
infants, and also absolute fat and lean mas were lower than in term born infants.219  The 
mechanisms and clinical consequences of this decreased adiposity are not clear. 
The strengths of our study were the prospective design and longitudinal measurement, 
which enabled us to model individual growth trajectories. A few considerations should 
be taken into account when interpreting our study results. First, only 64 infants had 
both body composition measurements, which hampers the comparability between 
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the first and second measurement. Second, the PEA POD® was used which is a 
validated, feasible, and patient–friendly device to measure body composition in infancy. 
This method provides however no information on fat distribution within the body 
[e.g., subcutaneous versus visceral], which is considered an important risk factor of 
adverse cardiometabolic health.18 It would have been interesting to study the effect on 
sex on the association between growth and body composition, but due to the small 
sample size it was not possible to do subgroup analysis. Furthermore, we did not take 
nutritional intake during hospital stay into account because all infants were treated 
according to the same protocol and macronutrient recommendations were expected to 
be within recommendations based on our earlier study.232 To answer clinical questions 
regarding the association between nutritional intake and body composition, nutritional 
intervention trials are required.   
Our findings show that rapid weight gain in early life of preterm infants is associated with 
increased relative fat mass up to 6 months corrected age. Although previous studies 
demonstrated that adiposity tracks into childhood, we have no data yet at older ages. 
Also, studying additional markers, such as fat distribution and vascular and endocrine 
parameters, are needed  to detect other early changes in cardiometabolic health. 
ConCluSion
In this prospective cohort study in very preterm infants, we found that in–NICU growth 
was mainly associated with lean mass in the first months of life, while increased in–
hospital growth was associated with increased adiposity. Although further conclusions 
should be taken with caution, this may suggest that in the early neonatal period high 
growth rates can be aimed for without adversely influencing body composition in early 
life. 
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SuPPlemenTal Table 3 | aSSoCiaTion beTween growTh [weighT gain] and body 
ComPoSiTion aT 6 weekS and 6 monThS Ca [baSiC model]
6 weeks [n=101] 6 months [n=80]
%Fm absolute Fm absolute lm %Fm absolute Fm absolute lm
in–niCu – – 5.6%*** – – 2.0%#
in–hospital 6.3%* 11.0%*** 10.8%*** – – 5.8%**
up to 6 weeks ca 30.1%*** 45.3%*** 26.9%*** – 8.8%** 10.5%***
up to 6 months ca NA NA NA 27.0%*** 46.5%*** 27.3%***
Legend: The variance [%] in body composition explained by early growth trajectories is presented. In the 
regression analyses, we adjusted for gestational age at birth, birth weight Z score, sex, corrected age at body 
composition measurement. 
Symbols: – indicates p value >0.1; # p value between 0.5 – 0.1; * p value between 0.5 – 0.01; ** p value between 
0.01 and 0.001; *** p value <0.001. 
Abbreviations: %FM, percentage fat mass relative to weight; FM, fat mass; LM, lean mass; NA, not applicable; 
ca, corrected age.
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abSTraCT
baCkground and PurPoSe Preterm infants are at risk for neurodevelopmental 
impairment, but reliable, bedside–available markers to monitor preterm brain growth 
during hospital stay are still lacking. The aim of this study was to assess the feasibility 
of corpus callosum – fastigium length as a new cranial ultrasonography marker for 
monitoring of preterm brain growth. 
maTerialS and meThodS In this longitudinal prospective cohort study, cranial 
ultrasound was planned on the day of birth, days 1, 2, 3, and 7 of life; and then weekly 
until discharge in preterm infants born before 29 weeks of gestation. Reproducibility 
and associations between clinical variables and corpus callosum – fastigium growth 
trajectories were studied. 
reSulTS Series of 1 – 8 cranial ultrasounds were performed in 140 infants [median 
gestational age at birth, 27+2 weeks [interquartile range, 26+1 – 28+1]; 57.9% male infants]. 
Corpus callosum – fastigium measurements showed good–to–excellent agreement 
for inter– and intraobserver reproducibility [intraclass correlation coefficients > 
0.89]. Growth charts for preterm infants between 24 and 32 weeks of gestation were 
developed. Male sex and birth weight SD score were positively associated with corpus 
callosum – fastigium growth rate.  
ConCluSion Corpus callosum – fastigium length measurement is a new reproducible 
marker that is applicable for bedside monitoring of preterm brain growth during 
neonatal intensive care stay.  
phd jor_book.indb   150 09/11/2017   21:11
515078-L-bw-roelants
Processed on: 13-11-2017 PDF page: 151
151
A new ultrAsound mArker for bedside monitoring of preterm brAin growth
inTroduCTion
Brain growth is an important predictor of neurodevelopmental outcome in preterm 
infants.98,233–235 In neonatal intensive care units [NICUs], brain growth is usually 
monitored by manual measurement of head circumference. however, head 
circumference measurement has a low interrater agreement and does not correspond 
well with actual brain development.99,236 Therefore, there is a need for a new reliable 
bedside marker for monitoring preterm brain growth in clinical practice.
Brain structures measured by cranial ultrasound [CUS] could provide clinically 
applicable markers for brain growth. A few sonographic markers of brain growth have 
been used in the past, mainly measuring the corpus callosum [CC] or cerebellum, 
thereby reflecting growth of a small part of the brain only.237–241 In addition to currently 
available markers of preterm brain development, we propose that the length between 
genu of the CC and the fastigium [roof of the fourth ventricle] could serve as a new 
marker for brain growth.
The aim of this study was to evaluate the usefulness of corpus callosum – fastigium 
[CCF] length and CC length, an existing marker, as markers for monitoring of brain 
growth in preterm infants during NICU stay. We assessed the reproducibility of CC 
and CCF length measurements, developed growth charts for preterm infants between 
24 and 32 weeks of gestation, and evaluated prenatal and postnatal characteristics 
possibly associated with CC and CCF growth trajectories. We hypothesized that both 
measurements are highly reproducible. Furthermore, we hypothesized that CCF and 
CC growth trajectories are associated with prenatal and postnatal determinants of 
neurodevelopmental outcome in preterm infants.
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meThodS
This prospective observational cohort study was performed at the level III NICU of 
the Erasmus MC – Sophia Children’s hospital, Rotterdam, the Netherlands. The 
local medical ethics review board approved this study. Written parental consent 
was obtained before participation. Between 2010 and 2012, all newly admitted 
singleton, preterm infants born before 29 weeks gestational age [GA] were eligible 
for enrollment. We applied the following exclusion criteria: [1] unknown GA at 
birth; [2] major congenital abnormalities, and [3] extensive brain injury [including 
intraventricular hemorrhage grade III, post hemorrhagic ventricular dilatation, and 
venous infarction]. The latter complications are expected to influence the validity of 
the measurements due to possible midline shift and expected altered brain growth. 
GA at birth was calculated by using the first day of last menstrual period and was 
confirmed by first trimester crown rump length measurement on sonography. 
Postnatal age was expressed by postmenstrual age, calculated as GA at birth + 
weeks and days of postnatal age. Pregnancy and neonatal characteristics were 
collected prospectively. Maternal characteristics were retrospectively collected 
from medical records. Pregnancy complications, including intra–uterine growth 
retardation, pre–eclampsia and hemolysis, elevated liver enzymes, low platelet 
count [hELLP] syndrome were obtained from obstetrical records and were defined 
based on clinical definitions according to national guidelines.242  
Cranial ulTraSound and meaSuremenTS
CUS was performed according to the standard local protocol on the day of birth, 
on days 1, 2, 3, and 7 of life and then weekly until discharge. The protocol was only 
disregarded on clinical grounds [e.g., hemodynamic instability]. One researcher 
[MR] performed all CUS by using a MyLab 70 scanner [Esaote, Genoa, Italy], with a 
convex neonatal probe [7.5 Mhz]. Measurements were performed off line by using 
the Mylab software [Esaote]. Measurements of CC and CCF length were performed 
on a standard sagittal plane. In this plane a complete corpus callosum [genu to 
splenium] and distinct vermis of the cerebellum, including the fastigium, had to be 
visualized. CCF length was measured from the genu of the corpus callosum [outer 
border] to the fastigium. CC length was measured from outer to outer border [genu 
to splenium, Figure 1]. All measurements were performed by 1 investigator [MR]. To 
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Figure 1 
Legend: In the upper part, we show the coronal view of the brain and the position of the sonography probe 
for assessment of the corresponding correct sagittal plane below. Measurements of the corpus callosum 
– fastigium length and corpus callosum length are displayed in the sagittal sonography view [left] and 
schematically [right]. S. Cinguli indicates sulcus cingula.
establish the reliability, a second investigator [JR], blinded to the previous results, 
measured 30 randomly selected scans of varying quality and of neonates with 
different GAs.
STaTiSTiCal meThodS
Data were analyzed by using SPSS [Release 21 for Windows; IBM, Armonk, New york] 
and R statistical and computing software [https://www.r–project.org]. P values <0.05 
were statistically significant. Median value and interquartile range and mean and SDs 
were used as appropriate. 
Intraobserver and interobserver agreements for CC and CCF lengths were evaluated 
by using the intraclass correlation coefficient [ICC] and Bland–Altman plots.137 The 
ICC was analyzed by using a 2–way mixed model. Cut–off values were in accordance 
with Landis and Koch.243 Growth charts were developed for CCF and CC growth as a 
function of postmenstrual age [weeks] and weight [grams]. To model the relation 
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between the measured CCF and CC lengths and a predefined list of covariates, linear 
mixed models were estimated using lme [in the R nlme package: https://www.inside–r.
org/r–doc/nlme/lme].244 To account for the within–subject correlation, we used a 
random intercept and random coefficient of GA as well as a power variance function to 
model the residual covariance. The predefined covariates were GA at birth, birth weight 
[BW] SD score, sex, intra–uterine growth retardation [defined as expected fetal weight 
below the 10th percentile], pre–eclampsia/hELLP, chorioamnionitis, death, sepsis, and 
days on mechanical ventilation. In all models both GA and GA2 [square of GA] were 
used as covariates. To this basic model the additional predictors were added separately 
[termed “univariable models” below] and also all at once [the “multivariable model”].  
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reSulTS
Of 336 infants admitted to our NICU during the study period, 152 were eligible for 
inclusion. Twelve infants were excluded because they met the exclusion criterion of 
extensive brain injury, resulting in a sample size of 140 infants. Baseline maternal and 
neonatal characteristics are listed in Table 1. The median gestational age at birth was 
27+2 weeks [interquartile range, 26+1;28+1]; the median birth weight was 955 grams 
[interquartile range, 780;1125]. The number of sonography scans per neonate ranged 
from 1 to 8. 
Table 1 | baSeline CharaCTeriSTiCS
n=140 missingb
maternal characteristics
Age [yr]  [mean,[SD]] 30 [5.6] 0
Ethnicity 0
Dutch 74 [52.9%]  
Other Western 9 [6.4%]  
Non–Western 57 [40.7%]  
Smoking during pregnancy 26 [18.6%] 17
IVF/ICSI 9 [6.4%] 0
IUGR 42 [30%] 4
PE/hELLP syndrome 37 [26.4%] 0
Chorioamnionitis 37 [26.4%] 0
PPROM 32 [22.9%] 0
neonatal characteristics
GA at birth [weeks+days]  27+2 [26+1 ;28+1] 0
Male sex 81 [57.9%] 0
BW [grams] 955 [780; 1125] 0
Use of antenatal steroids 127 [90.7%] 2
Apgar score at fifth minute 8 [7;9] 0
CRIB score 3 [1;6] 1
Death 17 [12.1%] 0
Days on mechanical ventilation 5 [1;14] 3
Days to regain birth weight 9 [7;12] 14
Sepsis 67 [47.9%] 0
IVh grade I or II 32 [22.9%] 0
Severe BPD 15 [10.7%] 33
Legend: Baseline data of maternal and neonatal characteristics are presented as median [interquartile range] 
or n [%] unless otherwise specified. Missing data were mainly due to early transfer to a secondary hospital. 
Ethnicity was reported to provide insight in the generalizability of the study population. 
Abbreviations:  IVF/ICSI, in vitro fertilization with or without intra–cytoplasmic sperm injection; IUGR, intra–
uterine growth retardation; PE, pre–eclampsia; PPROM, prolonged premature rupture of membranes; CRIB, 
clinical risk index for babies; IVh, intraventricular hemorrhage; BPD, bronchopulmonary disease.
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reProduCibiliTy
The mean interobserver difference was –0.3207 ± 1.4527 mm for CCF [p=0.244] 
and0.4600 ± 1.8463 mm for CC length [p=0.183].
The ICCs for interobserver and intraobserver analysis showed excellent agreementfor 
both CCF and CC length [respectively, intraobserver: 0.958; 95%CI 0.912;0.980; 
interobserver: 0.885; 95%CI 0.770;0.944]; and intraobserver: 0.922; 95%CI 
0.844;0.962; and interobserver: 0.893; 95%CI 0.783;0.948]. Figure 2 shows Bland–
Altman plots of interobserver and intraobserver agreement for both measurements.
CC and CCF lengTh
The mean CCF length was 40.9 ± 2.97 mm, with a range from 34.0 to 54.3 mm. The 
mean CC length was 36.3 ± 3.33 mm, with a range from 26.6 to 48.8 mm. Growth charts 
of CCF and CC lengths by post menstrual age and by weight are shown in Figure 3.
linear mixed modelS
Results of univariable analyses are shown in Table 2 for CC and CCF growth. The 
multivariable analysis confirmed a positive association between BW SD score and 
CCF growth rate and a negative association between female sex and CCF growth rate. 
For the CC growth rate, a positive association was found with BW SD score by using 
multivariable analysis.  
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Legend: Reproducibility of corpus callosum – fastigium and corpus callosum lengths by using Bland–Altman
plots. The middle dashed lines depict the average measurement bias in percentage differences. The bold
dashed horizontal lines represent the 95% limits of agreement for these percentage differences.
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Legend: Growth charts of corpus callosum – fastigium [left] and corpus callosum [right] length for preterm
neonates as a function of postmenstrual age [in weeks] and weight [in grams]. On the y–axis, corpus callosum
– fastigium [left] and corpus callosum [right] lengths are presented in centimeters. The grey areas indicate the
parts of the weight charts that should not be used as reference curves.
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diSCuSSion
In this report, we demonstrated that CCF length, measured by using CUS, is a 
reproducible and feasible marker that could serve as a new bedside tool to monitor 
preterm infant brain growth during NICU stay. We provided growth charts of CCF and 
CC length for preterm infants from 24 to 32 weeks postmenstrual age. We found that a 
higher BW SD score results in increased CCF and CC growth rate during hospital stay, 
while female infants have a slower CCF growth compared with male infants. 
Previous sonography studies have evaluated only a limited number of brain structures 
as potential markers for brain growth or predictors of neurodevelopmental outcome in 
preterm infants.237–240 One explanation for this is that the brain has few easily recognizable 
and consistent landmarks for reliable measurements on CUS. The CC, a flat bundle of 
white matter that connects the left and right hemispheres, is one of the brain structures 
that is easily visualized and recognizable on CUS.245 Prematurity is known to affect CC 
development, by the early transition from intra–uterine to extra–uterine life and by 
postnatal stress and injury,246 leading to both structural and functional impairment.247,248 
Associations have been found between the length and thickness of the CC and brain 
volumes and neurodevelopmental outcome.241,249,250 Further studies should elucidate 
whether CC length can be considered a proxy of telencephalon development, creating 
an impression of white matter development and brain maturation. 
The advantages of using CCF length in the monitoring of brain growth rely on anatomic 
and practical issues. CCF length may be considered a marker of diencephalon and 
mesencephalon development and vermis growth. The diencephalon includes the 
thalamus, a neural relay center crucial for adequate cognitive function.251 Altered 
development of the thalamus, and thus of the diencephalon, may lead to adverse 
neurodevelopmental outcome. Several studies showed impaired thalamus volume 
and extreme vulnerability of the thalamus to be risk factors after preterm birth.252,253 
Whether thalamic injury or growth impairment directly influences CCF length needs to 
be further studied. 
One of the other advantages of CCF length measurement is the use of CUS instead 
of MR imaging or head circumference measurement. In Table 3, the pros and cons 
of every method are depicted. Although volumetric MR imaging is increasingly used 
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for growth assessment of the preterm brain, its use for serial assessment is still very 
limited.233 head circumference measurement has a low interrater agreement and 
limited association with long–term outcome and does not measure actual brain growth, 
but growth of the skull and the subarachnoid spaces, which are frequently enlarged 
in preterm infants.99,236,254 Measurement of CCF length is not considered a burden 
compared with head circumference measurement as it can be performed on routine 
CUS, which are often recommended weekly in preterm infants.255 Both CCF length and 
CC length can already be measured prenatally because the CC and the fastigium are 
already visible on sonography around 18 weeks of gestation; this feature allows the use 
of the same marker prenatally and postnatally for monitoring of brain growth.256 
Table 3 | ProS and ConS oF diFFerenT meThodS For aSSeSSmenT oF brain growTh 
hC CuS mri
Patient friendly ++ ++ –
bedside available ++ ++ –
Serial measurements possible ++ ++ –
Fast measurement ++ + –
reproducible ± + ++
reflecting actual brain growth – + ++
low costs ++ + –
dimension 1D 2D 3D
Legend: ++ indicates very good, + indicates acceptable, –  indicates bad agreement with the corresponding item. 
Abbreviations: hC, head circumference; CUS, cranial ultrasound.
In accordance with previous studies, we showed satisfactory reproducibility for 
CC length.237 CCF reproducibility was excellent too; this finding suggests that both 
measurements are feasible for longitudinal evaluation of brain growth. Increasing 
lengths with increasing ages and weights, as shown in the growth charts, support the 
use of these markers in clinical practice. 
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We observed a nonlinear growth pattern for CC and CCF length. Previous studies found an 
intra–uterine constant growth rate of 0.20 – 0.22 mm/day of the CC.257,258 Also in preterm 
infants a constant–though–slower growth rate was observed.237 In contrast to previous 
studies, we performed longitudinal measurements [1 – 8 scans per infant], allowing a 
more reliable estimation of CC growth. Other brain structures, such as the vermis of the 
cerebellum, show a nonlinear growth pattern as well.238 Because we are the first to evaluate 
the use of CCF length, no literature is available for comparison. We did expect a nonlinear 
growth pattern based on current literature. 
In Figure 3, parts of the weight charts are colored grey because we advise not to use these 
parts of the curves as a reference curve. We chose to analyze and present the complete 
original data of infants with a postmenstrual age between 24 and 32 weeks and not to 
select ideal reference cases. The drawback is seen in in the upper part of the weight charts; 
the curves appear to go down above 1400 gram and, despite the very small numbers, the 
confidence interval narrows. This finding, of course, does not reflect an incline of brain size, 
but rather selection and censoring. These data are not “first measurements” [reflecting 
intra–uterine accomplished growth] but are follow–up data of patients with prolonged 
NICU admission, representing the most complex cases [e.g., with severe chronic lung 
disease] not stable enough to be discharged early. In conclusion, the last part of this curve 
depicts valid data that you would expect in a NICU population, but we consider these not 
representative for normal growth in preterm infants. 
The decreased growth rate of CCF length in female infants is in accordance with previous 
studies, which identified sex differences in brain structures and neurodevelopmental 
outcome.259,260 The positive association between BW SD score and CCF and CC growth rate 
is also in accordance with current literature.261      
One investigator who was trained in visualizing a standard sagittal plane performed all scans. 
This likely improved the quality of the scans and may have enhanced the reproducibility. 
We realize, therefore, that the clinical applicability is probably overestimated in our cohort. 
Reliable measurements and a correct sagittal plane using CUS depend on the experience of 
the observer but are easy to learn. Recently developed software to identify the sagittal plane 
automatically may further increase the reproducibility and clinical applicability.262
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This study has some limitations. First, in the Netherlands, preterm infants are 
transferred to a secondary hospital relatively early, accounting for very little data in our 
cohort of infants born at 29 weeks gestation and limited data of infants after 30 weeks 
gestation. Although white matter injury is already visible on scans after a few days, brain 
atrophy is often only noticeable after weeks to months.263 Our short follow–up time 
could explain why we did not find an association between expected clinical variables, 
such as sepsis and days on mechanical ventilation, and CCF or CC growth rate. Second, 
including all scans between 24 and 32 weeks postmenstrual age may have influenced 
the reliability of the growth charts; that preterm infants lose weight after birth and start 
to grow days later is a common finding. Brain growth may be limited before regain of 
birth weight [usually after 10 days]. This limitation may have increased variation in CC 
and CCF lengths. Extremely preterm and clinically unstable infants have a longer NICU 
stay and are likely to undergo more CUS. This might have biased our growth charts. On 
the other hand, our data reflect clinical practice in a neonatal intensive care setting.  
In future studies,  it would be interesting to compare fetal and preterm CCF growth. 
Currently, we are scanning fetuses in the second and third trimester of pregnancy 
to develop reference curves for fetal brain growth, which could also serve as an ideal 
growth curve for preterm infants. We were not able yet to assess the association 
between feeding regimens and growth during NICU stay and CCF growth trajectories. 
This is of interest because it may have clinical implications for nutritional practices. 
Moreover, CCF length can possibly be used as an outcome measure in nutritional and 
other intervention studies. It would be of main interest to assess whether CCF length, 
possibly combined with other available markers of brain growth such as CC length, 
could serve as predictor of neurodevelopmental outcome. The clinical applicability may 
extend beyond the NICU stay into the outpatient follow–up period because the anterior 
fontanelle can be used as an acoustic window until approximately 6 months in most 
infants. 
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ConCluSion
There is a lack of bedside markers for brain growth in preterm infants during NICU 
stay. We propose a feasible, new sonography measurement called ‘corpus callosum 
– fastigium length’ with high reproducibility for monitoring of brain growth in preterm 
infants during hospital stay. This marker may help clinicians determine whether 
preterm infants show adequate postnatal brain growth and may eventually be used 
as an outcome measure in nutritional and other intervention studies. Further research 
is warranted to assess whether this marker could also serve as an early predictor for 
short–term and long–term neurodevelopmental outcome. 
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abSTraCT 
baCkground and PurPoSe Most ultrasound markers for monitoring brain growth 
can only be used in either the prenatal or the postnatal period. We investigated whether 
corpus callosum length and corpus callosum – fastigium length could be used as 
markers for both prenatal and postnatal brain growth. 
maTerialS and meThodS  A three–dimensional [3D] ultrasound study embedded in 
the prospective Rotterdam Periconception Cohort was performed at 22, 26, and 32 
weeks gestational age in fetuses with fetal growth restriction [FGR}, congenital heart 
defects [ChD}, and controls. Postnatally, cranial ultrasound was performed at 42 weeks 
postmenstrual age. First, reliability was evaluated. Second, associations between 
prenatal and postnatal corpus callosum length and corpus callosum – fastigium length 
were investigated. Third, we created reference curves and compared corpus callosum 
length and corpus callosum – fastigium length growth trajectories of controls with 
growth trajectories of fetuses with FGR and ChD. 
reSulTS We included 199 fetuses; 22 with FGR, 20 with ChD, and 157 controls. 
Reliability of both measurements was excellent [intraclass correlation coefficient ≥0.97]. 
Corpus callosum growth trajectories were significantly decreased in FGR and ChD 
fetuses [β=–2.295; 95%CI –3.320;–1.270, p<0.01; β=–1.267; 95%CI –0.972;–0.562; 
p<0.01, respectively] compared with growth trajectories of controls. Corpus callosum 
– fastigium growth trajectories were decreased in fetuses with FGR [β=–1.295; 95%CI 
–2.595;0.003, p=0.05]. 
ConCluSionS Corpus callosum length and corpus callosum – fastigium length may 
serve as reliable markers for monitoring brain growth from the prenatal into the 
postnatal period. The clinical applicability of these markers was established by the 
significantly different corpus callosum and corpus callosum – fastigium growth 
trajectories in fetuses at risk for abnormal brain growth compared with those of controls. 
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inTroduCTion
In preterm and those small–for–gestational age, brain growth is an important predictor of 
neurodevelopmental outcome.98,233–235 Although prenatal growth often predicts postnatal 
growth, there is a traditional division between fetal and neonatal growth charts.108 This is 
mainly due to the lack of consistent measures of brain growth that can be used in both the 
prenatal and postnatal period.
Markers of brain growth that can theoretically be used in both the prenatal and postnatal 
periods include head circumference and a few ultrasound [US] and MR imaging 
measures. head circumference measured postnatally, however, lacks precision and does 
not correspond well with neurodevelopmental outcome.99,236 Prenatal and postnatal US 
markers are largely based on individual brain structures, only reflecting growth of a specific 
part of the brain.237–241 Moreover, these brain structures are not measured consistently 
during the prenatal and postnatal periods due to the absence of corresponding standard US 
planes. Although MR imaging provides more precise measures of brain growth, volume, and 
development, this technique is expensive and therefore not suitable for serial measurements.
Recently, we demonstrated that corpus callosum – fastigium [CCF] length is a 
reliable bedside–available US marker that can be used to monitor brain growth in 
preterm infants during neonatal intensive care unit stays.264 CCF length is considered 
a composite marker of diencephalon and mesencephalon size and thereby adds 
information to the more widely used corpus callosum [CC] length.264 We hypothesized 
that these two cranial ultrasound measures are feasible for use during prenatal US 
examinations. Thereby, these markers would provide a continuum for monitoring 
brain growth, bridging the period before and after birth.
Our main aim was to investigate whether CC and CCF length can be used as reliable US 
markers for monitoring fetal and neonatal brain growth. First, we assessed the reliability 
of the measurements. Second, we created reference curves from 22 weeks to 42 weeks 
gestational age [GA] by combining fetal and neonatal measurements. Finally, as a first 
step to evaluate the clinical applicability of these US markers, we investigated CC and CCF 
growth trajectories in fetuses at risk of abnormal brain growth and compared them with 
those of control fetuses. 
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meThodS
STudy deSign 
This three–dimensional [3D] US study was embedded in the Rotterdam Periconceptional 
Cohort [Predict study], an ongoing prospective cohort study at the Department of 
Obstetrics and Gynecology, Erasmus MC University Medical Center, Rotterdam, the 
Netherlands.104 At enrollment, all participating women and their partners gave written 
informed consent on behalf of themselves and their unborn child. This study was 
approved by the regional medical ethical and institutional review board of the Erasmus 
MC, University Medical Center in Rotterdam [MEC 2004–227; date of approval, January 
25, 2013]. 
Pregnant women were enrolled between November 2013 and July 2015. They were either 
enrolled before 12 weeks GA or between 22 and 32 weeks GA. Controls were enrolled 
before 12 weeks GA and were defined as fetuses without fetal growth restriction [FGR] 
before 32 weeks GA, born after 37 weeks GA, and without congenital anomalies. Cases 
included those pregnancies referred to our outpatient clinic with FGR or an isolated 
fetal congenital heart defect [ChD] between 22 and 32 weeks GA. The diagnosis was 
confirmed by an extended structural US examination at our hospital. FGR was defined 
as abdominal circumference or estimated fetal weight percentile of <5 according to 
hadlock.265  
For this analysis we excluded pregnancies ending in intra–uterine fetal death, termination 
of pregnancy, or only preterm birth [without FGR or ChD]. We also excluded fetuses 
with congenital anomalies other than ChD, with trisomy 21, and without US images.
STudy ParameTerS
According to Dutch clinical practice, GA in spontaneously conceived pregnancies 
was calculated based on first trimester crown–rump length measurements before 
13 weeks GA.172 In pregnancies conceived through in vitro fertilization, with or without 
intracytoplasmic sperm injection procedures, GA was calculated from the date of 
oocyte retrieval plus 14 days or from the day of embryo transfer plus 17 or 18 days after 
cryopreserved embryo transfer, depending on the number of days between oocyte 
retrieval and cryopreservation. 
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Data were collected on maternal characteristics, medical and obstetrical history, 
pregnancy course, and neonatal outcome from self–administered questionnaires in 
the first trimester, second trimester, and around delivery. Follow–up data on pregnancy 
outcomes were validated on the basis of an US report of the routine second trimester 
anomaly scan and on obstetric medical records.
PrenaTal SonograPhy
Prenatal 3D US examinations were performed on the Voluson E8 system [GE health 
Care, Milwaukee, Wisconsin] by using a 1 to 7 Mhz transabdominal transducer or 
a 6 to 12 Mhz transvaginal transducer. Primarily, we used an abdominal approach, 
but a transvaginal approach was considered when the fetus was in head–down 
presentation. Serial prenatal 3D US examinations and measurements were performed 
at 22, 26, and 32 weeks of gestation by 1 certified sonographer [IK]. Standard biometry 
were measured, including bi–parietal diameter, head circumference, abdominal 
circumference, and femur length. An estimation of fetal weight was calculated with the 
hadlock equation.265 Biometry was followed by detailed 3D neurosonography. Standard 
planes were obtained according to the International Society of Ultrasound in Obstetrics 
and Gynecology guidelines.266 CC and CCF length measurements were performed 
off–line in an exact mid–sagittal plane [Figure 1]. CC length is measured from genu to 
splenium, outer–outer border. CCF length represents the length between the genu of 
the CC and the fastigium [roof of the fourth ventricle].264 CCF length was only measured 
in images in which CC measurement was performed successfully. Manipulation of 
the 3D US volume to ensure an exact mid–sagittal plane for the measurements was 
performed in 4D View, Version 5.0 [GE healthcare].
PoSTnaTal aSSeSSmenTS
After birth, cranial ultrasound was planned between 42+0 and 42+6 weeks postmenstrual 
age, independent of GA at birth. Cranial ultrasounds were performed by an experienced 
team of researchers with MyLab 70 [Esaote, Genoa, Italy] with a convex neonatal probe 
[7.5 Mhz]. CC and CCF length measurements were performed offline by 1 researcher 
[JR] according to the method described above, with MyLab software. To enhance 
precision, we repeated all prenatal and postnatal measurements three times. The mean 
values were used in the statistical analyses.
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FIGURE 1 | PRENATAL MEASUREMENT OF CC AND CCF LENGTh 
Legend: [1] Corpus callosum [CC] length, outer–outer border; [2] Corpus callosum – fastigium length [CCF], 
from genu to the fastigium [roof of the 4th ventricle].
STaTiSTiCal analySiS 
For data analyses we used SPSS [Release 21 for Windows; IBM, Armonk, New york] 
and R statistical and computing software, version 3.1.3 [http://www.r–project.org]. 
Results with p values <0.05 were considered statistically significant. Previously, we 
demonstrated that postnatal measurements of CC and CCF length had good intra– 
and interobserver agreement.264 To evaluate the reliability and reproducibility of 
prenatal measurements, we randomly selected 30 US examinations of 30 different 
fetuses, equally divided across the three prenatal time points from the whole study 
population. CC and CCF length measurements were then performed in threefold by 
two independent observers [IK [1] and JR [2]]. We performed analyses for intra– and 
interobserver reliability, calculating the mean differences with 95% confidence intervals 
[CI] and intraclass correlation coefficients. Moreover, the extent of agreement was 
examined with the Bland–Altman method.
Generalized Additive Models for Location and Scale were used to create reference 
ranges of CC and CCF length measurements between 22 and 42 weeks GA in 
controls.267 To investigate whether cases showed deviations in CC and CCF growth, we 
created growth trajectories for each subject of the serial measurements of CC and CCF 
length between 22 and 42 weeks GA. A maximum–likelihood approach was used to test 
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whether polynomials of GA contributed to the best model fit. In the same manner, we 
tested the contribution of random and fixed effects of the intercept and slopes for all 
included polynomials. A quadratic model of GA with random intercept and slopes was 
designated as the best model. We placed the origin of the GA scale at 140 days GA. In 
this model, the variable indicating whether a fetus was FGR, ChD, or control was used 
as the covariate of interest [model 1]. Last, the final model [model 2] was adjusted for 
serial measurements of fetal weight and sex.
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reSulTS
STudy PoPulaTion
In total, 227 pregnant women were enrolled prenatally. After excluding pregnancies 
ending in intra–uterine fetal death [n=1], termination of pregnancy [n=1], preterm birth 
[n=14], congenital anomalies other than ChD [n=4], trisomy 21 [n=2], and withdrawals 
[n=6], the study population consisted of 199 pregnancies. Of these 199 fetuses, 22 
fetuses had FGR, 20 had ChD, and 157 were controls. The general characteristics of the 
study populations are listed in Table 1.
Table 1 | baSeline CharaCTeriSTiCS
Controls
[n=157]
Fgr
[n=22]
Chd
[n=20] missing
maternal characteristics
Age at enrollment [years] 32.3 [21;44] 29.7 [21;41] 33.0 [22;48] 7
Nulliparous 69 [44] 13 [68] 11 [58] 6
Mode of conception [IVF/ICSI] 48 [31] 2 [10] 2 [11] 3
Geographical background 6
  Western 126 [81] 15 [79] 18 [90]
  Non–Western 29 [19] 4 [21] 2 [10]
Educational level 8
  Low 20 [13] 4 [20] 0
  Intermediate 56 [36] 12 [60] 7 [39]
  high 79 [51] 4 [20] 11 [61]
Prepregnancy BMI [kg/m2] 22.9 [15.2;39.7] 22.9 [17.6;43.4] 23.4 [18.0;35.8] 19
Periconception folic 
acid initiation [yes]
149 [96] 15 [79] 18 [95] 6
Periconcepion smoking [yes] 25 [16] 3 [16] 3 [16] 8
Periconception alcohol 
consumption [yes]
44 [29] 4 [21] 10 [53] 9
neonatal characteristics
Birth weight [grams] 3345 [2035;4380] 1400 [400;2900] 3420 [1650 – 4140] 2
Gestational age at birth 
[weeks+days]
39+1 [37+0;41+5] 34+2 [26+3;39+3] 38+6 [28+4;41+5] 2
Males 82 [52] 11 [50] 13 [65] 0
Legend: Data are presented in median [interquartile range] or n [%]. Missing data were due to incomplete 
questionnaires.
Abbreviations: BMI, body mass index; IVF/ICSI, in vitro fertilization with or without intracytoplasmic sperm 
injection.  
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SuCCeSS raTeS and reliabiliTy analySeS
Of 542 prenatal 3D US scans, 377 contained a high quality mid–sagittal plane eligible 
for CC and CCF length measurements. Means and success rates of CC and CCF 
length measurements per gestational age are listed in Table 2. Success rates ranged 
between 61 and 75% for prenatal CC length measurements and between 59 and 72% 
for prenatal CCF length measurements. Postnatally, CC and CCF length measurements 
were successful in 97%. In 83% of the subjects, CC length was measured at least at two 
time points during the whole study period, and CCF length in 65%. 
Table 2 | SuCCeSS raTeS and meanS oF CC and CCF lengTh Per geSTaTional age
ga uS scans 
[n]
measurements
[n]
Success rate
 [%]
mean [Sd] 
[mm]
CC 22 166 124 75 26.35 [1.22]
26 188 138 73 34.33 [1.86]
32 188 115 61 41.56 [2.19]
42 143 138 97 48.09 [3.15]
CCF 22 124 89 72 33.09 [1.61]
26 138 82 59 39.39 [1.92]
32 115 81 70 45.86 [2.07]
42 143 138 97 52.26 [3.12]
 
Legend: Presented are the success rates, means and corresponding SD values of the CC and CCF 
measurements per full week of gestation. The success rates for CC length and postnatal CCF length were 
calculated by the number of successful measurements divided by the total number of US images. Success 
rates of prenatal CCF measurements were calculated by dividing the number of successful CCF measurements 
by the number of midsagittal images eligible for CC length.  
Abbreviations: CC, Corpus Callosum length in millimetres; CCF, Corpus Callosum – Fastigium length in 
millimetres; GA, gestational age in weeks; US, ultrasound; N, number.
The intra– and interobserver reliability and agreement are shown in Table 3. CC 
lengths measured by observer 1 were slightly smaller [mean difference, –1.109 mm; 
mean percentage difference, –3.4%] than those measured by observer 2. Ninety–five 
percent limits of agreement for all measurements represent excellent agreement when 
the CC and CCF length measurements were repeated by the same observer and good 
agreement when repeated by a second observer. Intraclass correlation coefficient 
values of both intra– and interobserver were ≥0.97, which represents excellent reliability.
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 Table 3 | inTra– and inTerobServer reliabiliTy For PrenaTal meaSuremenTS 
oF CC and CCF lengTh
absolute differences relative difference
mean 
difference
[mm]
95% Ci mean 
difference
[mm]
p value 95% limits of 
agreement 
[mm]
mean 
difference
[%]
95% limits of 
agreement
[%]
iCC
intraobserver CC 0.011 –0.228;0.250 0.923 –1.373;1.396 0.1 –4.1;4.3 >0.99
CCF 0.180 –0.157;0.517 0.284 –1.711;2.071 0.4 –4.7;5.4 >0.99
interobserver CC –1.109 –1.702;–0.515 0.001 –4.546;2.329 –3.4 –14.9;8.1 0.97
CCF –0.125 –0.741;0.492 0.684 –3.589;3.340 –0.4 –9.5;8.6 0.97
 
Legend: Intra– and interobserver reliability analyses for prenatal CC and CCF measurements in a random 
selection of 30 ultrasound scans. 
Abbreviations: CC, Corpus Callosum length; CCF, Corpus Callosum – Fastigium length; mm, millimeters; 
95%CI, ninety–five percent confidence interval; %, percentage; ICC, intraclass correlation coefficient.
linear mixed model analySeS 
In Figure 2A and 2B, the reference curves and individual growth trajectories of CC and 
CCF lengths are shown. The results of the linear mixed models estimating differences 
in the mean growth trajectories of CC and CCF length among controls and fetuses with 
FGR and ChD are shown in Table 4. Growth trajectories of CC length were significantly 
decreased in FGR and ChD fetuses compared with growth trajectories of controls. CCF 
growth trajectories were only significantly decreased in FGR fetuses compared with 
those of controls. In Figure 2C, these trajectories are graphically displayed.
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Legend: 
2A Reference curves between 22 and 42 weeks of gestation for CCF [left] and CC [right] length, with 5th, 10th, 50th, 
90th, and 95th percentiles.  
2B. Individual growth trajectories of CCF [left] and CC [right] length between 22 and 42 weeks of gestation. 
2C. Growth trajectories for controls [black], FGR [striped blue], and ChD [dotted red] fetuses.
Abbreviations: CC, corpus callosum; CCF, corpus callosum - fastigium; mm, millimeter. 
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Table 4 | linear mixed modelS: growTh TrajeCTorieS oF CC and CCF are inFluenCed 
by The PreSenCe oF FeTal growTh reSTriCTion and CongeniTal hearT deFeCTS
model 1 model 2
β 95% Ci p value β 95% Ci p value
CC Fgr –2.384 –3.262;–1.505 <0.01 –2.295 –3.320;–1.270 <0.01
Chd –1.252 –1.954;–0.549 <0.01 –1.267 –1.972;–0.562 <0.01
CCF Fgr –1.413 –2.500;–0.326 0.01 –1.295 –2.595;0.003 0.05
Chd 0.012 –0.829;0.963 0.98 0.000 –0.835;0.835 0.99
 
Legend: Data are presented in beta values [ß] with corresponding 95%CI and p values, compared to controls. 
Significant results [p<0.05] are in bold. Model 1 represents the crude model using GA and its polynomials 
as predictor and type of case as covariate of interest. Model 2 is the fully adjusted model adjusted for the 
covariates in model 1 and for serial measurements of fetal weight and sex.
Abbreviations: CI, confidence interval; CC, corpus callosum length; CCF, corpus callosum fastigium length; 
FGR, fetal growth restriction; ChD, congenital heart defect.
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diSCuSSion
here, we demonstrate that CCF and CC length may serve as reliable markers for 
monitoring prenatal and postnatal brain growth. Fetuses with FGR showed decreased 
growth of both CC and CCF length, while in fetuses with ChD, only CC growth was 
decreased between 22 and 42 weeks GA.
Our findings suggest that we are able to bridge the traditional division between fetal 
and neonatal US growth charts. To date, studies that combine fetal and neonatal US 
markers of brain growth in a single cohort are scarce. One explanation is that standard 
prenatal US planes containing easily recognizable landmarks of the brain do not 
correspond well with the standardized planes accessible by cranial ultrasound. This 
lack of correspondence results in differences in prenatal and postnatal measures and 
measuring methods. For example, head circumference assessed prenatally, calculated 
from the biparietal diameter and occipital frontal diameter, correlates poorly to direct 
postnatal measurement with a tape measure.99,268 Furthermore, changes in head shape 
can be induced by delivery [e.g., skull molding, edematous swelling, and hematomas]. 
In contrast to other prenatal US measurements, excellent reliability was shown for 
CC and CCF length, comparable with the reliability of the postnatal measurements.264 
On the basis of our data, we suggest that CCF length is the most reliable and relevant 
marker for monitoring brain growth. CCF length can be assumed to be a composite 
marker of multiple brain structures with different embryological origins. Therefore, CCF 
length may be a better representative of global brain growth than previous sonographic 
markers based on individual brain structures.237–241
Growth trajectories of CC and CCF length were decreased in fetuses at risk for abnormal 
brain growth and impaired long–term neurodevelopmental outcome. While studies using 
CCF length have not been published in literature before, CC length findings are in line with 
those in previous literature. The decreased CC growth trajectories in FGR fetuses are in 
accordance with findings of a recent MR imaging study that showed significantly reduced 
CC length in fetuses with FGR compared to CC length of appropriate–for–gestational–
age controls.269 Results from our previous study in preterm infants demonstrated a similar 
association between CCF length and birth weight SD score.264 There are, to the best of 
our knowledge, no publications on CC length in ChD fetuses with which to compare 
our results, though previous studies did report anomalies of the CC and reduction of 
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CC volume in children with ChD.270,271 The decreased growth trajectory of CC length 
in fetuses with ChD is, however, supported by accumulating evidence reporting that 
fetuses with ChD are at risk for abnormal brain growth and development.272–275 
Brain growth is an important predictor of neurodevelopmental outcome.98,234,276 
We hypothesize that the decreased CC and CCF growth trajectories observed in 
cases may have consequences for long–term outcome. In preterm infants, a shorter 
CC length is related to a higher risk of an adverse neurodevelopmental outcome 
at 2 years corrected age.235 Moreover, a significantly smaller corpus callosum was 
found in individuals with schizophrenia and autism.277,278 CCF length represents the 
diencephalon and thus includes thalamus development, which is crucial for cognitive 
functioning. Derangements in thalamus development are associated with adverse 
neurodevelopmental outcome.251 yet, the clinical relevance for neurodevelopmental 
outcome of differences in CC and CCF growth trajectories needs further investigation.
CliniCal aPPliCabiliTy
The landmarks used for CC and CCF length measurements are relatively easy 
to distinguish on US images. Prenatally, the main challenge is obtaining an exact 
midsagittal plane. The prenatal success rates are predominantly influenced by acoustic 
shadowing and the position of the fetus. 3D US can enhance precision by manipulating 
volumes to reconstruct the exact midsagittal plane.279–281 When a midsagittal plane 
is obtained, both measurements take <1 minute in experienced hands. Postnatally, a 
standard midsagittal plane is easy to obtain through the anterior fontanelle; also, the 
offline measurements of CC and CCF length take <1 minute. Newly developed software 
that enables the identification of the midline automatically could still improve the 
measurements for clinical practice.282
STrengThS and limiTaTionS 
Some considerations should be taken into account. First, our study was conducted 
in a tertiary hospital population, with a relatively high maternal age, mainly of western 
origin, and a high educational level. Therefore, replication of the data is warranted to 
validate our findings for the general population. Second, the small number of cases 
limits the conclusions of our study. We cannot exclude that absence of statistically 
significant findings may be due to lack of power. Third, the growth charts are based 
on measurements at four time points and may improve by including intermediate 
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time points to further smooth the curves. Finally, the US scans and measurements 
were performed by experienced observers, which potentially enhanced quality of the 
midsagittal images and thereby success rates and reliability. Clinical applicability may 
be overestimated as a consequence. Success rates of the measurements were mostly 
influenced by fetal position, which we assume to be independent of the variables in this 
study. We consider the prospective and longitudinal study design as strength of our 
study. Combining prenatal and postnatal measurements in one reference curve is an 
innovative method to facilitate monitoring of fetuses at risk of impaired brain growth.
FuTure imPliCaTionS For CliniCal Care and reSearCh
Tight collaboration between obstetric and neonatal researchers and caregivers is 
needed for bridging the gap when monitoring fetal and neonatal brain growth. This is of 
great importance for optimizing neurodevelopmental care in fetuses and infants at risk 
for abnormal brain growth and neurodevelopmental impairment. Easily applicable US 
tools that can be used independent of the prenatal or postnatal period will have clinical 
implications. We consider our reference curves useful for age–equivalent preterm 
infants as they are largely comparable to the postnatal reference curves between 24 
and 32 weeks in preterm infants from Roelants et al.264 In addition, CC and CCF length 
measurements may be applicable from midgestation onward and may theoretically be 
prolonged until closure of the anterior fontanelle in the first year of life. Future research 
should correlate these measurement to commonly used MR imaging markers and 
explore the link between the growth measures and functional neurodevelopmental 
outcome.
ConCluSionS
In this prospective cohort we demonstrated that CC and CCF length measurements 
are reliable markers for brain growth from the fetal into the early neonatal period. By 
combining prenatal and postnatal CC and CCF length measurements in 1 reference 
curve, we created a continuum for monitoring brain growth, irrespective of the intra– 
or extra–uterine environment. We demonstrated that fetuses at risk for abnormal 
brain growth [i.e., those with ChD and FGR] showed significantly decreased CC and 
CCF growth between 22 and 42 weeks GA. Whether these markers could serve as early 
predictors for neurodevelopmental outcome in later life warrants further research.
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abSTraCT
baCkground Very–low–birth–weight [VLBW] infants are at risk for neurodevelopment 
impairment. This study assessed the effect of early aggressive parenteral nutrition [PN] 
on long–term outcome in VLBW infants.  
maTerialS and meThodS Directly after birth, VLBW infants [birth weight <1500 g, 
n=142] were randomized to five different PN regimes. Controls [n=46] received glucose 
and standard–dose amino acids [AAs; 2.4 g/kg/d] from birth onward and pure soybean 
oil fat emulsion [SOy] on the second day of life. Two intervention groups received 
glucose, standard–dose AAs, and lipids from birth onward; SOy [n=24] or mixed fat 
emulsion [MIX, n=25]. The two other intervention groups received glucose, high–dose 
AAs [3.6 g/kg/d], and lipids from birth onward; SOy [n=24] or MIX [n=23]. The primary 
outcome of this follow–up study was the composite outcome of “death or major 
disability” at 2 years corrected age. Secondary outcomes were death, major disabilities, 
neurodevelopmental scores, and anthropometry. 
reSulTS Follow–up rate was 92% [n=134]. Thirty–five [26%] infants had died or 
had a major disability, with no differences between intervention groups and controls. 
Increased odds for death were observed in the standard–dose AA–MIX group  [OR 5.4, 
95% confidence interval 1.1;27.0]. Neurodevelopmental scores and incidence of major 
disabilities did not differ between groups. Growth in the high–dose AA–MIX group was 
enhanced compared with controls at 2 years corrected age [+0.51 [0.01;1.02] weight 
SD score]. 
ConCluSionS This randomized controlled hypothesis–generating study demonstrated 
no beneficial effect of early high–dose AA administration and mixed fat emulsions on 
survival and neurodevelopmental outcome in VLBW infants, although growth was 
enhanced. 
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inTroduCTion
Preterm birth is the leading cause of perinatal morbidity and mortality and contributes 
significantly to long–term neurodevelopmental impairment and growth failure.42,283 
Nutrition in the early postnatal phase is pivotal for growth and development of all organs, 
including the brain. This is especially true for very low–birth–weight [VLBW] infants. 
Over the past decades, major changes in nutritional regimes have been implemented 
in clinical practice aiming to prevent iatrogenic malnutrition. Current regimes include 
early parenteral feeding with carbohydrates and amino acids [AAs] from birth onwards, 
and the start of fat emulsions soon after birth.48  
Short–term effects of these “aggressive” parental feeding strategies have been well 
studied.284–286 Stable isotope and nitrogen balance studies showed higher anabolic 
rates after early, aggressive parenteral nutrition [PN].52,53,285 Long–term outcomes 
of nutrition intervention trials have been little studied.287–289 Several large cohort 
studies showed, however, that nutrient delivery in the first week of life has long–
term implications for growth, neurodevelopment, and the development of neonatal 
diseases.290–292 Randomized controlled trials [RCTs] assessing the long–term effect of 
high–dose AAs in combination with lipids from different sources from birth onward in 
VLBW infants have not been performed yet.  
In this report we describe the 2–year survival and neurodevelopmental outcome in 
VLBW infants who received different PN regimes in an earlier performed RCT. We 
hypothesized that giving high–dose AAs combined with lipid administration directly 
after birth would result in improved survival, neurodevelopmental outcome, and growth 
up to 2 years corrected age. Secondly, we hypothesized that mixed fat emulsions 
would improve neurodevelopmental outcome compared with pure soybean oil fat 
emulsions.  
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meThodS
STudy deSign 
This study describes the planned follow–up of an RCT on early PN in VLBW infants.53 This 
RCT was conducted between December 2008 and January 2012 at the level IV neonatal 
intensive care unit [NICU] of the Erasmus MC – Sophia Children’s hospital, Rotterdam, 
the Netherlands [registered at TrialRegister.nl: NTR1445]. Inborn infants with a birth 
weight <1500 grams were eligible for inclusion. The exclusion criteria were congenital 
anomalies [including chromosomal defects]; metabolic diseases; renal, hepatic or 
endocrine disorders; and other disorders interfering with growth or neurodevelopment. 
The local medical ethical review board approved the study protocol. Written informed 
consent was obtained prior to inclusion. The methods, including randomization 
procedure, and short–term outcome results [safety and efficacy assessed by nitrogen 
balances and stable isotope quantification] of this RCT were published previously.52,53,207 
The nutritional interventions are summarized below.  
nuTriTion ProToCol 
Immediately after birth, all infants received 6 mg/kg/min glucose and 2.4 g/kg/d AAs 
as standard care. Within 6 hours after birth, they were randomized, in a factorial trial 
design, to one of five study groups [Supplemental table 1]: 
 
ConTrol grouP Glucose and standard AA administration was continued during the first 
2 days of life. Lipid administration [pure soybean oil fat emulsion, SOy] was started at 1.4 
g/kg/d on the second day of life and increased to 2.8 g/kg/d the next day.  
STandard [ST] aa + Soy/mix Glucose and AA dosage was similar to that of the con-
trol group. Lipids were started at 2 g/kg/d immediately after birth and increased to 
3 g/kg/d on the second day of life. Infants were 1:1 randomized to either SOy or mixed 
fat emulsion [MIX].  
high aa + Soy/ mix Standard glucose was given, similar to the other study groups. In ad-
dition, a higher dose of AAs [3.6 g/kg/d] and 2 g/kg/d lipids were given from birth onward. 
Lipids were increased to 3 g/kg/d on the second day of life. Infants were 1:1 randomized to 
either SOy or MIX.
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After day 3, the intervention ended and thereafter the attending physician followed the 
local standardized protocol.195 The enteral nutrition [EN] protocol included minimal 
enteral feeding at day 1 and a daily gradual increment of approximately 20 mL/kg/d 
of enteral bolus feeding from day 2 or 3 onwards until 150–180 mL/kg/d was reached. 
PN was ceased when 130 mL/kg/d of enteral feeding was tolerated. Breastfeeding was 
strongly encouraged, but if expressed breast milk was insufficiently available, preterm 
formula was supplemented to realize the intended enteral intake [Nenatal Start; 
Nutricia, Zoetermeer, the Netherlands]. Breast milk was fortified when infants tolerated 
at least 100 mL/kg/d enterally until discharge. Formula fed infants received Nenatal 1 at 
discharge home [Nutricia, Zoetermeer, the Netherlands].195  
All infants received the same AA solution: Primene 10% [Baxter, Utrecht, the 
Netherlands]. Infants in the control group received lipids based on pure soybean oil, 
Intralipid 20% [SOy], while infants in the intervention groups were randomized to either 
Intralipid 20% or SMOFlipid 20%, which is a MIX containing 30% soybean oil, 30% 
medium–chain triacylglycerol, 25% olive oil, and 15% fish oil [both Fresenius Kabi, Bad 
homburg, Germany].  According to the local protocol, parenteral AA administration was 
temporarily lowered if plasma urea concentrations were >10 mmol/l and temporarily 
stopped if plasma urea concentrations were >14 mmol/l. Similarly, parenteral lipid 
administration was temporarily lowered when triacylglycerol concentrations were >3 
mmol/l, and temporarily stopped if triacylglycerol concentrations were >5 mmol/l.8 
Nutritional intakes were in accordance with the study protocol.53 Data of all infants were 
analyzed based on the “intention–to–treat” principle. 
ouTCome meaSureS 
The primary outcome [adverse outcome] was defined as the composite outcome of 
death or major disability at 2 years corrected age. Secondary outcomes were death; 
major disabilities; neurodevelopmental scores [mental and psychomotor score] based 
on the Bayley Scales of Infant and Toddler Development, Third Edition [BSID III] at 2 
years corrected age; and anthropometry at 6 weeks and 2 years corrected age.  
Major disabilities included cerebral palsy [CP, Gross Motor Function Classification 
System level [GMFCS] ≥2]293, severe hearing loss [deaf or neurosensory hearing loss 
partly corrected by hearing aids], severe visual impairment [blind or severe visual 
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impairment], and mental or psychomotor score <70 points [<–2 standard deviation 
[SD]]. 
All surviving infants were examined at the outpatient clinic at 6 weeks and 2 years 
corrected age as part of our standard assessment program on neurodevelopment 
and growth after NICU admission. Study group allocation was blinded to all examiners. 
Certified psychologists and developmental therapists assessed the neurodevelopmental 
outcome using the composite BSID III scores of cognition [mental score] and motor 
development [psychomotor score]. The diagnosis CP was confirmed by an experienced 
pediatric–neurologist. 
Anthropometric data at birth, discharge or 40 weeks corrected age, whichever came 
first [both Fenton growth chart], and at 6 weeks and 2 years corrected age [both World 
health Organization [WhO] growth chart] included sex and gestational age–corrected 
SD scores for weight, length, and head circumference [hC] of surviving infants.171 222 
Weight and hC data at birth were available. Length was not measured at birth. Mean 
delta [Δ] SD scores for weight and hC were calculated between birth and 6 weeks and 
between birth and 2 years corrected age, taking into account the time between the 
measurements. The following formulas were used: 
Mean ΔSD/week:   [SD score 6–weeks – SD score birth]
   [[date of measurement – date of birth]/7]
Mean ΔSD/month:   [SD score 2–years – SD score birth]/
   [[date of measurement – date of birth]/31]
In case of missing data, all available clinical information was reviewed on the presence 
of major disabilities. The occurrence of an adverse outcome, death or major disability 
[yes/no] in infants who were not tested at two years corrected age was established 
from medical records and information from parents if available. They were left out of 
the scores for the separate tests of the BSID III. 
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CliniCal daTa 
Obstetrical data, neonatal data on gestational age at birth, birth weight, sex, socio–
economic status [SES], and data on neonatal morbidity and neonatal outcomes were 
collected during the study. Definitions of neonatal outcomes have been published 
before.53 SES SD scores were validated ZIP–code–derived SD scores based on local 
average income, low–income rate, low educational level rate, and unemployment rate.294
STaTiSTiCal analySiS 
The data are presented as mean [SD], median [interquartile range [IQR]] or number 
[percentage]. A 2–tailed p value of <0.05 was considered statistically significant. 
Sample size calculation was based on the original trial’s primary, short–term outcome: 
nitrogen balance.53
Differences in baseline characteristics between children included in the analyses and 
those lost to follow–up were analyzed using Mann–Whitney test or the Fisher exact 
test, as appropriate. 
Associations between the interventions and the primary and secondary outcomes were 
analyzed using multivariable logistic or linear regression analysis as appropriate and 
expressed in odds ratios [OR] or effect sizes [β] with 95% confidence intervals [CIs]. If 
the count of outcomes was zero in a group and regression analysis was therefore not 
possible, univariable analysis was performed using the Fisher’s exact test. Based on 
the literature and availability of prospectively collected data we identified the following 
potentially relevant confounders for the multivariable analyses: gestational age at 
birth, birth weight SD score [or hC SD score for analyses using hC as an endpoint], 
sex, and SES SD scores. All intervention groups were added to the model as a dummy 
variable. Collinearity diagnostics were performed on these covariates before definite 
decision on their use in the multivariable regression model. Correlations between the 
covariates were <0.60. All residuals of the linear regression analyses were distributed 
approximately normally. Potential effect modification between the AA and lipid 
interventions [AA dosage * lipid source] on the primary and secondary outcomes was 
assessed by adjustment for interaction terms. 
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Differences between groups in mental and psychomotor scores were assessed 
with univariable analysis using Kruskal Wallis and multivariable analysis using linear 
regression. No correction for multiple testing was applied.295  
Data were collected prospectively and analyzed using SPSS package 21.0 [IBM SPSS 
Statistics, Armonk, Ny].
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reSulTS
Of the 144 infants included in the original trial, two infants were excluded because of 
congenital disorders interfering with neurodevelopmental outcome. Eight infants [6%] 
were lost to follow–up, mainly due to emigration [Supplemental figure 1]. The BSID III 
was administered in 103 infants [93% of the surviving infants]. These children all 
completed the mental assessment. Ninety of these infants [87%] also completed the 
psychomotor assessment. In Table 1, baseline and neonatal characteristics are given 
for the whole group [n=134] and for the different study groups. Baseline characteristics 
did not differ between included and those lost to follow–up [data not shown].  
Primary ouTCome 
In total, 35 infants [26%] had an adverse outcome at 2 years corrected age; 23 infants 
had died and 12 infants had one or more major disabilities. No association was found 
between study group allocation and the primary outcome [Table 2]. The addition of 
an interaction–term to evaluate potential effect modification between the AA and lipid 
interventions did not alter the results of the analyses. 
SeCondary ouTComeS 
The presence of major disabilities at 2 years corrected age did not differ between study 
groups [Table 2 and 3]. however, after adjustment for potential confounders, infants 
in the standard AA and mixed fat emulsion group had a 5.4 [95%CI 1.1;27.0, p=0.040] 
times higher odds for death before 2 years corrected age than infants in the control 
group. Effect modification between AA and lipid interventions was not found.    
The mental and psychomotor scores in all infants were 100 [IQR, 90;105] and 100 [IQR, 
91;107], respectively. No differences were found between study groups [Supplemental 
table 2].
Weight SD score dropped between birth and 6 weeks corrected age in all groups. 
hereafter, catch–up growth was seen for all groups up to 2 years corrected age [Table 
4 and Figure 1]. hC SD score was stable or had even slightly increased between birth 
and 6 weeks corrected age, and also showed catch–up growth between 6 weeks and 2 
years corrected age. At 6 weeks corrected age, SD and Δ SD scores for weight and hC 
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were significantly higher in the infants given high–dose AA and mixed fat emulsion [high 
AA + MIX] compared to those in the control group. At 2 years corrected age, only the 
weight scores were higher in the high AA + MIX group [Table 4]. Length SD scores did 
not differ between groups at both time points [data not shown]. 
Table 1 | baSeline CharaCTeriSTiCS For ToTal CohorT [n=134] and Per STudy grouP
all infants   
 [n=134]
Control group 
[n=44]
St aa + Soy 
[n=21]
St aa + mix
[n=24]
high aa + 
Soy
[n=24]
high aa+mix
[n=21]
Sex [male] 64 [48] 23 [52] 10 [48] 11 [46] 13 [54] 7 [33]
ga [weeks+days] 26+6 27+3 26+2 27+1 26+5 27+1
[25+5;29+0] [26+2;29+3] [25+2;28+1] [25+6;28+6] [25+2;28+2]  [26+2;28+2]
bw [grams] 848 863 808 846 775 850 
[680;1000]  [651;1013] [665;920] [726;1000]  [680;988] [685;1078]
bw Sd score –0.4 –0.7 –0.2 –0.4 –0.6 –0.4 
[–1.3;0.3] [–1.6;0.1] [–1.4;0.5] [–0.8;0.3] [–1.2;0.2] [–1.2;0.5]
Sga at birth 
[<–2 Sd for weight]
8 [6] 6 [14] 0 [0] 0 [0] 1 [4%] 1 [5%]
Prenatal steroids 
[0/1/2 doses]
3/26/105 
[2/19/79]
1/5/38 
[2/11/87]1
1/2/18 
[5/9/86]
0/9/15 
[0/38/62]
1/5/18
 [4/21/75]
0/5/16 
[0/24/76]
Caesarean section 87 [65] 29 [66] 14 [67] 16 [67] 14 [58] 14 [67]
apgar score [5 min] 8 [6;9] 8 [7;9] 8 [7; 9]3 8 [6;9] 7 [6;9] 8 [7;9]
Crib score 4 [1;8] 4 [1;9] 4 [1;8] 4 [1;7] 4 [1;9] 5 [1;8]
SeS Sd score –0.5 
[–1.8;0.4]
–0.3 
[–1.8;0.5]
–0.5 
[–2.1;0.4]
–0.5 
[–1.7;0.4]
–0.7 
[–1.7;0.3]
–0.4 
[–1.2;0.3]
neC stage≥ iia 5 [4] 2 [5] 2 [10] 1 [4] 0 [0] 0 [0]
late–onset sepsis 40 [30] 7 [17] 11 [48] 6 [26] 9 [41] 7 [32]
roP gr iii or higher 4 [3] 2 [5] 0 [0] 0 [0] 2 [8] 0 [0]
mechanical ventilation 
days
5 [1;18] 5 [0;12] 11 [1;24] 4 [1;7] 7 [1;22] 5 [0;16]
Severe brain injury2 7 [5] 2 [5]3 0 [0] 2 [8] 1 [4] 2 [10]3
 
Legend: All data is presented in n,% or median [interquartile range]. 1 One mother received four doses of prenatal 
steroids. 2 Severe brain injury is defined by intraventricular hemorrhage grade III or IV [based on Papille], periventricular 
leukomalacia grade II or higher, venous infarction. 3 1 missing value. 
ROP and days on mechanical ventilation were not scored in infants who had died. NEC was not scored in the infants who 
died of another cause than NEC.   
Abbreviations: AA, amino acid; BW, birth weight; CRIB, clinic risk index for babies; GA, gestational age at birth; MIX, 
mixed lipid emulsion; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; SD score, standard deviation 
score based on Fenton; SES, socio–economic status; SOy, soybean oil lipid emulsion; St, standard–dose.
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Table 3 | adverSe ouTComeS For ToTal grouP and Per STudy grouP
all infants
 [n=134]
Control 
group 
[n=44]
St aa + 
Soy 
[n=21]
St aa + 
mix
[n=24]
high
aa + Soy 
[n=24]
high
aa + mix
[n=21]
number 
missing/
available 
infants
death 23 [17] 5 [11] 4 [19] 6 [25] 5 [21] 3 [14] 0/134
mental score <70 5 [4] 2 [5] 0 [0] 1 [4] 1 [4] 1 [5] 8/111
Psychomotor score 
<70
4 [3] 2 [5] 0 [0] 1 [4] 0 [0] 1 [5] 21/111
Severe visual 
problems
1 [3] 1 [2] 0 [0] 0 [0] 0 [0] 0 [0] 3/111
Severe hearing 
problems
0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 0 [0] 3/111
Cerebral palsy 7 [5] 1 [2] 0 [0] 1 [4] 2 [8] 3 [14] 0/111
major disability 12 [9] 4 [9] 0 [0] 1 [4] 3 [13] 4 [19] 0/134
adverse outcome 35 [26] 9 [20] 4 [19] 7 [29] 8 [33] 7 [33] 0/134
 
Legend: All data are presented in number [%]. 
Multiple major disabilities in one patient is possible. An adverse outcome is defined as one or more major disabilities 
or death before 2 years corrected age. Of the patients alive with missing data, information was obtained from medical 
records and parents to categorize them in major disability yes/no. 
Abbreviations: AA, amino acid; MIX, mixed lipid emulsion; n, number; SOy, soybean oil lipid emulsion; St, standard–
dose.
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Table 4 | anThroPomeTriC analySeS aT 6 weekS and 2 yearS CorreCTed age uSing 
mulTivariable linear regreSSion
St aa + Soy St aa + mix high aa + Soy high aa + mix
adjusted β 
[95%Ci]
p value
adjusted β 
[95%Ci]
p value
adjusted β 
[95%Ci]
p value
adjusted β 
[95%Ci]
p value
6 weeks weight SD score 0.11 
[–0.42;0.64]
p=0.68
0.27 
[–0.24;0.79]
p=0.29
0.42 
[–0.10;0.94]
p=0.11
0.81 
[0.29;1.33]
p=0.003
ΔSD/week 0.006 
[–0.02;0.03]
p=0.68
0.014 
[–0.01;0.04]
p=0.30
0.023 
[–0.004;0.05]
p=0.09
0.043 
[0.02;0.07]
p=0.002
hC SD score 0.03 
[–0.62;0.69]
p=0.92
0.08 
[–0.56;0.71]
p=0.82
0.32 
[–0.35;0.99]
p=0.35
0.83 
[0.20;1.47]
p=0.011
ΔSD/week -0.01
[-0.04;0.03]
p=0.96
0.00 
[–0.03;0.03]
p=0.99
0.02 
[–0.02;0.05]
p=0.31
0.05 
[0.00;0.08]
p=0.008
2 years weight SD score –0.18 
[–0.69;0.33]
p=0.48
–0.22 
[–0.73;0.29]
p=0.40
–0.03 
[–0.54;0.48]
p=0.90
0.51 
[0.01;1.02] 
p=0.048
ΔSD/month –0.006 
[–0.03;0.01]
p=0.51
–0.008 
[–0.03;0.01]
p=0.44
–0.001 
[–0.02;0.02]
p=0.90
0.02 
[0.00;0.04]        
p=0.047
hC SD score –0.69 
[–1.4;0.01]
p=0.053
–0.48 
[–1.23;0.26]
p=0.20
–0.30 
[–1.00;0.41]
p=0.40
0.61 
[–0.07;1.28]
p=0.08
ΔSD/month –0.025 
[–0.05; 0.00]
p=0.06
–0.018 
[–0.046;0.01]
p=0.20
–0.010 
[–0.04;0.02]
p=0.44
0.02 
[–0.002;0.05]
p=0.07
 
Legend: Shown are the results of multivariable linear regression [effect size, 95% confidence interval and p value] of 
standard deviation [SD] score and SD score change from birth to 6 weeks corrected age per week [n=109] and from 
birth to 2 years corrected age per month [n=103] per study group compared to the control group. Significant results 
[p<0.05] are printed in bold. Data are adjusted for birth weight SD score or head circumference SD score [if head 
circumference was used as outcome], gestational age at birth, sex, and socio–economic status.  
Abbreviations: AA, amino acid; MIX, mixed lipid emulsion; SOy, pure soybean oil emulsion; St, standard–dose. 
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Figure 1| growTh Per STudy grouP From birTh To 2 yearS CorreCTed age
Legend: On the x–axis are depicted the 4 different time points of growth assessment: birth, discharge or 40 weeks 
corrected age [term age], 6 weeks corrected age, and 2 years corrected age. On the y–axis is depicted the SD score of 
weight using the Fenton growth chart [birth and discharge] and the WhO growth chart [6 weeks and 2 years corrected 
age].  
Abbreviations: AA, amino acid; ca; corrected age; MIX, mixed lipid emulsion; SD, standard deviation; SOy, soybean oil 
lipid emulsion; st, standard–dose.
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diSCuSSion
To our knowledge, this is the first RCT investigating the long–term effect of high–
dose AA and mixed lipid administration in the first days of life in VLBW infants. This 
hypothesis–generating study did not find a beneficial effect of the interventions on 
survival with normal neurodevelopmental outcome at 2 years corrected age. Neither 
did it find a beneficial effect of any of the interventions on neurodevelopmental scores 
and incidence of major disabilities. however, infants who had received high–dose AA 
and mixed fat emulsion from birth onward showed enhanced growth up to 2 years 
corrected age. Surprisingly, the odds for death were higher in the standard–dose AA 
and mixed fat emulsion group, which will be discussed below. 
Small nutritional interventions in the first days of life can have long–lasting effects.296 
When we were designing this study, we hypothesized that the interventions in this 
trial would influence long–term outcome based on the following mechanisms. First, 
increased AA provision leads to increased protein synthesis and thus growth and 
development, provided sufficient energy is supplied.297 Early start of parenteral lipids 
can, at least partly, improve the caloric intake. Second, mixed fat emulsions might be 
more beneficial for long–term development than pure soybean oil emulsion, based on 
three biological mechanisms: [1] a higher supply of very long–chain polyunsaturated 
fatty acids [e.g., docosahexaenoic acid [DhA]], essential for central nervous system 
development; [2] administration of fewer phytosterols, which are thought to be the 
hepatotoxic component of soybean oil fat emulsion; and [3] possibly decreased 
rates of septicemia, which could prevent brain injury.298,299–301 The short–term results 
of this study indeed showed improved nitrogen balances, enhanced growth, higher 
albumin synthesis rates, and lower phytosterol levels in blood. Effects on other possible 
mechanistic factors for later outcome, such as septicemia, bilirubin levels, or duration 
of intravenous fluids, were not found.52,53,300
In this follow–up study, we found insufficient evidence for any positive effect of early 
high–dose AA administration, early lipid administration, or the use of a mixed fat 
emulsion on neurodevelopmental outcome. These results need to be interpreted with 
caution because of the low power: absence of evidence is not evidence of absence. The 
failure to detect a neurodevelopmental effect might be due to several reasons. First, 
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the actual differences in intake might have been too small and the intervention period 
might have been too short to generate a long–lasting effect on neurodevelopmental 
outcome in a relatively small sample size.53 Second, the effect might also be diluted by 
the heterogeneous study group of infants. Extremely low–birth–weight infants can be 
expected to benefit most from the interventions. Unfortunately, the small sample size 
did not allow for subgroup analysis in this specific patient group. Third, the instruments 
used to detect neurodevelopmental impairment might not be sensitive enough to detect 
small differences in cognitive outcome. Specifically the BSID III may lack sensitivity to 
detect subtle differences in clinical outcome that may still be clinically relevant.302 
It is certainly also possible that there was truly no effect of the interventions on 
neurodevelopment. Other trials with comparable AA intakes, but without lipid 
interventions, also found no effect on neurodevelopmental outcome.288,289 The ideal 
composition of AA solutions and the balance between energy and AA intake, necessary 
for optimal protein synthesis and long–term effects, are still unknown. In addition, 
recent insights on the developmental origins of health and disease [DOhaD] hypothesis 
suggest that the effect of fetal programming may be more relevant on the long–term 
outcome than interventions postnatally.4 
Unexpectedly, we found increased odds for death in the study group that had received 
standard–dose AA together with mixed fat emulsion. We wonder whether this finding 
reflects a true effect, as no such effect was seen in the other groups with comparable 
AA dosage [st AA + SOy] or in the other group that also received a mixed fat emulsion 
[high AA + MIX]. Moreover, proper judgement on mortality is difficult due to the small 
sample size. Correction for multiple testing would lead to the conclusion that the finding 
was not statistically significant. The finding cannot easily be explained by differences 
in baseline characteristics between the randomized study groups.53 Also in current 
literature comparable findings cannot be found: mixed lipid emulsions from birth onward 
were not associated with an increased risk of adverse outcome in prior research.303,304 
Moreover, previous literature questioned the safety of high–dose AA administration, but 
not of standard–dose AA administration.212,213 A biochemical explanation for a harmful 
interaction thus seems not likely. 
however, to further explore the trend for mortality and to increase power, we performed 
three multivariable post–hoc analyses on the three outcomes. In these analyses, we 
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combined intervention groups according to [1] lipid source: MIX [n=45] vs SOy [n=45], 
[2] AA dosage: high–dose [n=45] vs standard dose [n=45], and [3] timing of lipid 
introduction as follows: early lipid [all intervention groups combined, n=90] vs late 
introduction [controls, n=44]. In the first two post–hoc analyses, which only included 
intervention groups, no significant associations were found for all outcomes [data not 
shown]. The third analysis showed a nonsignificant adjusted OR for death of 2.7 [95%CI 
0.76;9.4, p=0.128]. For the other outcomes, we did not find a significant association 
either [data not shown].  
In conclusion, we believe that the increased risk for death in the standard AA + MIX 
group most likely reflects no true effect but rather a false–positive finding [type I error]. 
Large multicenter trials are needed to confirm our findings, but those are difficult to 
perform in this specific vulnerable study population. Therefore, meta–analysis of 
multiple RCTs is likely necessary to draw conclusions on long–term effects of early 
nutrition interventions. 
The neurodevelopmental scores in our study may seem rather high for preterm infants, 
even taking into account the general overestimation of the BSID III compared to the 
BSID II.305–307 An overall improvement of neurodevelopmental outcome over time may 
explain this finding. Note, however, that fewer motor scores than mental scores were 
available. This reflects refusal of assessment or incomplete assessment due the fatigue 
in most cases. Fatigue may also have influenced the results of tests that were fully 
performed, possibly resulting in lower scores. however, the contrary is also plausible; 
infants who are less capable of performing the test might have had a higher refusal rate, 
which might have led to selection and overestimation of the capacities of the group. The 
BSID III is widely applied in clinical practice and in research but does not seem a very 
sensitive test for assessment of neurodevelopment in infants. Follow–up into school 
age may reveal more subtle differences in brain function.
Between birth and discharge, weight SD score decreased in all study groups, while 
hC SD scores remained relatively stable. Between discharge and 6 weeks and 2 years 
corrected age, weight and hC showed catch–up growth. In the first period, in which brain 
sparing is observed, this might be the result of non–individualized nutrition practices 
and restrictions in nutrient intake by fluid restriction and [biochemical] intolerance of 
PN and EN. The catch–up growth after 6 weeks corrected age might be the result of 
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a high caloric and protein intake via discharge formula and of nutrition practices more 
geared to the infants’ needs and personal appetite.  
Of interest is the higher growth from birth onward observed in the high AA + MIX 
group. Analyses showed an increased SD change at both time points for the high AA 
+ MIX group: +0.04 SD score/week at 6 weeks and +0.02 SD score/month at 2 years 
corrected age. This means that an infant in the high AA + MIX group, born, for example, 
at 28 weeks, has on average a 0.04 x [40 – 28 + 6] = 0.72 higher SD score for weight 
at 6 weeks corrected age compared to an infant in the control group born at the same 
gestational age. We realize that we did not correct for multiple testing, and therefore the 
effect might be a false positive finding. however, the observed difference is rather large 
and may well be of clinical relevance. As the increased growth was not accompanied 
with measurable improved neurodevelopmental outcome, one can debate whether this 
increase in growth benefits metabolic health. Unfortunately, we do not have data on 
body composition or other markers of cardiometabolic health in this study. 
limiTaTionS
Some aspects of the design are worth mentioning. Despite the high follow–up rate [92%], 
the sample size remained relatively small, which is reflected by the wide confidence 
intervals. As a result of the small sample size, we were not able to perform per protocol 
analysis in addition to the intention–to– treat analysis. As discussed above, due to the 
limited power in our study, we consider our data as hypothesis generating. 
We decided to adjust for different maternal and perinatal characteristics and not for 
postnatal variables. hereby, we prevented adjustment for factors that may actually 
be the result of the nutrition interventions, but we may have overlooked relevant 
confounders.  
We did not correct for multiple testing, as it is still unclear when and how correction for 
multiple testing should be performed. We advise to judge the clinical relevance of the 
different findings on the effect sizes and confidence interval rather than on p values and 
their cut–offs.295,308
The question of which growth chart to use in the neonatal period and during follow–
up of preterm infants is still under debate. As recommended, we used two consecutive 
references, the Fenton and the WhO growth charts, which complicates the interpretation 
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of growth between discharge and 6 weeks corrected age.197 Focus should therefore 
primarily be on the post–discharge long–term growth. We did not have information on 
EN after the intervention period, such information may have provided more insight in 
the long–term growth findings. 
ConCluSion
We reported on the 2–year follow–up of an earlier performed nutrition intervention 
RCT on the effect of parenteral high–dose AA combined with mixed fat emulsion 
administration from birth onward in VLBW infants. No beneficial effects of the 
interventions on survival and neurodevelopmental outcome at 2–years corrected age 
could be demonstrated, although enhanced growth was observed. We recommend 
future researchers studying nutrition interventions in VLBW infants to focus on follow–
up with sensitive tests for the detection of neurodevelopmental impairment and to 
strive for large study populations. 
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SuPPlemenTal Table 1 | nuTriTion ProToCol during inTervenTion Period
 
day 1 day 2 day 3
Controls Glucose mg/kg/min 6 6 6
AA        g/kg/d 2.4 2.4 2.4
Lipids g/kg/d 0 1.4 2.8
Protein energy   kcal/kg/d 9.6 9.6 9.6
Total energy kcal/kg/d 44.6 50.2 63.4
Protein:energy ratio % 21.5 19.1 15.1
Standard–dose aa Glucose mg/kg/min 6 6 6
AA        g/kg/d 2.4 2.4 2.4
Lipids1 g/kg/d 2 3 3
Protein energy   kcal/kg/d 9.6 9.6 9.6
Total energy kcal/kg/d 62.6 66.3 71.6
Protein:energy ratio % 15.3 14.5 13.4
high–dose aa Glucose mg/kg/min 6 6 6
AA        g/kg/d 3.6 3.6 3.6
Lipids1 g/kg/d 2 3 3
Protein energy   kcal/kg/d 14.4 14.4 14.4
Total energy kcal/kg/d 67.4 71.1 76.4
Protein:energy ratio % 21.3 20.2 18.8
 
Legend: 1Lipids are either mixed lipid emulsion or pure soybean oil lipid emulsion. 
Abbreviations: AA, amino acid; d, day; mg, milligram; min, minute; kcal, kilocalories; kg, kilogram. 
SuPPlemenTal Table 2. median [iQr] menTal and PSyChomoTor SCoreS in Children 
aT 2 yearS CorreCTed age, Shown For all inFanTS and Per STudy grouP
all infants
[n=103&90]
Control group
[n=36&33]
St aa + Soy
[n=16&13]
St aa + mix
[n=17&17]
high aa+Soy
[n=17&15]
high aa+mix
[n=17&12]
mental score 100 [90;105] 98 [86;105] 100 [95;105] 100 [93;105] 95 [88;100] 100 [90;110]
Psychomotor score 100 [91;107] 100 [91;107] 100 [97;105] 97 [91;107] 97 [91;107] 104 [92;109]
 
Legend: No significant differences between groups. 
Abbreviations: AA, amino acid; MIX, mixed lipid emulsion; n, number of developmental scores; IQR, interquartile range; 
SOy, soybean oil emulsion; St, standard–dose. 
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SuPPlemenTal Figure 1 | ConSorT Flow diagram
Assessed for eligibility 
[n=415]
Randomized [n=146]
Included in analyses of 
original study [n=144]
Withdrawn from study [n=2]
Excluded [n=269]:
– No informed consent [n=123]
– No opportunity to obtain consent 
within 6 h after birth [n=130]
– Consent but not included [n=10]
– Language barrier [n=6]
Excluded based on congenital 
disorders [n=2]
Eligible infants for follow up  
[n=142]
Control group 
[n=46]
St AA + SOy 
[n=24]
St AA + MIX
[n=25]
high AA + SOy
[n=24]
high AA + MIX
[n=23]
Lost
[n=2]
Lost
[n=3]
Lost
[n=1]
Lost
[n=0]
Lost
[n=2]
Control group 
[n=44]
St AA + SOy 
[n=21]
St AA + MIX
[n=24]
high AA + SOy
[n=24]
high AA + MIX
[n=21]
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This thesis describes research that crosses the borders between prenatal and postnatal 
life – an important step in joining both fields at a scientific level. Although from the 
maternal perspective, embryonic, fetal, and neonatal life may be a continuum; clinical 
care is traditionally divided into different departments for pregnancy and neonatal care. 
The staff’s different background, training, and goals and points of view can complicate 
close cooperation. For the individual patient but also on a population scale, loss of 
information and lack of knowledge about previous [for neonatologists] or future [for 
obstetricians] care can have implications for health on the long term. In this chapter, we 
attempt to link the prenatal to the postnatal life.  
idenTiFying PregnanCieS aT riSk oF an adverSe ouTCome
PregnanCy ouTCome 
In clinical practice, embryonic growth and development are assessed using two–
dimensional [2D] ultrasonography [US] between 9 and 14 weeks of gestation. The 
development of three–dimensional [3D] US techniques has tremendously improved 
imaging of the embryo, making it now possible to visualize the embryo from 6 weeks 
of gestation onward.111 3D measures are more sensitive for detection of altered growth 
trajectories than 2D measures: crown–rump length [CRL], a 2D measure, increases 
from approximately 1 centimeter at 7 weeks to 5 cm at 11 weeks of gestation – a 5–
fold increase. Embryonic volume, a 3D measure, increases 30–fold within the same 
time frame [Chapter 2]. We hypothesized that by using 3D measures and virtual 
reality it becomes possible to identify pregnancies at risk of an adverse birth outcome 
already early in the first trimester. In Chapter 2, we investigated the association 
between embryonic size and growth parameters and the risk of preterm birth, small 
for gestational age, congenital anomalies, and perinatal mortality [adverse birth 
outcomes]. We showed that already early in the first trimester, a small sized embryo 
has increased odds of an adverse birth outcome: with each cm3 increase in embryonic 
volume the odds of an adverse birth outcome decreases with 12%. These data add 
to findings of previous studies conducted at the end of the first trimester.108,115,116 We 
additionally evaluated the association between embryonic growth [growth rate between 
time points] and birth outcome. For CRL growth between 6 and 13 weeks of gestation, 
we did not observe a statistically significant association. Embryonic volume growth in 
this period was negatively associated with the odds of being small for gestational age at 
birth.  
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These data confirm that embryonic growth is not uniform and that pregnancies 
at increased risk of an adverse outcome can be identified already early in the first 
trimester. These findings add to the growing body of evidence on the relevance of the 
periconceptional period for embryonic, fetal, and neonatal health.
An important aspect of the methodology of this study is the procedure of pregnancy 
dating. Information on the menstrual cycle is often lacking, requiring pregnancy dating 
based on CRL measurement. This methodology assumes that embryonic development 
is uniform until the moment of dating – which we, and previous studies, showed not 
to be true.309 To minimize the bias of ignoring variation in growth, pregnancy dating 
on the basis of CRL should be performed as early in pregnancy as possible. Our 
study suggests, however, that no large effect of bias has been introduced by dating 
based on CRL [1/4th of our cohort]. This might be the result of dating around 9 
weeks of gestation, rather than at 11 – 14 weeks which is usual in clinical care.27  
Using current 3D techniques we are now able to reliably measure embryonic growth from 
around 7 – 8 weeks of gestation onward.29,111 We therefore advocate to date early in the 
first trimester. In clinical care this is challenging as the Dutch obstetric care system follows 
pregnancies from around 10 – 14 weeks of gestation onward. Moreover, high–quality US 
devices and expertise are necessary for reliable measurements this early in pregnancy and 
those are not yet widespread available.  
Prediction of pregnancies at risk of an adverse outcome would preferably be done as 
early in pregnancy as possible, to extend the time window for interventions. Despite the 
use of 3D US, using current markers we are not able to detect differences in growth before 
9 weeks of gestation [Chapter 2]. Improvements of 3D techniques and measures may 
further improve detection of growth differences already in this very early period. 
Prediction of pregnancies at risk of an adverse birth outcome should not only include 
measures of growth and development, but also risk factors such as [epi]genetic profiles, 
maternal age, the occurrence of prior adverse pregnancy outcomes, and geographical 
background.309–312 Other markers that should be considered are measures of environmental 
conditions such as maternal inflammation levels, and later in pregnancy measures of 
placental health, volume, and functioning.313,314
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neonaTal adiPoSiTy 
Obesity is a multifactorial disorder, with genetics, epigenetics, and healthy and lifestyle 
conditions playing a role in its development.118 In early life, adiposity is considered an 
important marker of obesity and cardiometabolic health. As obesity may be difficult, if 
not impossible, to reverse, we would also like to identify embryos and fetuses at risk for 
adiposity. Previous studies identified several fetal markers of neonatal adiposity. Those 
markers include maternal characteristics [e.g., maternal BMI], laboratory measures 
[e.g., glucose and hbA1c] and 2D and 3D US measures. Based on our systematic 
review, we could not recommend the use of specific measures to identify fetuses at 
risk of neonatal adiposity. The use of 3D US measures seemed nevertheless promising 
[Chapter 3]. We therefore looked into the use of fetal fractional thigh volume, a 3D US 
measure, as marker of neonatal adiposity and showed that this measure was negatively 
associated with neonatal adiposity at 22 weeks of gestation. Additionally, we showed 
that also fractional thigh volume growth between 22 and 32 weeks of gestation was 
negatively associated with neonatal adiposity [Chapter 4].  
Most studies assessed the use of US measures as markers of neonatal adiposity 
only in the third trimester of pregnancy [Chapter 3]. This is probably the result of the 
physiological fetal growth pattern, with in the first and second trimester only lean mass 
accretion and fetal fat accretion starting in the third trimester.5 This does, however, not 
imply that [tissue–specific] measurements should not be performed before the third 
trimester. Important differences in body composition might already be present and 
detectable early in pregnancy, especially because high adiposity levels may either be 
the result of increased fat mass or of decreased lean mass [Chapter 4].
Despite lack of useful prenatal markers of neonatal adiposity in current literature, it 
is important to identify fetuses at risk of neonatal adiposity. Risk profiles for neonatal 
adiposity should include risk factors for increased adiposity levels, such as maternal 
BMI, ethnicity, and age, but also genetic profiles [Figure 1].118,153 3D US measures 
to assess differences in body composition should also be included. Fractional thigh 
volume, assessed in Chapter 3, is a relatively feasible marker for clinical practice, as it 
is measured on a standard US plane and quickly performed.167 Our results on the use 
of fractional thigh volume are, however, not completely in line with other studies on 
fractional thigh volume.147,169 The use of this marker for clinical practice has thus not been 
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established yet. Another interesting marker, because of the underlying hypothesis and 
more consistent findings across studies, is fetal liver blood flow. An increased fetal liver 
blood flow is associated with increased hepatic nutrient synthesis and adiposity.145,315 
We did not study this marker because a major disadvantage of this marker is that under 
circumstances of nutrient excess,  fat accretion is suggested to be less dependent 
on hepatic nutrient synthesis, making the marker less reliable in this patient group.315 
Thus, as currently available 3D measures of body composition showed either limited 
association with body composition, inconsistent findings, or are only useful in a selected 
patient population, we propose that new measures should be developed.  
early human brain growTh 
Markers for fetal and neonatal brain growth are very scarce. Prenatally, brain growth is 
regularly monitored using bi–parietal diameter and occipital frontal diameter, which 
are used to estimate head circumference. These are however very rough measures. 
Moreover, they are not used postnatally, while ideally the same markers could be used 
throughout pregnancy and in early infancy. Therefore, we created an US measure based 
on the corpus callosum and the fastigium [roof of the 4th ventricle] [Chapter 7]. Corpus 
callosum – fastigium length is an US measure that reflects a large part of the brain, covers 
brain structures of different embryonic origins, and is measured on a standard midsagittal 
US plane, making it feasible for both prenatal and postnatal clinical care. We showed that 
this marker is feasible and can reliably be measured in both the prenatal and postnatal 
environment [Chapter 7 & 8]. The corpus callosum is the largest white matter structure 
in the human brain, connecting the left and right cerebral hemisphere, thereby enabling 
interhemispheric communication.245,316 Being formed in the first trimester, it keeps on 
growing up to adulthood – making it an ideal marker for serial monitoring.317 A disadvantage 
of corpus callosum – fastigium length is that it can only be visualized from 20 weeks of 
gestation onward, while alterations in brain development may already be present earlier.258  
We showed in Chapter 8 that fetuses with fetal growth restriction had decreased 
corpus callosum – fastigium length growth trajectories, supporting the theory that this 
measure might be useful to detect differences in brain growth in the prenatal period. 
Before implementation in clinical care, the predictive value of the measure for long–
term outcome should be established.
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inTervenTionS
As shown above, it is generally believed that pathways leading to increased risk of 
adverse birth outcomes are often related to prenatal maternal health and lifestyle 
factors – often referred to as environmental factors, as the mother is the environment 
of the fetus – in the periconceptional period.41 Ideally, prevention should thus take 
place in the preconceptional period. Improving environmental factors will likely improve 
embryonic and fetal health, but the effect of interventions need further study. Also 
means of effective implementation should be focus of research, as many parents–to–
be are unaware of the relevance of a healthy lifestyle for health of their offspring and 
future generations. To increase awareness, local, national, and European governments 
should in our opinion focus more on the relevance of a healthy lifestyle for becoming 
healthy pregnant and delivering a healthy neonate. There is also an important task for 
general practitioners, midwifes, and other healthcare professionals dealing with parents 
and their offspring, in informing people about the detrimental effects of poor lifestyle 
behavior on short–term and long–term health. The use of mobile health [mhealth] 
might be helpful in providing tailored and repeated information to parents–to–be and 
monitoring of the effects of lifestyle improvements.318 
Realistically, improving lifestyle behavior will not be that easy and the prevalence of 
adverse birth outcomes will thus only slowly decline. As plasticity is high in the first 
1000 days, it might be possible to reverse programming by [lifestyle] interventions in 
pregnancy or even after birth. Early identification of pregnancies at risk of an adverse 
outcome may therefore still be beneficial for health on the long term. By using risk 
profiles throughout gestation, and specifically monitoring of growth and biomarkers, 
risks can be re–estimated and the effect of interventions can be evaluated. This 
longitudinal evaluation might help obstetricians and neonatologists when making 
decisions on timing of termination of pregnancies. 
An important aspect of this monitoring is placental functioning. Postnatally assessed 
placenta size [length, thickness, and weight] is associated with birth weight, but does 
not add to the prenatal prediction of pregnancy outcome. US measures of placental 
functioning mainly consist of Doppler measures of the uterine artery.319 Prior research 
looked into the use of placental growth factor and soluble fms–like tyrosine kinase–1 as 
biomarkers of placental functioning, but mainly focused on its use for predicting severity 
of pre–eclampsia, and not for their usefulness in predicting pregnancy outcome.320,321 
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Thus, more research is thus needed to adequately monitor placental functioning during 
pregnancy, especially because the placenta is also an important target for interventions 
by improving nutrient and oxygen transfer to the fetus. 
PreTerm inFanTS  
SeTTing The SCene
Improvements of neonatal care in the last decades have resulted in change of focus 
in research concerning preterm infants; from survival toward improving long–term 
health. health outcome of preterm infants is influenced by many factors in early life, 
including gestational age at birth, neonatal morbidity, and parental health and lifestyle. 
The relevance of nutrition and growth in early life on neurodevelopmental outcome 
and cardiometabolic health has been well recognized, but many questions remain on 
optimal nutrition and growth for long–term outcome. 
The general recommendation that fetal growth rates should be mimicked postnatally in 
preterm infants for optimal health outcomes is lacking solid evidence.55,56 Clear evidence is 
available of the harmful effects of growth retardation and the associated nutritional deficits 
on the presence of major neonatal morbidities and organ development and functioning 
of, amongst others, the brain, bones, and kidney.50,322,323 Moreover, also consequences of 
postnatal growth retardation on cardiometabolic health have been described – supporting 
the DOhaD paradigm in neonatal life.324 To date, we still don’t know whether optimal outcome 
is achieved when fetal growth rates are mimicked postnatally. First, because in most 
published research, fetal growth rates are not mimicked during neonatal intensive care unit 
[NICU] stay, and second, because mostly only short–term follow–up is performed.  
Let’s assume that fetal growth rates should be mimicked postnatally to achieve 
optimal health outcomes. Besides differences between the intra–uterine and extra–
uterine environment which hamper growth in early life as mentioned in Chapter 1, 
there are also some practical issues that greatly influence the chance of meeting the 
targets. After healthy term birth, weight loss of ~10% is considered a physiological 
phenomenon, and within 2 weeks, healthy infants catch up their loss and continue 
growing on their initial growth trajectory.325 In our study, we confirmed that preterm 
infants experience a similar drop in weight in the first week after birth, but their pattern 
of recovery is different [Chapter 5]. This postnatal weight loss was an important 
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determinant of growth retardation in the first month of life. It explains why growth 
targets are not met when calculated from birth onward, but met when this period of 
weight loss was not taken into account in growth evaluation [Chapter 5]. Despite also 
other studies observing this phenomenon in preterm infants, knowledge is still lacking 
on the influence of this early weight loss for long–term outcome: should we aim for 
less weight loss postnatally, or should it be considered a physiological phenomenon 
necessary for adapting to the extra–uterine life after preterm birth?326 These findings 
emphasize the importance of establishing which growth periods are most important for 
cardiometabolic and neurodevelopmental outcome.     
After the initial period of growth retardation, we and others observed that many infants 
show rapid or so–called catch–up growth, sometimes already during hospital stay, 
but mostly in the first months thereafter [Chapter 6 and 9].67 Nowadays, increasing 
concerns are expressed on the influence of rapid growth on long–term cardiometabolic 
health. Rat studies showed that enhanced intake in growth restricted rats resulted in 
catch–up growth, with improved neurodevelopmental outcome but also increased 
body adiposity.327,328 This supports the hypothesis that catch–up growth in preterm 
infants might be beneficial for neurodevelopmental outcome, but harmful for 
cardiometabolic health on the long–term.68 Timing of catch–up growth seems to be 
relevant for its influence on outcome. In term born infants, the first three moments of 
life have been identified as critical window for cardiometabolic health.219,329 In preterm 
infants, however, the critical window has not been determined yet. Some studies 
show beneficial, while others found harmful effects of catch–up growth in the first 2 
years.69,324,330 In Chapter 9, we showed that increased parenteral amino acid and lipid 
intakes in the first days after birth resulted in higher growth rates in infancy and early 
childhood, but without beneficial effects on neurodevelopmental outcome. Although 
we do not have information on body composition in those infants, if the rapid growth 
consisted merely of fat and not of lean mass, it may reflect increased cardiometabolic 
risk as a result of rapid growth in the first 2 years of life. 
In Chapter 6 we showed that growth in early postnatal life is associated with body 
composition at 6 weeks after term age, while body composition around 6 months after 
term age is more determined by growth after term age. Because we only have short–term 
outcome measures, the effect on long–term health – which should be considered the 
most important outcome measure –  remains unclear. Previous studies demonstrated 
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that relative fat mass is higher around term age in preterm infants, but normalizes or 
decreases even below levels of term born infant 3 – 4 months hereafter.77,231 In our cohort, 
relative fat mass was comparable or already lower than relative fat mass of term born 
infants. At 6 months after term age, relative fat mass was almost 1 SD lower.219 It is still 
unclear why relative fat mass – often referred to as adiposity – of preterm infants is high 
in early life, while later it normalizes or even goes below adiposity of term born infants in 
early infancy, and then increases again in childhood and adulthood.77,82,330 Although the 
effect in childhood is thought to be related to programming in early postnatal life [DOhaD 
paradigm], the underlying mechanism of the increased adiposity around term age is 
still unclear. Some suggestions are a direct effect of programming due to an imbalance 
between nutrient supply in–utero and ex–utero; inadequate protein:energy ratio or 
amino acid composition during neonatal intensive care unit [NICU] stay, resulting in 
fat rather than lean mass growth; and increased fat accumulation for energy storage 
and thermal regulation.58 The decrease in adiposity in infancy may reflect differences 
in energy expenditure, due to impaired neurodevelopment and related physical activity 
patterns, or early metabolic or endocrine changes. 
The importance of parenteral nutrition on short–term outcomes such as survival and 
growth has been well established, but long–term outcome data remain scarce. In a 
randomized controlled trial [RCT] we found no beneficial effects of early high–dose [3.6 
g/kg/d] amino acid and mixed lipid administration after birth on neurodevelopmental 
outcome. In the standard–dose [2.4 g/kg/d] amino acid and mixed lipid emulsion group 
we observed increased odds for death. This unexpected finding can be considered an 
accidental finding in our study with low power [Chapter 9]. however, also other studies 
showed worrying results on the use of parenteral nutrition and specifically of early 
high–dose amino acid administration in preterm infants.212–214,331 Also in critically ill term 
born infants increasing concerns are expressed on the use of parenteral nutrition and 
amino acids.216,332 Undoubtedly, supply of amino acids is essential in early life of preterm 
infants, as the infant otherwise depends on its own limited protein stores for obligatory 
protein catabolism. The optimal amino acid dosage, which may partly depend on the 
postnatal age and the level of illness, has however not been established yet. Probably, 
there are circumstances during which [high] amino acid provision is harmful, for 
example in periods of septicaemia.332,333 This supports more individualized nutritional 
practices in the NICU setting to improve outcomes and survival rates.  
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GENERAL DISCUSSION
enTeral nuTriTion 
The relevance of parenteral nutrient supply in early life for growth is very well 
established.182 After the acute phase, enteral nutrition is an important determinant of 
growth. Own mothers milk is believed to be most beneficial for neurodevelopment and 
cardiometabolic health.334 Still, many infants depend on formula milk during NICU stay, 
of which the optimal composition has not been established yet. Also in own mothers 
and donor milk, composition of the milk is not always optimal for the developing 
preterm infant.335 Personalized supplementation of milk, based on breast milk analyses, 
may improve growth and health outcomes.336 In Chapter 6 we showed that high weight 
gain in the stable growing phase is associated with high relative fat mass – emphasizing 
the relevance of adequate enteral nutrition for an optimal growth and body composition 
in this period.  
underlying meChaniSmS oF adverSe healTh ouTComeS aFTer PreTerm birTh  
Underlying mechanisms of the risk for an adverse long–term outcome after preterm 
birth still need to be unraveled, especially as it may provide targets for interventions. 
Different pathways are suggested to be involved in the increased risk of abnormal 
organ development and functioning. Proposed pathways are presented in Figure 1 
and include genetic predisposition; epigenetic changes induced by prematurity; rapid 
telomere shortening due to prematurity and environmental conditions related to 
prematurity; epigenetic changes by early life conditions such as nutrition and stress; 
and changes in the hypothalamic–pituitary adrenal [hPA]–axis.337–340 Disturbances of 
physiological processes have also been suggested to increase the risk for an adverse 
outcome. A physiological process of interest is the circadian rhythm.341 The circadian 
rhythm is the biological clock, regulating day–night rhythm of cells and organs.342 
This rhythm can be disturbed by environmental conditions such as stress, light, and 
nutrition. In preterm born infants, the [development of] a circadian rhythm is likely 
disturbed as a consequence of the shorter maternal clock guidance and the unnatural 
NICU environment, with unnatural light–dark cycles, noise, artificial feeding schemes, 
and disturbed sleep.343,344 As the circadian rhythm is involved in glucose homeostasis, 
insulin secretion, and energy metabolism, chronodisturbance can have detrimental 
effects on cardiometabolic health.345,346 Animal and human adult studies also showed 
adverse effects of chronodisturbance on brain development.347–349  
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Another system involved in both neurodevelopmental and cardiometabolic outcome 
is the gut–brain axis. The gut microbiome – a collective word for millions of bacteria 
that colonize the gut – interacts with the brain via immunological, endocrine, and 
neural pathways. The microbiome is suggested to influence the risk of an adverse 
neurodevelopmental and cardiometabolic health via the hPA axis, via upregulation of 
energy from the diet, and by the induction of chronic inflammation.350,351 
Important to mention is that brain structure, volume, and functioning are related to 
obesity levels in animals, adults and children.352,353 The exact underlying mechanisms 
are unclear, but may relate to brain alterations interfering with glucose homeostasis and 
control of food intake [Figure 1], thereby increasing metabolic derangement, increasing 
obesity levels which will increase inflammation levels, which in turn will again influence 
brain functioning.354 Whether this association is also present in preterm infants needs to 
be established, as no solid conclusions can be drawn based on current literature.355–357 
inTervenTionS
Preterm infants all have different phenotypes, based on their prenatal condition, gestational 
age and weight at birth, neonatal morbidities, feeding type, and geographical and socio–
economic background. Based on these factors, the risk of an adverse outcome varies widely 
between preterm infants. Ideally, risk profiles will be developed in the future to identify those 
at risk of an adverse health outcome, including parental, prenatal, and postnatal conditions. 
Using this profiling, more adequate estimations can be given in early life to parents with 
regard to long–term outcome, which may support ethical decision–making. Later in life, 
more targeted therapy and advices can be given to parents, including advices on lifestyle, 
nutrition, and exercise, and guidance by physio– and speech therapists.  
Effective interventions to improve health outcomes of preterm infants may be related to 
nutrition.72 In Chapter 5 we showed that energy intakes in the first day of life are lower 
than recommended by the ESPGhAN guideline, and also lower than necessary for 
targeted growth. Improving energy supply, for example by increasing early parenteral 
lipid intake, may be beneficial for early growth and thereby for long–term health 
outcomes. Other important aspects of parenteral nutrition which can be improved are 
the protein:energy ratio and the amino acid composition of the parenteral and enteral 
solutions, as plasma amino acid levels determine protein synthesis rates.358 Tailored 
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made parenteral solutions, providing an optimal amount of amino acids and energy for 
protein synthesis, might in the future improve both short–and long–term outcomes. 
Another nutritional target of interest are probiotics, which showed to reduce 
the occurrence of necrotizing enterocolitis, and may be beneficial for brain 
and cardiometabolic health by decreasing morbidities rates and by reducing 
inflammation.359,360   
The development of a circadian rhythm may also be an interesting target for 
interventions. Prevention of chronodisturbance may have beneficial effects on both 
neurodevelopmental and cardiometabolic health.361,362 It can be influenced via several 
pathways: light–dark cycling combined with reduced noise may promote the 
development of a circadian rhythm, and thereby improve growth.362 But also nutrient 
supply may greatly influence this; parenteral nutrition can be given in intervals rather than 
continuously, or with varying dosages over the day, and also provision of enteral nutrition 
can be improved. human milk composition changes over time, and also during the day, to 
meet the infants’ changing nutritional demands.363 Although in milk of mothers who have 
delivered prematurely this is less well investigated, it might be that the non–physiological 
feeding schemes, including breast milk given disrespected of moment of expression, 
greatly influence the development of the infant’s circadian system, making it an easy 
target for improvement. 
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meThodologiCal ConSideraTionS 
The studies described in Chapter 2, 4, and 8 have been conducted in the Predict 
study and the embedded DREAM study. These prospective observational cohort 
studies are conducted in a tertiary hospital population that is not representative of the 
general population.104 Studying a high–risk population is advantageous for unravelling 
underlying mechanisms, but limits the external validity of the findings. Many data 
used in these studies were obtained via self–administered questionnaires. Although 
the most common health and lifestyle factors, such as alcohol and smoking, were 
additionally checked by the research team at the first visit, misclassification may have 
occurred. In our study, for example, smoking status may have been underreported as 
the prevalence was only 16% in periconceptional period [Chapter 2].364 Moreover, a 
well–trained research team performed the 3D ultrasounds and the subsequent 3D 
measurements, likely increasing the reliability and precision of the measurements. 
The BOND study, described in Chapter 5 and 6, is conducted on a large tertiary NICU. 
Generalizing our results to intensive care settings with lower level of care and less 
extremely preterm infants is difficult. In addition, discharge policies in the Netherlands 
are different than in other countries, resulting in a relatively short duration of NICU stay. 
This may have influenced our growth data, and the external validity of our NICU findings. 
By including data from the high care centers and collecting post discharge growth data 
we were still able to study the most important period of growth. 
All studies, but especially follow–up studies that require active parent participation, 
automatically select parents who are willing to participate in such studies. This selection 
may limit the generalizability to the source population and may induce selection bias, as 
participation correlates with social, educational, and health conditions. It was, however, 
previously demonstrated that this selection is less likely to introduce bias than loss to 
follow–up.365 Actual loss to follow–up was limited to only two infants in our study, but not 
all infants did completely follow the study protocol. This was mainly caused by purely 
logistic problems such as availability of the devices, and not related to maternal, fetal, or 
neonatal characteristics. Therefore, we expect that this has barely biased our findings.  
The last consideration is the use of the PEA POD® for body composition measurement. 
Although the PEA POD® is generally considered the gold standard, its value is limited 
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by only two compartments [lean and fat] that are evaluated, compared to the three 
compartments which can be assessed using DEXA or MRI [lean, fat, and bone].13 
Moreover, as mentioned in Chapter 1, the PEA POD® does not provide any information 
on fat distribution [subcutaneous versus visceral], which is a known and important risk 
factor for cardiometabolic health.366 With regards to preterm infants, the PEA POD® 
has been validated from 30 weeks of gestation onward, which is relatively early, but 
its use in this period is hampered as infants need to be without oxygen supply for 
approximately 5 minutes, decreasing the feasibility during NICU stay. 
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ConCluSionS 
In conclusion, we learned that embryonic size and growth parameters are associated 
with birth outcome in early pregnancy, with the 3D measure of embryonic volume 
being more sensitive for detection of deviations in growth trajectories than standard 
2D measures. 
Continuing into fetal life, we showed that fractional thigh volume is a promising 3D 
soft tissue marker for prediction of neonatal adiposity in midgestation. We additionally 
showed that brain growth can be monitored reliably pre– and postnatally by using the 
newly developed ultrasound measure corpus callosum – fastigium length. 
Continuing into postnatal life of preterm infants, we showed that preterm infants are 
still at high risk for growth retardation in the neonatal period, despite meeting the 
macronutrient recommendations from birth onward. Postnatal weight loss greatly 
influences neonatal growth outcomes, making this an interesting target for future 
research. We also learned that growth rates in the first weeks to months of life are 
associated with adiposity levels up to 6 months after term age. Additionally, we did 
not demonstrate a beneficial effect of parenteral high–dose amino acid and mixed 
lipid emulsion administration from birth onward in very–low–birth–weight infants on 
neurodevelopmental outcome, despite enhanced growth. 
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FuTure reSearCh on idenTiFying PregnanCieS aT riSk 
 
Research on identification of pregnancies at risk of an adverse outcome is still in 
its infancy, and many opportunities remain for future research. A few important 
considerations should be taken into account when designing future research projects. 
The Third dimenSion 
The use of 3D techniques in prenatal care is increasing, but the additional value is 
limited by the evaluation on a 2D screen. In Chapter 2, we used a virtual reality system 
allowing for 3D evaluation by creating a hologram; a 3D image created via photographic 
projection. The recent development of a desktop version of this system is promising 
for future research and clinical care, as it allows for real–time bedside evaluation of 3D 
scans.121
Size or growTh?
Many people use growth interchangeably for size and growth. But what exactly 
is size, and what is growth? And should we indeed consider growth, and not size as 
an important marker of health status? Size represents weight or length at a specific 
moment, not taking into account the size before that specific moment. In clinical care, 
size is most often assessed, although sometimes the terminology suggests otherwise 
[e.g., ‘[intra– or extra–uterine] growth retardation’]. In Chapter 4, we show that 
decreased thigh volume is associated with increased relative fat mass. In Chapter 2, 
we demonstrated that a smaller embryonic size is associated with higher odds of an 
adverse birth outcome. Being small thus has implications, but being small is actually 
the outcome of a growth trajectory. Evaluation of growth trajectories might therefore be 
even more relevant for short– and long–term health. In Chapter 2, 4, and 8 we indeed 
showed that altered growth trajectories are associated with the occurrence of adverse 
birth outcomes. Future research should thus not only focus on size, but also on growth 
trajectories.   
From PrenaTal To PoSTnaTal liFe
Ideally, the same growth marker is used both prenatally and postnatally. A major 
limitation of continuous growth evaluation is however the lack of markers that can 
be used consistently in both periods, or even throughout pregnancy. New markers 
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should be developed that can be used both prenatally and postnatally, as in clinical 
care postnatal growth trajectories should be evaluated in light of the prenatal growth 
trajectory. 
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FuTure reSearCh on nuTriTion and growTh in 
PreTerm inFanTS
Although much research has been performed on nutrition and growth, many questions 
remain. The focus of research on nutrition and growth in preterm infants should not 
be on mimicking of fetal growth rates but on establishing growth rates for optimal 
health outcome. To establish this, we should first determine which outcomes should be 
evaluated, and when they should be assessed. 
whiCh ouTComeS Should be evaluaTed?  
Currently, follow–up of preterm infants mainly focusses on psychomotor and mental 
outcome. however, using current tests, subtle differences may not be recognized while 
significantly influencing everyday life. More specific measures of brain functioning, such 
as eye-tracking [assessment of processing of visual input], might provide additional 
information on functioning in daily life.  Also assessment of executive functioning 
could be integrated in follow–up of preterm infants in childhood. Assessment of 
insulin sensitivity [fasting insulin and homeostasis Model Assessment [hOMA]–IR], 
inflammation [CRP], stress [cortisol], and body composition might also be helpful in 
identification of infants and children at risk for obesity. For parents and their infants, 
quality of life may be most important, which should be included more often as 
outcome measure in research. Assessment of risk factors such as the microbiome and 
chronodisturbance, during the period on the NICU as well as in infancy and childhood, 
may provide additional information on the risk of an adverse health outcome. 
Timing oF evaluaTion 
Long–term rather than short–term outcome should be considered the most important 
outcome as the long–term relevance of short–term outcomes is often unclear and 
many outcomes are not detectable yet in infancy and childhood using currently 
available markers. Ideally, infants should be followed up into adulthood to provide an 
adequate estimation on the influence of early life on health throughout the life course. A 
downside of long–term follow–up is the large time window between interventions and 
outcomes, hampering the clinical relevance and decreasing the applicability in practice 
at moment of publication. Moreover, follow–up over a longer time results in higher loss 
to follow–up rates, thereby potentially inducing bias.365 Using assessments at regular 
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time intervals [for example every 3 to 4 years] may limit the numbers lost to follow–up 
and provides intermediate effects of the intervention.  
randomized ConTrolled TrialS or CohorT STudieS? 
For well–defined clinical questions randomized controlled trials [RCTs] and meta–
analyses are needed. RCTs efficiently deal with confounders that cannot sufficiently be 
adjusted for in cohort studies. But RCTs are no longer considered the only way to obtain 
unbiased evidence.367 Clinical practice is often more complex than can be mimicked 
in an RCT, and the magnitude of beneficial effects found in RCTs are often not found 
in cohort studies after clinical implementation. Furthermore, RCTs often need external 
funding, which may create conflicts of interests in case of industry–sponsored research. 
In future research, important knowledge can be derived from cohort studies, provided 
that study design and analyses are chosen with care and results are interpreted 
carefully.368 As multiple outcomes combined with long–term follow–up require large 
sample sizes, collaboration between centers is strongly recommended. This does not 
only provide the opportunity to include more infants in a shorter timeframe, it also 
increases external validity of the findings. 
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Summary
The development from an embryo to a newborn and from their onward into a healthy 
child and adult is a complex process, with genetic and prenatal environmental conditions, 
including maternal health and lifestyle, increasingly being recognized as relevant 
influencing factors. In this thesis we focus on the influence of nutrition and growth on the 
development of the body [fat and lean mass] and the brain [size and functioning] of the 
embryo, fetus, neonate, infant, and child.  
In Chapter 1 we present background information on topics that are addressed in 
the following chapters: the development from an embryo into a neonate, the DOhaD 
paradigm, and the complex interaction between body composition, brain development, 
and environmental factors. We present gaps in current research on the use of three–
dimensional [3D] ultrasonography in pregnancy to predict birth outcome, body 
composition, and for monitoring of brain growth. Additionally, we discuss clinically 
relevant questions regarding body composition and brain development of preterm 
infants, with focus on the influence of parenteral nutrition and growth. 
ParT i The early human body 
In Chapter 2 we describe the associations between embryonic size and growth 
parameters and the risk of the following adverse birth outcomes: preterm birth, small 
for gestational age, congenital anomalies, and fetal and early neonatal mortality. To 
describe embryonic size we used two 3D ultrasonography parameters: crown–rump 
length [CRL] and embryonic volume [EV]. No statistically significant associations were 
observed between embryonic size parameters at 7 and 9 weeks of gestation and any 
of the adverse birth outcomes. At 11 weeks, a larger embryo is associated with smaller 
odds of small for gestational age. And already at 9 weeks of gestation, embryonic size 
is positively associated with birth weight. These findings emphasize that embryonic 
growth is not uniform across pregnancies and may help to identify pregnancies at risk of 
an adverse birth outcome already early in pregnancy.   
In a systematic review we searched for markers that can predict neonatal body composition 
during pregnancy [Chapter 3]. Of the 16 papers included in this review, only four studies were 
of methodological and statistical moderate to high quality. From these studies, we identified 
ChaPTer 11
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three markers of interest: maternal prepregnancy BMI, fasting glucose level, and hbA1c level. 
The results of these studies are inconclusive. We therefore concluded that to date no single 
marker is available to adequately predict neonatal body composition during pregnancy. In 
our opinion, 3D ultrasonography should be considered an interesting technique for future 
development of prenatal markers of neonatal body composition.
In Chapter 4 we describe a prospective cohort study in which we assessed the 
association between fetal fractional thigh volume, a 3D ultrasonography marker, and 
neonatal body composition. We measured this marker at 22, 26, and 32 weeks of 
gestation. We found that a smaller fetal thigh volume at 22 weeks is associated with 
higher relative fat mass after birth. At the other time points we did not observe an 
association. We concluded that fractional thigh volume is a promising marker to identify 
fetuses at risk of neonatal adiposity.   
From prenatal life we shift into the postnatal life of preterm infants.  
In a prospective cohort we evaluated the nutritional intake of preterm infants during 
neonatal intensive care stay, and investigated achievement of recommended growth 
rates in this period [Chapter 5]. We observed that macronutrient [carbohydrate, 
protein, and fat] recommendations were met from birth onward. Energy 
recommendations were however not met before day 5 of life in the majority of the 
infants. Possibly as a result of this, most infants did not reach the intended growth 
rates when calculated between birth and discharge from the neonatal intensive 
care to a secondary hospital. Most infants achieved the intended growth rates 
when growth rates were calculated between the moment of maximum weight loss 
postnatally and discharge to a secondary hospital. 
In Chapter 6 we present a prospective cohort study of 118 preterm born infants. We 
evaluated the influence of weight gain during hospital stay on body composition 
measured at 6 weeks and 6 months after term age. Weight gain during hospital stay was 
significantly associated with body composition in infancy. Although the association was 
strongest with lean mass, faster weight gain after discharge to a secondary hospital was 
associated with increased fat accumulation, resulting in increased relative fat mass. The 
long–term relevance of these findings for cardiometabolic health needs further study.    
Summary
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ParT ii The early human brain 
In Chapter 7 we describe the development of a new ultrasound marker to monitor 
preterm brain growth. We show that the reproducibility of this marker, called corpus 
callosum – fastigium length, is good, and created reference curves for preterm 
infants. We found that boys have increased corpus callosum – fastigium length growth 
trajectories. Also with increasing birth weight, increasing corpus callosum – fastigium 
length were observed. No statistically significant associations were found between 
clinical outcomes such as sepsis or ventilation days and corpus callosum – fastigium 
length growth trajectories. 
There is a need for markers that allow for monitoring of brain growth in both the prenatal 
and the postnatal period. Therefore we investigated the feasibility and reproducibility of 
corpus callosum – fastigium length in fetal life [Chapter 8]. These analyses showed that 
measurement of corpus callosum – fastigium length is also feasible and reproducible in 
the prenatal period. We found that growth trajectories of corpus callosum  – fastigium 
length of fetuses with fetal growth restriction are decreased compared to those of healthy 
control fetuses. We additionally created reference curves between 22 and 42 weeks of 
gestation, which are largely comparable to the reference curves of preterm infants as 
presented in Chapter 7. 
Quantity and quality of [parenteral] nutrition in early life of preterm infants are pivotal 
for their developmental potential. In a randomized controlled trial we assessed the 
long–term effects of parenteral high–dose amino acid and mixed lipid administration 
from birth onward in preterm infants [Chapter 9]. No beneficial effects of the nutritional 
interventions were found on neurodevelopmental outcome, but growth was enhanced 2 
years after term age, suggesting a possible beneficial effect of the interventions. 
In the general discussion [Chapter 10] we discuss the clinical implications and address 
limitations and strengths of the studies that are presented in this thesis. Moreover, we 
evaluate which questions regarding growth in prenatal and postnatal life have been 
answered, but also which questions remain to be answered to improve health of the 
developing embryo, fetus, and infant in the upcoming years. 
  
ChaPTer 11
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SamenvaTTing
De ontwikkeling van een bevruchte zaadcel via een pasgeborene naar een foetus en van 
daar naar een gezond kind en volwassene is een complex proces. Er is steeds meer bewijs 
dat genetische en omgevings– en leefstijlfactoren van de moeder voor de bevalling dit 
proces sterk kunnen beïnvloeden. In dit proefschrift richten wij ons op de invloed van 
voeding en groei op de lichaamssamenstelling [verhouding vetmassa en vetvrije massa] 
en de hersenen [omvang en functie] van het embryo, de foetus, de pasgeborene, en het 
kind.  
In hoofdstuk 1 introduceren wij de onderwerpen die in de hierop volgende 
hoofdstukken besproken worden. Eerst belichten wij de ontwikkeling van de foetus 
en het DOhaD paradigma, en de complexe verbanden tussen omgevingsfactoren, 
lichaamssamenstelling en hersenontwikkeling. We schetsen de bestaande hiaten in het 
gebruik van foetale driedimensionale [3D] echografie om zwangerschapsuitkomsten te 
voorspellen en om hersengroei te volgen. Daarnaast bespreken we vragen met betrekking 
tot de ontwikkeling van de lichaamssamenstelling en de hersenenontwikkeling van te 
vroeg [prematuur] geboren kinderen, met specifieke aandacht voor de invloed van 
infuusvoeding en groei. 
deel i heT menSelijk liChaam in heT vroege leven  
In hoofdstuk 2 beschrijven wij het verband tussen groei van het embryo in de eerste 
weken van de zwangerschap en de uitkomst van de zwangerschap. We vergeleken de 
embryonale groei van een groep met een normale zwangerschapsuitkomst, met een 
groep waarin het kind overleed, te vroeg werd geboren [prematuriteit], met een te 
laag geboortegewicht werd geboren [dysmaturiteit] en/of een ernstige aangeboren 
afwijking had. Als maat voor groei van het embryo maakten wij gebruik van kruin–stuit 
lengte en het embryonaal volume, gemeten op 3D echo’s. Wij vonden geen verband 
tussen de metingen gedaan bij 7 en 9 weken zwangerschapsduur en de verschillende 
zwangerschapsuitkomsten, maar wel bij 11 weken zwangerschapsduur. Een groter 
embryonaal volume bij 11 weken is geassocieerd met een lagere kans op een combinatie 
van de verschillende gecompliceerde zwangerschapsuitkomsten. Daarnaast zagen we 
dat er een positief verband was tussen kruin–stuit lengte en embryonaal volume en 
het geboortegewicht. Deze bevindingen laten zien dat groei in de eerste weken van de 
nederlandSe SamenvaTTing
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zwangerschap niet uniform is, en kunnen in de toekomst helpen met het identificeren van 
zwangere vrouwen met een verhoogd risico op een nadelige zwangerschapsuitkomst.   
In een systematische literatuurstudie zochten wij naar factoren die al tijdens de 
zwangerschap de lichaamssamenstelling van pasgeborenen kunnen voorspellen 
[hoofdstuk 3]. Van de 16 artikelen in de wereldwijde medische literatuur die dit 
onderwerp onderzocht hebben bleken er slechts vier van goede methodologische en 
statistische kwaliteit. Uit deze vier studies zijn de volgende drie relevante factoren naar 
voren gekomen: body mass index [BMI] gemeten voor de zwangerschap, nuchtere 
bloed glucosewaarde en hbA1c [maat voor gemiddelde bloedsuikerspiegel in de 
afgelopen weken] van de zwangere. De resultaten van deze vier studies waren niet 
eenduidig. Op basis van ons overzicht concludeerden wij dan ook dat er niet één ideale 
voorspeller is voor neonatale lichaamssamenstelling, en dat voorspellers die specifiek 
de fetus betroffen niet goed onderzocht zijn. Wij opperen dat 3D echografie tijdens 
de zwangerschap een veelbelovende techniek is voor toekomstige ontwikkeling van 
voorspellers van neonatale lichaamssamenstelling. 
In hoofdstuk 4 beschrijven wij een prospectieve observationele studie, waarin wij 
het verband onderzochten tussen een foetale 3D echografische meting en neonatale 
lichaamssamenstelling. We keken specifiek naar het foetale dijvolume gemeten bij 
22, 26 en 32 weken zwangerschapsduur. We zagen dat een kleiner dijvolume bij 22 
weken geassocieerd is met een hogere relatieve vetmassa na de geboorte. Later in de 
zwangerschap vonden wij geen verband. We concludeerden dat het foetale dijvolume 
een veelbelovende marker is om foetussen te identificeren die een verhoogd risico 
hebben op neonatale adipositas. 
Van het prenatale leven richten we ons vervolgens op het postnatale leven van prematuur 
geboren kinderen. 
In een prospectieve cohort studie keken wij naar de voedingsinname van prematuur 
geboren kinderen tijdens de opname op de intensive care neonatologie en onderzochten 
of de aanbevolen groeisnelheden werden bereikt [hoofdstuk 5]. het bleek dat aan de 
aanbevelingen van glucose–, eiwit– en vetinname vanaf de geboorte werd voldaan. 
Echter, de aanbeveling voor de energie werd in het merendeel van de kinderen niet 
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gehaald voor de 5e levensdag. Mogelijk hierdoor haalden de meeste kinderen niet de 
beoogde groeisnelheid wanneer de groei werd berekend tussen geboorte en ontslag van 
de intensive care neonatologie. De beoogde groeisnelheid werd wel bereikt wanneer wij 
deze berekenden vanaf het moment van maximaal gewichtsverlies na de geboorte tot 
ontslag van de intensive care neonatologie. 
In hoofdstuk 6 presenteren wij een prospectieve cohort studie waaraan 118 
prematuur geboren kinderen deel hebben genomen. We evalueerden de invloed van 
gewichtstoename tijdens de ziekenhuisopname op lichaamssamenstelling gemeten 
6 weken en 6 maanden na de uitgerekende datum. hierbij werd gevonden dat er 
gewichtstoename tijdens de ziekenhuisopname significant geassocieerd was met 
lichaamssamenstelling in de eerste maanden na de geboorte. hoewel het verband 
tussen gewichtstoename het sterkste was met vetvrije massa, vonden wij ook dat 
snellere gewichtstoename tot ontslag naar huis geassocieerd was met een verhoogde 
vetmassa in verhouding tot de vetvrije massa. De langere termijn consequenties voor 
cardiometabole gezondheid van deze bevindingen zullen in toekomstig onderzoek 
onderzocht moeten worden. 
deel ii heT menSelijk brein in heT vroege leven
In hoofdstuk 7 wordt de ontwikkeling van een nieuwe echografische meting beschreven 
om hersengroei te evalueren bij prematuur geboren kinderen. In dit hoofdstuk wordt 
getoond dat de reproduceerbaarheid van deze meting, de zogeheten corpus callosum – 
fastigium lengte, goed is, en presenteerden wij referentiecurves voor prematuur geboren 
kinderen. Daarnaast toonden wij aan dat jongens een hogere corpus callosum – fastigium 
lengte groeisnelheid hebben, en ook dat een hoger gewicht bij geboorte geassocieerd is 
met een hogere corpus callosum – fastigium lengte groeisnelheid. Er werd geen verband 
gevonden tussen klinische uitkomsten zoals het voorkomen van een ernstige infectie of 
het aantal beademingsdagen en de groeisnelheid van de corpus callosum – fastigium 
lengte.
Er is behoefte aan meetinstrumenten waarmee de hersengroei zowel voor als na de 
geboorte geëvalueerd kan worden. Daarom onderzochten wij of corpus callosum – 
fastigium lengte, welke na de geboorte betrouwbaar gemeten kan worden, in het foetale 
leven ook betrouwbaar gemeten kan worden [hoofdstuk 8]. hieruit bleek dat de meting 
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van de corpus callosum – fastigium lengte ook tijdens de zwangerschap goed uitvoerbaar 
en reproduceerbaar is. Tevens vonden wij dat de groeisnelheid van de corpus callosum 
– fastigium lengte tussen 22 en 42 weken zwangerschapsduur lager was in foetussen 
met groeivertraging dan in gezonde foetussen. Wij maakten referentiecurves welke 
grotendeels vergelijkbaar zijn met de referentiecurves van prematuur geboren kinderen 
zoals gepresenteerd in hoofdstuk 7. 
De hoeveelheid en kwaliteit van [infuus]voeding in de eerste dagen van het leven 
van prematuur geboren kinderen is cruciaal voor hun ontwikkelingspotentieel. 
In een geblindeerde gerandomiseerde studie keken wij naar de effecten van een 
voedingsinterventie direct na de geboorte op de neurologische ontwikkeling 2 jaar 
later. Op basis van loting kregen sommige kinderen vanaf de geboorte een hogere 
dosis aminozuren en/of een vetemulsie [hoofdstuk 9]. De neurologische ontwikkeling 
werd vergeleken tussen kinderen die wel of niet deze aangepaste voeding kregen. De 
voedingsinterventie lijkt de neurologische ontwikkeling niet te verbeteren, maar mogelijk 
wel de groei, hoewel dat nog in een grotere onderzoeksgroep bevestigd zal moeten 
worden.  
In de algemene discussie [hoofdstuk 10] bediscussiëren wij het belang van onze 
bevindingen voor de praktijk en bespreken wij de beperkingen en kracht van het 
onderzoek gepresenteerd in dit proefschrift. Daarnaast laten wij zien welke vragen met 
betrekking tot groei in het foetale en postnatale leven zijn beantwoord, en welke nog 
beantwoord moeten worden om de gezondheid van de fetus en de pasgeborenen te 
bevorderen.  
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%FM  percentage fat mass 
2D US  two–dimensional ultrasonography 
3D US  three–dimensional ultrasonography  
AA  amino acids 
AC  abdominal circumference 
ADP  air displacement plethysmography 
BC  body composition 
BMI  body mass index  
BPD  bi–parietal diameter 
CA  corrected age 
CC  corpus callosum 
CCF  corpus callosum – fastigium 
ChD  congenital heart defect 
CI  confidence interval 
CRL  crown–rump length 
CUS  cranial ultrasound 
DEXA  dual x–ray absorptiometry 
EFW  estimated fetal weight 
EV  embryonic volume 
FGR  fetal growth restriction
FL  femur length 
FFM  fat free mass  
FM  fat mass  
GA  gestational age 
hC  head circumference 
ICSI  intracytoplasmic sperm injection 
IQR  interquartile range 
IVF  in vitro fertilization 
IVh  intraventricular hemorrhage 
LMP  last menstrual period 
MRI  magnetic resonance imaging 
NEC  necrotizing enterocolitis 
NICU  neonatal intensive care unit 
PhVD   post hemorrhagic ventricular dilatation  
PMA  postmenstrual age 
SD[s]  standard deviation [score] 
SGA  small for gestational age 
TVol  fractional thigh volume 
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